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Abstract 
 
 
 
 
Introduction: 
 
 
An interaction exists between cardiovascular risk factors (e.g. obesity) and antiretroviral 
treatment (ART) in the pathogenesis of cardiovascular disease. While ART reverses HIV- 
related weight loss, studies investigating ART effects in the context of obesity are lacking. 
 
Objective: 
 
 
To investigate the effects of Odumine® (first-line fixed ART-drug combination) on several 
cardio-metabolic parameters in a high fat/sucrose diet (HFD) rat model of obesity. 
 
Methods: 
 
 
Groups: Lean, untreated (C/-ART); HFD, untreated (HFD/-ART); Lean, treated (C/+ART); 
HFD, treated (HF/+ART). Sample size: n = 28 - 34 / group; male Wistar rats. The HFD 
feeding programme followed for 16 weeks and ART treatment programme for the last 6 
weeks of HFD feeding programme. The Endpoints measured included: Food and water 
consumption for the first 31 days during the drug treatment programme; Biometric 
measurements: Total body mass (TBM), intra-peritoneal (IP) fat mass, heart mass and 
liver mass; Blood and serum: Glucose, insulin, total cholesterol (TC), triglycerides (TGs); 
Thiobarbituric acid reactive substance (TBARS) and conjugated dienes (CD); Isolated 
heart perfusion: Functional recovery (Global ischaemia-reperfusion) and infarct sizes 
(Regional ishcaemia-reperfusion); Western blot (Pre- and post-ischaemia-reperfusion): 
Nitric oxide synthase (NOS) signalling (eNOS, PKB/Akt and AMPK), indicators of reactive 
oxygen species (ROS) (Nitrotyrosine and p22 phox) and an indicator of pro-inflammatory 
NF-κB signalling (IκBα) in heart tissue. 
 
Results: 
 
 
The HFD was validated by increases in TBM, IP fat mass and heart mass. The HFD was 
further validated by increased TG and TBARS levels (lipid peroxidation). Pre-ischaemia- 
4  
Stellenbosch University  https://scholar.sun.ac.za 
 
 
 
reperfusion, the HFD was associated with reduced oxidative stress (nitrotyrosine and p22 
phox) vs. C/-ART. Reduced oxidative stress was associated with increased activation of 
the pro-inflammatory NF-κB pathway. The HFD upregulated eNOS post-ischaemia- 
reperfusion, downregulated PKB/Akt and increased NF-κB activation. Lastly, the HFD was 
associated with reduced functional recovery vs. C/-ART and HF/+ART, and increased 
infarct size vs. C/-ART and HF/+ART. 
 
ART treatment did not affect the food and water consumption, was associated with 
reduced insulin levels vs. C/-ART and HF/+ART, increased TC levels vs. C/-ART and 
elevated levels of oxidative stress (increased TBARS) vs. C/-ART. Pre-ischaemia- 
reperfusion, ART improved oxidative stress in heart tissue (reduced p22 phox) vs. C/-ART 
and reduced inflammation (downregulated IκBα). Post-ichaemia-reperfusion, ART 
upregulated eNOS in the heart tissue, downregulated PKB/Akt and increased oxidative 
stress (nitrotyrosine) vs. C/-ART. ART per se did not affect functional recovery or infarct 
size. 
 
The HFD combined with ART increased liver mass vs. HF/-ART. Pre-ischaemia- 
reperfusion, HFD/+ART improved oxidative stress (decreased nitrotyrosine and p22 phox) 
vs. HF/-ART, but decreased NF-κB activation vs. HF/-ART. Post-ischaemia-reperfusion, 
ART combined with HFD upregulated eNOS, downregulated PKB/Akt and increased 
oxidative stress (p22 phox) vs. HF/-ART and C/+ART. Post-ischaemia-reperfusion, ART 
with HFD seemed to improved functional recovery vs. HF/-ART and ameliorated the 
increased infarct size vs. HF/-ART. 
 
Discussion and Conclusion: 
 
 
Our study demonstrates the detrimental effect of HFD/obesity on cardiovascular health. 
Interestingly, when combined with ART, cardiovascular function seem to be improved vs. 
HFD/-ART. ART alone, affected cardiovascular health to a lesser extent in our study vs. 
HF/-ART and HF/+ART, and did not affect functional recovery and infarct size vs. C/-ART 
at all. 
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Opsomming 
 
 
 
 
Inleiding: 
 
 
‘n Interaksie bestaan tussen kardiovaskulêre risikofaktore (bv. vetsug) en antiretrovirale 
behandeling (ART) in die ontwikkeling van kardiovaskulêre siekte. Terwyl ART HIV- 
verwante gewigsverlies kan omkeer, is daar min bekend oor ART-effekte in die konteks 
van vetsug. 
 
Doelstelling: 
 
 
Om die effekte van Odumine® (eerste-linie ART-middel kombinasie) op verskeie kardio- 
metaboliese parameters in ‘n hoë vet/sukrose dieet (HFD) rotmodel van vetsug te bepaal. 
 
Metodes: 
 
 
Groepe: Kontrole/geen ART (C/-ART); HFD/geen ART (HFD/-ART); Kontrole/met ART 
(C/+ART); HVD/met ART (HF/+ART). Aantal proefdiere: n = 28-34/groep; manlike Wistar 
rotte. Die HFD voedingsprogram was 16 weke lank en ART was gedurende die laaste 6 
weke van die voedingsprogram daagliks toegedien. 
Die Eindpunte was: Voedsel- en waterinname vir die eerste 31 dae van die 
middeltoedieningsprogram; Biometriese metings: Totale liggaamsmassa (TLM), intra- 
peritoneale (IP) vetmassa, hart- en lewermassa; Bloed and serum: Glukose, insulien, 
totale cholesterol (TC), triglisseriede (TGs); “Thiobarbituric acid reactive substance” 
(TBARS) and gekonjugeerde diëne (CD); Geisoleerde hartperfusies: Funksionele herstel 
(Globale isgemie-herperfusie) and infarkgrootte (Regionale isgemie-herpurfusie); Western 
blot (Voor- na na-isgemie-herperfusie): Stikstofoksied sintase (NOS) seintransduksie 
(eNOS, PKB/Akt en AMPK), merkers van reaktiewe suurstofspesies (ROS) (Nitrotirosien 
en p22 phox) en ‘n merker van pro-inflammatoriese NF-κB seintransduksie (IκBα). 
 
Resultate: 
 
 
Die  HFD  is  bevestig  deur  ‘n  betekenisvolle  toename  in  die  TLM,  IP  vetmassa  en 
hartmassa. Die HVD was verder bevestig deur die toename in die TG en TBARS vlakke 
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(lipiedperoksidasie). Die HFD was geassosieer met verlaagde eindpunte van oksidatiewe 
stres in die hartweefsel (nitrotirosien and p22 phox) versus C/-ART. Verlaagde oksidatiewe 
stres was met verhoogde NF- κB aktivering geassosieer. Isgemie-herperfusie het eNOS in 
die HFD hartweefsel opgereguleer, PKB/Akt afgereguleer en NF- κB aktivering verhoog in 
die HFD groep. Laastens was die HFD was geassosieer met verlaage funksionele herstel 
versus C/-ART en HF/+ART, en verhoogde infark grootte versus C/-ART en HF/+ART. 
 
ART toediening het geen effek op die voedsel- en waterinname gehad nie, was 
geassosieer met verlaagde  insulienvlakke versus C/-ART en HF/+ART, verhogde TC 
vlakke versus C/-ART, en verhoogde oksidatiewe stres (verhoogde TBARS) versus C/- 
ART. Voor blootstelling aan isgemie-herperfusie, het ART-toediening oksidatiewe stres in 
hartweefsel verlaag (verlaagde p22 phox) versus C/-ART en pro-inflammatoriese NF- κB 
aktivering verhoog (afgereguleerde IκBα). Na blootstelling aan isgemie-herperfusie het 
ART-toediening eNOS opgereguleer, PKB/Akt afgeruguleer en oksidatiewe stres verhoog 
(nitrotirosien) versus C/-ART. ART het geen effek op funksionele herstel of infark grootte 
gehad nie. 
 
ART-toediening aan HFD diere het die lewermassa verhoog versus HF/-ART. Voor 
isgemie-herperfusie blootstelling, het ART-toediening in HFD diere oksidatiewe stres 
verbeter (verlaagde nitrotirosien and p22 phox) versus HF/-ART, maar NF-κB aktivering 
verlaag versus HF/-ART. Na isgemie-herperfusie-blootstelling, het ART-toedining in HFD 
diere eNOS opgereguleer, PKB/Akt afgereguleer en oksidatiewe stres verhoog (p22 phox) 
versus HF/-ART en C/+ART. Verder was die funksionele herstel beter en die infark-grootte 
kleiner na isgemie-herperfusie in die HFD-groep. 
 
Bespreking en Gevolgtrekking: 
 
 
Ons studie het die skadelike effekte van HFD/vetsug op kardiovaskulêre gesondheid 
gedemonstreer. ‘n Interessante waarneming was dat die kombinasie van vetsug met ART 
tot n mate kardiovaskulêre funksie verbeter het versus HFD/-ART. ARV self het 
kardiovaskulêre gesondheid tot ‘n mindere mate geaffekteer versus HF/-ART en 
HF/+ART, en het nie funksionele herstel en infarkt grootte in kontrole diere geaffekteer nie. 
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Chapter 1 - Literature Review 
 
 
1.1. General Introduction to Study 
 
 
According to the World Health Organisation (WHO), the burden of disease in high-income 
countries consists predominantly of non-communicable diseases (NCDs) such as 
cardiovascular disease (CVD), while low- and middle-income countries are experiencing a 
double burden of an increasing NCD prevalence as well as an on-going communicable 
(infectious) disease epidemic (Alwan, 2010; Mathers et al., 2008; Remais et al., 2012). 
CVD remains the biggest contributor to the global burden of disease (GBD) in terms of 
mortality   and   premature   mortality,   while   human   immunodeficiency   virus/acquired 
immunodeficiency  syndrome  (HIV/AIDS)  ranks  6th   globally  and  number  one  in  Sub- 
Saharan Africa (SSA) (Alwan, 2010; Lozano et al., 2013; Byass et al., 2013). Projections 
further indicate that both CVD and the number of people living with HIV/AIDS (PLWH) are 
currently on the rise (especially in the developing world) and often affect the same 
communities (Alwan, 2010; Remais et al., 2012; Lozano et al., 2013; Mathers and Loncar, 
2006). 
 
Before the introduction of antiretroviral therapy (ART), HIV/AIDS was a fatal disease, 
characterised by severe weight loss and the occurrence of opportunistic infections, but 
ART revolutionised HIV/AIDS care, transforming it into a chronic, but manageable, disease 
requiring lifelong treatment (Sharp and Hahn, 2011; De Cock et al., 2012; Ruelas and 
Greene, 2013). Soon after the introduction of ART, reports on metabolic abnormalities 
(such as insulin resistance and hypercholesterolaemia) and anthropometric abnormities 
including lipodystrophy (lipohypertrophy in the abdominal area and/or lipoatrophy in the 
peripheral area) associated with ART-use started to emerge (Levitt et al., 2011; Mayosi et 
al., 2009). 
Furthermore, traditional cardiovascular risk factors such as overweight and obesity seen in 
the general population have become more prevalent in HIV/AIDS population (Remais et 
al., 2012; Mayosi et al., 2009; Islam et al., 2012; Fedele et al., 2011). Higher rates of CVD 
have previously been observed in HIV/AIDS populations compared to the general 
population  (Remais  et  al.,  2012;  Islam  et  al.,  2012;  Fedele  et  al.,  2011).  The  rising 
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prevalence of CVD in HIV/AIDS populations is of particular concern in regions such as 
SSA and developing countries including South Africa (SA) that are currently undergoing 
epidemiological transition against the background of very high HIV/AIDS rates (Mathers 
and Loncar, 2006; WHO, 2010; Narayan et al., 2014). The increasing numbers of PLWH 
are as a result of the success of ART (improved live expectancy and health in general) 
and the dramatic up-scaling of HIV/AIDS treatment roll-out programmes (Mathers and 
Loncar, 2006; WHO, 2010; Narayan et al., 2014). 
 
Epidemiological transition in lower-income countries is resulting in the convergence of 
NCDs such as CVD and still highly prevalent communicable diseases such as HIV/AIDS 
(Remais et al., 2012; Signorini et al., 2012; Fedele et al., 2011). Furthermore, CVD is 
emerging as a major contributor in terms of both mortality and morbidity in PLWH (Remais 
et al., 2012; Sinorini et al., 2012; Fedele et al., 2011), while the relationship between 
HIV/AIDS and CVD (and their risk factor profiles) is not yet fully understood. (Remais et 
al., 2012; Sinorini et al., 2012; Fedele et al., 2011). Factors, such as the increased 
incidence of CVD in PLWH and the fact that the mechanistic interplay between CVD, 
HIV/AIDS and risk factor profiles of these diseases is not yet understood, warrant the need 
for further scientific investigation. 
 
 
 
1.2. Cardiovascular Disease (CVD) 
 
 
1.2.1. Ischaemic Heart Disease (IHD): Overview 
 
 
Ischaemic heart disease (IHD), or coronary artery disease, is the greatest contributor to 
CVD mortality globally. Atherosclerosis plays a central role in the development of IHD 
(American Heart Association (AHA); Reviewed: July, 2015; Naseem, 2005; Chabra N, 
2009). The pathogenesis of atherosclerosis involves arterial plaque-formation due to a 
high cholesterol-rich fraction in the blood (AHA; Reviewed: July, 2015; Naseem, 2005). 
The continuous lipid deposition of this cholesterol-rich fraction in the arterial wall 
progressively leads to a decreased arterial lumen diameter and restricts arterial blood flow 
(AHA; Reviewed: July, 2015; Naseem, 2005). This reduced blood supply (also oxygen 
supply) to an area of tissue results in ischaemia (AHA; Reviewed: July, 2015; Naseem, 
2005). 
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More specifically, the aetiology of atherosclerosis starts with the passive low-density 
lipoprotein (LDL) -diffusion into the arterial wall where it becomes trapped (due to its 
association with protein moiety, appolipoprotein B100 matrix proteoglycans) (Naseem, 
2005; Barbaro, 2003). LDLs then oxidatively changed though exposure to reactive oxygen 
species (ROS) and reactive nitrogen species (produced by monocytes and machropages) 
in a protective response to localised damaged caused by the LDL (Naseem, 2005; 
Barbaro, 2003). Oxidised LDL then furthermore leads a pro-inflammatory response in the 
surrounding cells (the production of chemokines such as monocytes, chemotactic protein- 
1 and growth factors) (Naseem, 2005; Barbaro, 2003). Oxidised LDL also stimulates the 
expression of adhesion molecules such as P-selectin, vascular adhesion molecule-1 and 
intercellular adhesion molecule-2 in the endothelial cells (ECs) (Naseem, 2005; Barbaro, 
2003). The increased amount of adhesion molecules on the EC’s surface causes entry of 
recruited monocytes into the arterial wall (Naseem, 2005). 
 
Ultimately, this process advances to the formation of lipid-laden foam cells (Naseem, 
2005) and a necrotic core of oxidized lipids, which is highly thrombotic (Naseem, 2005). 
The highly thrombotic core of the plaque subsequently ruptures to form platelet-rich 
thrombi (Naseem, 2005). 
 
 
 
1.2.2. Epidemiology of Cardiovascular Disease (CVD) 
 
 
CVD is the top cause of mortality in the world although it has substantially decreased in 
high-income countries over the last 20 years (due to population wide intervention 
strategies), while low- and middle-income countries have experienced a substantial 
increase in CVD mortality (Alwan, 2011; Mathers et al., 2008; Malaza et al., 2012). CVD 
mortality in low- and middle-income countries currently accounts for more than 80 % of the 
global CVD mortality rate (Alwan, 2011; Mathers et al., 2008; Malaza et al., 2012). In 
2008, 39 % of NCD deaths (36 million) under the age of 70 were due to CVD, while in 
2010, approximately 17 million deaths (48 % of all NCD deaths) were due to CVD (Alwan, 
2011; WHO, 2011). More specifically, IHD remained the most prominent contributor to 
global mortality (almost 13 million; 13.3 % of total deaths globally) in 2010 (Alwan, 2011; 
Lozano et al., 2013). 
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Evidence, in terms of mortality and morbidity rates, also suggests that CVD is evolving into 
a major public health concern in SSA (Dalal et al., 2011; Tibazarwa et al., 2009). The 
WHO projected a doubling of IHD rates in the SSA Region by 2030 (Adeboye et al., 2012). 
In SA, CVD, and in particular IHD, is one of the increasing causes of NCD mortality in all 
population groups (Norman et al., 2006; Levitt et al., 2011; Tibazarwa et al., 2009). “The 
Heart of Soweto” study found cardiovascular risk factors highly prevalent in an urban SA 
community: Obesity (43 %), systolic or diastolic hypertension (33 %), and elevated total 
cholesterol (TC) levels (13 %; non-fasting) (Tibazarwa et al., 2009). 
 
Recent global projections also indicate an increase of 6 million deaths (from approximately 
16.7 million to about 23.9 million) due to CVD over the next two decades globally, while 
IHD is expected to remain one of the top three leading causes of the GBD (Alwan, 2011; 
Dalal et al., 2011; Islam et al., 2012). 
 
 
 
1.2.3. Cardiovascular Risk Factors 
 
 
Traditional cardiovascular risk factors can be classified as controllable/modifiable or 
uncontrollable/non-modifiable (Fedele et al., 2011; WHO, 2012). They affect physiological 
pathways and/or processes such as blood pressure control directly or indirectly and 
subsequently lead to the pathogenesis of, and eventual progression toward, CVD (Fedele 
et al., 2011; WHO, 2012) (Table 1.1). 
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Table 1.1. Modifiable and Non-Modifiable Cardiovascular Risk Factors. Abbreviations: 
LDL: Low-Density Lipoprotein; HDL: High-Density Lipoproteins (Poulter, 2003). 
 
 
Modifiable Risk Factors Non-modifiable Risk Factors 
 High LDL cholesterol 
 High blood pressure 
 Smoking 
 Low HDL cholesterol 
 Lack of exercise 
 Diabetes and glucose 
intolerance 
 Left ventricular hypertrophy 
 Central obesity 
 Age 
 Sex 
 Family history 
 Ethnic origin 
 Birth weight 
 
 
 
Total cardiovascular risk and the rate of progression toward CVD depend on the amount of 
cardiovascular risk factors present, as well as the degree of intensity that each risk factor 
presents itself (WHO, 2011). Intervention anywhere along the continuum of events that 
may lead to CVD could disrupt the pathophysiological process (Fedele et al., 2011). 
 
 
 
1.3. Overweight and Obesity 
 
1.3.1. Introduction 
 
 
Overweight/obesity is recognised by the WHO as a chronic disease, characterised by an 
increase in total body mass (TBM) and adiposity due to an imbalance between energy 
intake and expenditure leading to multiple comorbidities such as hypertension, insulin 
resistance and diabetes (Haslam and James, 2005; Van der Merwe and Pepper, 2006). 
Overweight/obesity also negatively impacts cardiovascular health directly and/or indirectly 
and is thus classified as a major cardiovascular risk factor (WHO, 2014). The WHO 
furthermore describes obesity as “one of the most blatantly visible, yet most neglected, 
public health problems that threatens to overwhelm both more and less developed 
countries” and classifies a person as being overweight if the body mass index (BMI) falls 
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between 25-29.9 kg / m2 and obese as having a BMI of greater than 30 kg / m2 (Haslam, 
2005; Lavie et al., 2009; Tchernof and Després, 2013). 
 
 
 
1.3.2. Epidemiology of Obesity 
 
 
An estimated 205 million men and 297 million women over the age of 20 were obese in 
2008, a total of more than half a billion adults worldwide (Alwan, 2011). Obesity is also the 
6th most important risk factor contributing to the overall GBD worldwide (Haslam and 
James, 2005). It is estimated that more than 2.8 million people die each year as a result of 
being obese (5 % of global deaths) with women in particular significantly more obese than 
men (prevalence twice as high compared to that of men in some communities) (Alwan, 
2011;  Levitt  et al.,  2011).  Approximately  1.1  billion adults  and 10  %  of  children are 
currently classified as overweight/obese (Haslam and James, 2005). More recently, in 
2014, it was estimated by the WHO that 39 % of the world’s population was obese (WHO, 
2014). 
 
Overweight/obesity among men and women is not only a great health challenge in high- 
income countries, but also a growing health concern in the lower-income countries and 
regions such as SSA (Alwan, 2011; Lim et al., 2012; Dalal et al., 2011; Prentice M, 2006). 
According to the WHO, 15 % - 24.9 % of SA’s population older than 18 years of age is 
classified as obese compared to 39 % of the world’s population (WHO, 2014). As is the 
case with developed countries, obesity is on the rise in SA (highest rate if obesity among 
SSA countries and is expected to take an even stronger hold as the coverage of SA’s 
ART-programme increases and HIV/AIDS related weight loss is reversed (Malaza et al., 
2012; Strijdom, 2012; Mbanya et al., 2014; Puoane et al., 2002). 
 
 
 
1.3.3. Overweight/Obesity and Comorbidities Associated With Cardiovascular 
Disease (CVD) 
 
Obesity-associated comorbidities include hypertension, type 2 diabetes mellitus, 
dyslipidaemia, certain cancers, and CVD (Alwan, 2011; Lavie et al., 2009; Tchernof and 
Després, 2013). These obesity-related comorbidities can manifest though many complex 
physiological pathways (Alwan, 2011; Lavie et al., 2009; Tchernof and Després, 2013). 
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Central adiposity in particular poses a great cardiovascular and health risk, as it is the 
driving force behind the development of most obesity-associated comorbidities such as 
insulin resistance and ectopic triglyceride (TG) deposition in the liver, heart, pancreas, and 
kidneys (Fig. 1.1) (Tchernof and Després, 2013). 
 
 
 
 
 
Increased Cardiovascular Risk 
 
 
 
Fig. 1.1. Obesity and Factors Associated with Increased Cardiovascular Risk. 
Abbreviations: IL-6: Inter Leukin-6; TNF-α: Tumor Necrosis Factor Alpha. Symbols: = 
Increase; = Decrease. (Tchernof and Després, 2013; Alwan, 2011; Fedele et al., 2011; 
Tchernof and Després, 2013; Bastien et al., 2014; Mokdad et al., 2003) 
 
Dyslipidaemia is a major contributor to health complications in obesity and can be 
associated by any of the following: elevated TC, TG, LDL cholesterol, non-high density 
lipoprotein (HDL) cholesterol, apolipoprotein-B, and small dense LDL levels, or decreased 
HDL cholesterol levels (Alwan, 2011; Fedele et al., 2011; Tchernof and Després, 2013). 
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1.4. Human Immunodeficiency Virus and Acquired 
Immunodeficiency Syndrome (HIV/AIDS) 
 
1.4.1. Introduction 
 
 
HIV/AIDS was first described by the Centres for Disease Control and Prevention in the 
United States of America (USA) in 1981 (De Cock et al., 2011; Sharp and Hahn, 2012). 
The human immunodeficiency (HI) virus was isolated two years later, and confirmed as the 
cause of AIDS in 1984 (De Cock et al., 2011; Sharp and Hahn, 2012; De Cock et al., 
2012). Little did anyone know that this newly described disease, would become one of the 
most prominent global pandemics in human history (De Cock et al., 2011; Sharp and 
Hahn, 2012; De Cock et al., 2012). Approximately 15 years after AIDS was first described, 
ART was introduced, which represented a major milestone in the history of the disease 
(De Cock et al., 2012). Since its introduction in (1996) ART quickly revolutionised HIV-care 
(De Cock et al., 2011; Does et al., 2003). Enormous international efforts followed and are 
still continuing across the globe to treat PLWH (De Cock et al., 2011; Does et al., 2003). 
 
 
 
1.4.2. Epidemiology of HIV/AIDS 
 
 
Between 1990 and 2010, HIV/AIDS, and the subsequent introduction of ART, both had 
dramatic effects on the mortality rates in SSA and the rest of the world characterised by an 
initial increase in the mortality rate due to HIV/AIDS, followed by a substantial reduction in 
HIV/AIDS-related mortality after the successful introduction of ART, and a subsequent 
increase in the number of PLWH (Lozano et al., 2013; Houle et al., 2014; Kassebaum et 
al., 2014). More than 35 million people have died as a result of HIV/AIDS since its 
discovery (Ruelas and Greene, 2013). It is also estimated that around 2012, 34 million 
people were living with HIV/AIDS (2.7 million newly infected) and 1.8 million of these 
people died that year (De Cock et al., 2012). 
 
HIV/AIDS remains the leading burden of disease in SSA (22.5 million PLWH in 2009). It is 
estimated that one in every 20 individuals in SSA are HIV-positive and this represents 
more than two-thirds of the global HIV/AIDS population (De Cock et al., 2012; Ruelas and 
Greene, 2013). HIV/AIDS resulted in a 13-year drop in the median life expectancy (49 
years for men is and 52.5 years for women; 2011) in SA (Levitt et al., 2011; Houle et al., 
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2014; Dorrington, 2000). Furthermore, SA contributes to approximately 17 % of the global 
HIV/AIDS population (Houle et al., 2014). 
 
 
 
1.4.3. The Human Immunodeficiency (HI) Virus (HIV) 
 
 
HIV is classified as a retrovirus (Ribonucleic acid; RNA) virus that replicates by inserting a 
deoxyribonucleic acid (DNA) copy of its genome into the host cell (Kirchhoff, 2013; Ruelas 
and Greene, 2013). After entering the body, the virus starts its lifecycle by binding to a 
cluster of differentiation-4 (CD4)- receptors and one of two co-receptors that is located on 
the surface of a CD4+ T-lymphocyte (Fig. 1.2) (Kirchhoff, 2013; Ruelas and Greene, 2013; 
Does et al., 2003; Stricker, 2003). 
 
 
 
 
 
 
Fig. 1.2.      The Lifecycle of HIV and Role of ART in Blocking Key Steps in the Lifecycle 
of the HIV. Abbreviations: HIV: Human Immunodeficiency Virus; RNA: Ribonucleic Acid; 
mRNA: Messenger RNA; DNA: Deoxyribonucleic Acid’ PI: Protease Inhibitor; NRTI: 
Nucleoside Reverse Transcriptase Inhibitor; NNRTI: Non-Nucleoside/Nucleotide Reverse 
Transcriptase Inhibitor. Symbols: - = Inhibit (Kirchhoff, 2013; Ruelas and Greene, 2013; 
Munir et al., 2013; Arts and Hazuda, 2012; Palmisano and Vella, 2011; Sierra and Walter, 
2012). 
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After fusing with the host cell, the virus releases its genetic material into the host cell’s 
cytoplasm (Kirchhoff, 2013; Munir et al., 2013; Does et al., 2003; Stricker, 2003). 
Subsequently, the HIV reverse transcriptase enzyme converts the single-strand virus RNA 
into double-strand linear HIV DNA (Kirchhoff, 2013; Munir et al., 2013; Does et al., 2003; 
Stricker, 2003), which enters the host cell’s nucleus and integrates with the host’s DNA via 
integrase enzyme actions (Kirchhoff, 2013; Does et al., 2003; Stricker, 2003). The host 
cell’s RNA-polymerase causes replication of the HIV genomic material, including shorter 
strands messenger RNA (mRNA) (Kirchhoff, 2013; Stricker, 2003). The mRNA is utilised 
as a blueprint to generate long-strand HIV proteins (Kirchhoff, 2013; Stricker, 2003). HIV 
proteases cut the long-strand HIV proteins into smaller HIV proteins (Kirchhoff, 2013; Arts 
and Hazuda, 2012), which assemble with HIV RNA genetic material leading to the 
formation of a new HIV-particle (Kirchhoff, 2013). 
 
Finally, the newly formed HIV particle buds off from the host cell taking with it part of the 
host cell’s outer envelope (Kirchhoff, 2013; Arhel, 2010; Stricker, 2003). The surface of the 
newly formed HIV particle becomes studded with HIV glycoproteins (protein/sugar 
combinations) that are used to bind to CD4 cell co-receptors to infect other cells (Kirchhoff, 
2013). 
 
 
 
1.4.4. Anti-Retroviral Therapy (ART) 
 
 
More than thirty anti-HIV drugs are currently approved globally and in use to fight 
HIV/AIDS by altering or inhibiting the HI virus’ life cycle (Ruelas and Greene, 2013; Arts 
and Hazuda, 2012; Palmisano and Vella, 2011). ART drugs are designed to block key 
steps in viral replication and are classified according to their target viral enzymes (Fig. 1.2) 
(Arts and Hazuda, 2012; Palmisano and Vella, 2011; Sierra and Walter, 2012). 
 
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) inhibit the key retroviral 
enzyme called reverse transcriptase and only act once the host cell is infected (Arts and 
Hazuda, 2012; Palmisano and Vella, 2011; Sierra and Walter, 2012). This group of drugs 
also includes non-NRTIs (NNRTIs) that block viral DNA-synthesis (Does et al., 2003; Arts 
and Hazuda, 2012; Sierra and Walter, 2012). 
On the other hand, protease inhibitors (PIs) act later in the life cycle of HI virus, by 
blocking the protease enzyme (involved in the cleavage of the viral polypeptide to produce 
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functional viral enzymes)  (Does et al., 2003;  Palmisano and Vella, 2011; Sierra and 
Walter, 2012). Other ART drug classes furthermore include chemokine receptor 
antagonists, fusion inhibitors that act on proteins involved in the viral uptake, and 
integrase-inhibitors that block the enzyme activity of enzymes involved in the integration of 
viral-DNA into the host cell DNA (Arts and Hazuda, 2012; Palmisano and Vella, 2011; 
Sierra and Walter, 2012). 
 
Highly active ART (HAART) is the term used to describe a regimen of 3 or more ART- 
drugs taken simultaneously (Does et al., 2003; Arts and Hazuda, 2012; Palmisano and 
Vella, 2011). This helps to prevent the virus (highly mutational) from becoming drug 
resistant (Does et al., 2003; Arts and Hazuda, 2012; Palmisano and Vella, 2011). 
 
 
 
1.5. HIV/AIDS, ART, Obesity and CVD 
 
 
1.5.1. Introduction 
 
 
The HI virus per se, ART drug class, and duration of ART have all been associated with 
increased cardiovascular risk (Islam et al., 2012). HIV, ART, and their associated 
metabolic abnormalities such as dyslipidaemia, lipodystrophy and insulin resistance are 
also directly and/or indirectly implicated in CVD pathogenesis (Mayosi et al., 2009; 
Barbaro et al., 2003). HIV- and ART-associated comorbidities are becoming a concern as 
the duration of exposure to ART and the HI virus parallels the increased exposure to 
traditional cardiovascular risk factors due to improved longevity seen in HIV-infected 
populations on ART (Islam et al., 2012; Fedele et al., 2011). HIV and ART seem to 
increase cardiovascular risk and risk to experience an adverse cardiovascular event (Islam 
et al., 2012). 
 
Many studies, most notably the Data collection on Adverse events of Anti-HIV Drugs 
(D:A:D) study, found an increased incidence of myocardial infarction (MI) in the HIV- 
infected study population compared the HIV-negative control group; furthermore, the study 
population had higher serum levels of cholesterol and TGs compared the HIV-negative 
control group (Lo and Plutzky, 2012). Furthermore, a recent study found an increased 
prevalence of subclinical coronary artery disease in young HIV-infected patients (6.5 % 
had severe obstructive coronary artery disease) with no prior history of CVD compared to 
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HIV-negative controls who were of similar age, sex, family history, BMI, smoking status, 
TC and LDL-cholesterol (Lo et al., 2010). In hospital-based studies from SSA, increased 
incidence of macrovascular arteritis, pulmonary hypertension, cardiomyopathy and 
tuberculosis-pericarditis were found in HIV/AIDS populations compared to the general 
population (Mayosi et al., 2009). Carotid intima thickness was found to be higher in HIV 
patients compared to age-matched HIV-negative controls and was positively associated 
with HIV-infection and its treatment (Lo et al., 2010; Eira et al., 2012). This evidence of 
increased cardiovascular risk in PLWH is further underlined by studies that found a higher 
prevalence of MI in HIV-infected patients compared to non-infected patients (Lo et al., 
2010; D’Ascenzo et al., 2012). 
 
 
 
1.5.2. Factors Associated with Cardiovascular Disease (CVD) in HIV/AIDS 
 
 
CVD in HIV/AIDS seems to be multifactorial in nature and includes increased traditional 
cardiovascular risk factors, overlap of risk factors, and the interplay of risk factors such as 
the virus, HAART, and traditional cardiovascular risk factors (Fig. 1.3) (Fedele et al., 2011; 
Berrueta et al., 2010; Cioe et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3. Cardiovascular Risk Factors in PLWH. Abbreviations: CVD: Cardiovascular 
Disease; HIV: Human Immunodeficiency Virus; ART: Antiretroviral Therapy (Fedele et al., 
2011). 
Tradi*onal CVD Risk Factors 
CVD 
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Both HIV-infection and many ART drugs have been associated with detrimental 
cardiovascular effects (Dubé et al., 2015) and increased cardiovascular risk is in part due 
to their effects on the body’s  metabolism, and in part  due to direct  vascular effects 
(Torriani et al., 2008; Franciscia et al., 2009; Ismail et al., 2009; Ross et al., 2009) (Table 
1.2). 
 
Table 1.2. Effects of HIV-Infection and ART on the Vasculature. Abbreviations: EC: 
Endothelial Cell; ED: Endothelial Dysfunction; HIV: Human Immunodifficiency Virus; ART: 
Antiretroviral Therapy (Dubé et al., 2015; Chaves et al., 2003; Gil et al., 2003; Lagathu et 
al., 2014; Obel et al., 2007). 
 
 
HIV ART 
 ED 
 Lipid Disorders 
 Viral Protein EC Activation 
 
 Systemic inflammation 
 
 Direct HIV-infection of the 
Endothelium 
 Enhanced Atheroma Formation 
 
 
 Pro-thrombotic State 
 ED 
 Increased EC Permeability 
 Increased Oxidative Stress 
 Increased Mononuclear Cell 
Adhesion 
 Insulin Resistance 
 
 Accelerated Lipid Accumulation in 
Vessel Wall 
 Impaired Response to Vascular 
Injury 
 Lipodystrophy 
 Inflammation and Immune 
Activation 
 
 
1.5.3. The HI Virus and CVD 
 
 
An increased incidence of adverse cardiovascular events has been noted in treatment- 
naïve PLWH when compared to HIV-patients treated with ART, which points to a role for 
the HI virus in the pathogenesis of CVD (Fedele et al., 2011; Lo et al., 2010; Jiang et al., 
2006). Numerous factors associated with the HI virus have been implicated (Fig. 1.4). 
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Fig. 1.4. Factors Involved in the Pathogenesis of CVD in PLWH. HIV: Human 
Immunodeficiency Virus; AIDS: Acquired Immunodeficiency Syndrome; CVD: 
Cardiovascular Disease (Malaza et al., 2012; Fedele et al., 2011; Lo and Plutzky, 2012; Lo 
et al., 2010). 
 
It appears that the HI virus can contribute to the pathogenesis of CVD via chronic immune 
activation, inflammation, and direct viral actions that lead to endothelial dysfunction (ED) 
and ultimately other CVDs (Malaza et al., 2012; El Assar et al., 2013; Lo et al., 2010). 
Chronic inflammation is known as a cardiovascular risk factor and has been reported in 
HIV-infected patients due to the HI virus itself as the HI virus protein, Tat, is known to be 
involved in the production of ROS and increased apoptosis (Masiá et al., 2007; Wu et al., 
2007; Vilhardt et al., 2013). 
 
 
 
1.5.4. Antiretroviral Therapy (ART) and CVD 
 
 
Although HAART considerably improved the survival rate of PLWH, the use of ART has on 
the other hand also been associated with an increased incidence of cardiovascular risk 
factors such as insulin resistance, hypertension, dyslipidaemia, lipodystrophy, and 
diabetes mellitus (Signorini et al., 2012; Islam et al., 2012; Fedele et al., 2011). A study in 
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2011 found that 26.2 % of HIV patients presented with at least one HAART-associated 
comorbidity, such as hypertension (16.7 %), vascular diseases (5.6 %), and diabetes 
mellitus (3.9 %) (Signorini et al., 2012). A systematic review and meta-analysis 
furthermore found that the relative risk of developing CVD was 1.61-fold higher in HIV- 
infected without ART patients (HIV-ART) compared to HIV-infected patients on ART- 
treatment (HIV+ART), and 2-fold higher in HIV-infected patients receiving no ART- 
treatment (HIV-ART) compared to HIV- and ART-naïve controls (-HIV-ART) (Islam et al., 
2012). 
 
Specific ART drug classes have been shown to increase cardiovascular risk per year of 
exposure (1.05 for PIs, 1.11 for NRTIs and 1.04 for NNRTIs) (Islam et al., 2012). PIs have 
been linked to the pathogenesis of ED, whereas NRTIs and NNRTIs seem to be less 
detrimental; however, the specific mechanisms underlying their contribution to CVD 
remains to be fully elucidated. (Torriani et al., 2008; Dubé et al., 2015; Francisci et al., 
2009). Furthermore, findings in studies related to ART and endothelial function often 
generate contradictory findings (Dubé et al., 2015; Francisci et al., 2009; Kristoffersen et 
al., 2009). 
Nonetheless, ED seems to be the link between ART and CVD (Dubé et al., 2015; Francisci 
et al., 2009). The pathogenesis of ART-induced ED appears to be related to decreased 
nitric oxide (NO) production through reduction in nitric oxide synthase (NOS) expression 
and the increased production of ROS that reduces bioavailability of antioxidants (Dubé et 
al., 2015; Masiá et al., 2007; Mondal et al., 2004). Increased hydrogen peroxide levels 
have been positively correlated to increased C-reactive protein and LDL cholesterol levels 
(Masiá et al., 2007). Also, hydrogen peroxide levels were found to be significantly lower in 
patients receiving NNRTIs compared to PIs (Masiá et al., 2007). 
 
Although data from developed countries shows an association between ART and 
increased risk of developing premature CVD and experiencing cardiovascular events, 
population-based studies on the effects and outcomes of ART in populations from SSA are 
scarce (Malaza et al., 2012; Islam et al., 2012). 
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1.5.5. Obesity in HIV/AIDS and CVD 
 
 
Improved life expectancy and the subsequent dramatic increase in the number of PLWH 
(more than 33 million globally), contribute to the emergence of NCDs such as CVD in HIV 
populations (Islam et al., 2012; Fedele et al., 2011). Furthermore, increased exposure to 
general NCD and cardiovascular risk factors (also experienced by the general population) 
in PLWH (due to improved longevity) is an emerging challenge (Islam et al., 2012; Fedele 
et al., 2011). Many studies found that the prevalence of traditional cardiovascular risk 
factors in PLWH is high and in some cases even higher than the general population 
(Fedele et al., 2011). However, the relative contribution of each cardiovascular risk factor 
to the pathogenesis of CVD in PLWH seems to differ from the general population and 
suggest a more complex interplay between the disease, treatment, and traditional 
cardiovascular risk factors (Fedele et al., 2011). 
 
HIV/AIDS and obesity are both major public health concerns (Keithley et al., 2009). 
Although ART can reverse HIV-associated weight loss, the emergence of obesity in PLWH 
is becoming of greater concern (Amarosa et al., 2005; Lakey et al., 2013; Taylor et al., 
2014). 
Studies have shown that the prevalence of obesity in HIV populations is either 
approaching or mimicking that of the general population (Amarosa et al., 2005; Wanke et 
al., 2000). A study in the USA found that 63 % of HIV-infected participants was 
overweight/obese (Crum-Cianflone et al., 2008). Another study showed that 49 % of the 
HIV-infected study population was overweight/obese while other estimates indicate 30 % 
to 40 % of the HIV-infected population in the USA to be obese (Leite and de Mattos 
Marinho Sampaio, 2008). 
It was furthermore found that HIV/AIDS and ART influences adipose tissue biology and 
distribution (Giralt et al., 2011; Grima et al., 2010). Lipodystrophy that includes peripheral 
adipose tissue atrophy and/or visceral fat hypertrophy has been reported and is estimated 
to affect about half of HIV/AIDS patients on treatment (including children) (Giralt et al., 
2011; Arpadi et al., 2009). One study found that 45.7 % of its study population presented 
with central obesity (Jaime et al., 2006). NRTIs, NNRTIs, and PIs have all been implicated 
in lipodystrophy (Giralt et al., 2011; Mallon et al., 2003; Anuurad et al., 2010). These 
complications are becoming increasingly relevant as HIV populations on ART are aging 
and becoming treatment experienced (Lo and Plutzky, 2012; Gupta et al., 2012; Bertisch 
et al., 2011). 
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1.6. HIV/AIDS: The South African (SA) Context 
 
 
1.6.1. Introduction 
 
 
Soon after the discovery of HIV, two types of HIV were identified (De Cock et al., 2011; De 
Cock et al., 2012). HIV type-1 (HIV-1; a virus that is thought to have crossed the animal 
(chimpanzees) to human barrier in Western Africa) was identified as the predominant 
cause of the HIV/AIDS epidemic the world and also in SA (De Cock et al., 2011; Sharp 
and Jaffe, 2012; De Cock et al., 2012). HIV type-2 (HIV-2) was identified soon after HIV-1 
(also thought to have originated in Western Africa), but is rarely found outside central 
Africa (De Cock et al., 2011; Sharp and Jaffe, 2012; De Cock et al., 2012). 
 
SA has the largest HIV/AIDS population and Government-sponsored ART roll-out 
programme in the world (Vermund, 2013; Houle et al., 2014; Hontelez et al., 2013). SA is 
furthermore in the midst of epidemiological transition that involves a shift in pattern of 
disease from more prevalent pre-transitional infectious diseases to more affluent NCDs 
such as CVD, due to factors such as economic growth, urbanisation, and westernization 
(Mayosi et al., 2009; Fedele et al., 2011; Beleta et al., 2014). Also, more affluent NCD risk 
factors such as an unhealthy diet that is high in fat and sugar and a sedentary lifestyle are 
becoming more prevalent nationwide (Mayosi et al., 2009; Fedele et al., 2011). 
 
 
 
1.6.2. South Africa’s First-Line ART Fixed Drug Combination (FDC) 
 
 
The SA Government’s new, once daily, first-line ART fixed drug combination (FDC) was 
implemented in April 2013 and prescribed to millions of HIV-infected patients (Southern 
African H. I. V, 2013. It consists of two NRTIs (Emtricitabine (FTC): 200 mg / day; 
Tenofovir disoproxil fumarate (TDF): 300 mg / day) and a NNRTI (Efavirenz (EFV): 600 mg 
/ day) (Southern African H. I. V, 2013; South African Antiretroviral Guidelines, 2015; 
Meintjes et al., 2014). A once daily FDC decreases the burden of patients subjected to a 
multiple tablet regime and improves treatment adherence (Meintjes et al., 2014). HIV- 
positive patients in SA with a CD4+ count of < 500 cells / µl are placed on ART (South 
African Antiretroviral Guidelines, 2015 (available at www.doh.gov.za)). 
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1.6.2.1. Emtricitabine (FTC) 
 
 
FTC (molecular weight: 247.2 g / mol) is a NRTI that is a synthetic nucleoside analogue of 
cytidine (HIV Druginteractions, 2011). Cellular enzymes phosphorylate FTC to FTC-5’- 
triphosphate which in turn competes with the natural substrate, deoxycytidine 5’- 
triphosphate and is subsequently incorporated into the nascent viral DNA and leads to 
chain termination (Arts and Hazuda, 2012; Meintjes et al., 2014; HIV Druginteractions, 
2011). The recommended daily allowance for FTC is 300 mg / day (Meintjes et al., 2014). 
 
 
 
1.6.2.2. Tenofovir Disoproxil Fumarate (TDF) 
 
 
TDF (molecular weight: 287.2 g / mol) is also a NRTI and an acyclic nucleoside 
phosphonate diester analogue of adenosine monophosphate (AMP) and requires initial 
diester hydrolysis to convert to TDF before being phosphorylated by cellular enzymes and 
subsequently converted into TDF diphosphate (Arts and Hazuda, 2012; Palmisano and 
Vella, 2011; Sierra and Walter, 2012).  TDF diphosphate inhibits HIV-1 reverse 
transcriptase through competition with the natural substance deoxyadenosine 5’- 
triphosphate and leads to DNA chain termination after incorporation into the viral-DNA 
(Does et al., 2003; Arts and Hazuda, 2012; Palmisano and Vella, 2011). The 
recommended daily allowance for TDF is 300 mg / day (Meintjes et al., 2014). 
 
 
 
1.6.2.3. Efavirenz (EFV) 
 
 
EFV (molecular weight: 315.7 g / mol) is a NNRTI that is selective for HIV-1 and diffuses 
into the host cell and binds next to the active site of the reverse transcriptase enzyme 
(Palmisano and Vella, 2011; Sierra and Walter, 2012; Meintjes et al., 2014). This binding 
results in a conformational change in the enzyme that inhibits its function (Does et al., 
2003; Arts and Hazuda, 2012; Palmisano and Vella, 2011). It is further a non-competitive 
inhibitor of HIV-1 reverse transcriptase with respect to template, primer or nucleoside 
triphosphates (Does et al., 2003; Arts and Hazuda, 2012). The recommended daily 
allowance for EFV is 300 mg / day administered at night (Meintjes et al., 2014). 
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1.7. Conclusion 
 
 
The emergence of CVD as a major contributor to mortality and morbidity in PLWH appears 
to be multifactorial in nature (Hsue et al., 2004; Fedele et al., 2011; Sudano et al., 2006). 
The HI virus itself contributes to the CVD continuum through its effect on the serum lipid 
profile and direct infection of vascular ECs (Hsue et al., 2004; Fedele et al., 2011; Sudano 
et al., 2006). On the other hand, it is suggested that ART can reduce cardiovascular risk in 
PLWH though suppressing viral replication, but is also associated with cardiovascular risk 
through its many associated metabolic abnormalities such as insulin resistance, diabetes 
mellitus, dyslipidemia, and lipodystrophy (Signorini et al., 2012; Fedele et al., 2011; 
Behrens et al., 2003). Although the mechanism through which ART directly contributes to 
the pathogenesis of CVD is unknown, an increased incidence for CVD events and 
disorders has been found to be associated with certain combinations of drugs and drug- 
classes (Hsue et al., 2004; Sudano et al., 2006; Calza et al., 2008). 
Furthermore, improved longevity and quality of life in PLWH,  due to  the  success  of 
HAART, manifests with increased traditional cardiovascular risk factors similar to those 
seen in the general population (Hsue et al., 2004; Fedele et al., 2011). Obesity  in 
particular is becoming increasingly prominent in HIV-populations, as studies have found 
rates of overweight and obesity to approach or mimic that of the general population 
(Amarosa et al., 2005; Crum-Cianflone et al., 2008; Keithley et al., 2009). Obesity is a well- 
known cardiovascular risk factor and comorbidities such as lipodystrophy, insulin 
resistance, and dyslipidemia are shared with ART (Keithely et al., 2009; Lavie et al., 2009; 
Therchof and Després, 2013). However, the mechanistic interplay between factors 
including obesity, HAART, and theirs risk factor profiles in PLWH is not well understood 
(Crum-Cianflone et al., 2008; Keithley et al., 2009; Lakey et al., 2013). 
 
This interplay between risk factors is of great concern in countries such as SA where 
obesity, HIV/AIDS and ART-use are highly prevalent and on the rise in conjunction with 
epidemiological transition and the emergence of traditional cardiovascular risk factors 
(Norman et al., 2006; Levitt et al., 2011; Mayosi et al., 2009). Taking all these factors in 
consideration, it is of great importance that the cardiovascular effects of SA’s first line ART 
in the context of obesity is investigated as it could potentially affect millions of lives. 
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1.8. Problem Identification and Aims of the Study 
 
 
1.8.1. Problem Identification 
 
 
The SA Government recently introduced a new first line ART FDC (Odimune®) (Southern 
African H. I. V, 2013; South African Antiretroviral Guidelines, 2015; Meintjes et al., 2014). 
Although the precise effects and mechanisms of ART on the cardiovascular system are 
not well understood, many comorbidities are associated with the use of ART and are 
impacting CVD outcomes (Fedele et al., 2011). Increasing numbers of overweight/obesity 
have been reported in HIV-infected populations (Amarosa et al., 2005; Wanke et al., 2000; 
Keithley et al., 2009; Taylor et al., 2014). The complex interplay between HIV, ART, and 
traditional cardiovascular risk factors such as obesity needs further investigation (Fedele et 
al., 2011). 
 
Therefore,  the  overall  aim  of  this  study  was  to  investigate  the  cardiovascular  and 
metabolic effects of the first line FDC used in SA in the context of obesity. 
 
 
 
1.8.2. Main Aim of the Study 
 
 
To investigate the cardiovascular effects of SA’s new first line ART FDC in a rat model of 
obesity: an in vivo and ex vivo approach. 
 
 
 
1.8.3. Specific Aims of the Study 
 
 
a. To induce obesity by feeding a high fat/sucrose diet (HFD) to male Wistar 
rats. 
b. To determine the effects of ART on cardiometabolic parameters in 
obese/lean age matched male Wistar rats. 
c. To determine the effects of ART in isolated hearts from obese and lean age 
matched male Wistar rats subjected to ischaemia-reperfusion injury. 
d. To determine the effects of ART on the expression and phosphorylation of 
important vascular signaling proteins in cardiac tissue from baseline and 
ischemia-reperfusion hearts. 
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Chapter 2 - Materials and Methods 
 
 
2.1. Materials 
 
 AEC Amersham (Buckinghamshire, United Kingdom): Enhanced 
chemiluminescence (ECL) detection reagent, and Horseradish peroxidise-linked 
anti-rabbit immunoglobulin Gene (IgG; Secondary antibody). 
 Afrox Ltd. (Johannesburg, Gauteng, SA): 5 % CO2 / 95 % O2 (To gas the perfusate). 
 Bayer (Pty) Ltd. (Isando, Gauteng, SA): Eutha-naze (Sodium pentobarbitone; 
C11H17N2NaO3) 
 BIO-RAD Inc. (Hercules, California, USA): Chemidoc™  MP Imager System with 
Image Lab™- 5 software. 
 Cell Signaling Technologies (Beverly, Massachusetts, USA): Antibodies for the 
detection of: Total- and phosphorylated eNOS; Total- and phosphorylated PKB/Akt, 
Total- and phosphorylated AMPK; IκBα, and β-Tubulin. 
 Cipla MedPro (Pty) Ltd. (Bellville, Western Cape, SA): Odimune® Tablet (SA’s first- 
line antiretroviral FDC), GlucoPlus™ (Conventional glucose meter). 
 Greiner Bio-One Inc. (Monroe, North Carolina, USA): Cryo tubes. 
 Merck (Pty) Ltd. (Darmstadt, Germany): Sodium chloride (NaCl), Sodium 
bicarbonate (NaHCO3), Potassium chloride (KCl), Potassium dihydrogen phosphate 
(KH2PO4), Magnesium sulphate heptahydrate (MgSO4.7H2O), Sodium Sulfate 
(NaSO4), Calcium chloride dihydrate (CaCl2.2H2O), D(+)-Glucose anhydrous 
(C6H12O16), 2,3,5-Triphenyltetrazolium chloride (TTC; C19H15ClN4), Sodium 
dihydrogen phosphate dehydrate (NaH2PO42H2O), Disodium 
hydrogenorthophosphate (Na2HPO4), Formaldehyde (CH2O), Sodium 
pyrophosphate (Na4O7P2), Acrylamide (C3H5NO), Methanol (CH4O), Glycine 
(NH2CH2COOH), and Tris (hydroxylmethyl aminomethane), Hydrochloric acid (HCl), 
Glycerol (C3H8O3), Polyvinylidene difluoride (PVDF) membrane (Immobilon™-P), 
Enzyme-linked immunosorbent assay (ELISA) kit for rat/mouse insulin (96 well plate 
assay; Cat. EZRMI-13K), Ethanol (C2H6O), phosphoric acid (H3PO4). 
 Roche Diagnostics (Pty) Ltd. (Cape Town, Western Cape, SA): Bovine serum 
albumin (BSA). 
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 Santa Cruz Biotechnologies Inc. (Santa Cruz, California, USA): Antibodies for the 
detection of: NADPH oxidase sub-unit p22 Phox, and Nitrotyrosine. 
 Sigma (St. Louis, MO, USA): Evans blue (C34H24N6Na4O14S4), Phenylmethylsulfonyl 
flouride (PMSF; C7H7FO2S), Ethylenediaminetetraacetic acid (EDTA; C10H16N2O8), 
β-glycerophosphate (C3H7Na2O6P), Sodium orthovanadate (Na3VO4), Sodium 
dodecyl sulfate (SDS; C12H25NaO4S), Triton
® X-100 (C18H28O5), Mercaptoethanol 
(C2H6OS), Ponceau red (C18H14N2Na2O7S2), Ammonium persulfate (APS; 
H8N2O8S2), Commassie brilliant blue (C37H34N2Na2O9S3), Aprotinin 
(C284H432N84O79S7), Leupeptin (C20H38N6O4), Polyethylene glycol sorbitan 
monolaurate (Tween® 20; C58H114O26), and 1,2-Bis(dimethylamino)ethane 
(TEMED), Bromophenol blue (C19H10Br4O5S). 
 Thermo Scientific (Lithuania, European Union): PageRuler Prestained Protein 
Ladder (Molecular marker for Western blot). 
 The Scientific Group (Pty) Ltd. (Milnerton, Western Cape, RSA): SGVac tubes 
(Blood collection tubes for serum, containing clot activator and serum separating 
gel). 
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2.2. Methods 
 
 
2.2.1. Ethics Clearance 
 
 
The study was approved by The Research Ethics Committee: Animal Care and Use of the 
University of Stellenbosch (US; Faculty of Medicine and Health Sciences; Protocol 
Number: SU-ACUM13-00025). The animal handling and care throughout the study 
complied with the accepted standards for the use of animals in research and teaching as 
reflected in the South African National Standards document (SANS 10386: 2008, available 
at www.sun.ac.za/research) of the South African Bureau of Standards (SABS). 
 
 
 
2.2.2. Infrastructure and Expertise 
 
 
The research study was performed at the Division of Medical Physiology, US. All the 
required materials, techniques, facilities, and expertise were established and available for 
the successful completion of this study. There was access to an animal care facility 
(Accredited by the Association for Assessment and Accreditation of Laboratory Animal 
Care), a heart perfusion laboratory, a Western blot laboratory, and appropriate storage 
facilities for all samples. For specialized biochemical analysis, samples were analyzed by 
Dr Blackhurst of the Division of Chemical Pathology at University of Cape Town (UCT). 
 
 
 
2.2.3. Animal Selection and Care 
 
 
Age matched male Wistar rats (Initial weight range: 151 g – 272 g) were used for all 
experimental purposes. The US (Faculty of Medicine and Health Sciences) animal care 
facility on campus provided, housed, and cared for all the animals during the whole study. 
All the animals were housed (Maximum 4 animals / cage) in a properly controlled 
environment (22 °C; 40 % humidity; 12 hour artificial day / night cycle) during the course of 
this study. 
 
The drug suspension and vehicle (water) were administered to the rats via oral gavage 
once daily during the 6-week ART-treatment programme by a qualified staff member (Mr. 
Noël Markgraaff; Manager: Care and Use of Laboratory Animals, SU). The procedure of 
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gavaging involved the insertion of a feeding tube along the roof of the animal’s oral cavity 
towards the animal’s left side and down the animal’s esophagus and into the stomach of 
the animal. The ART-suspension (ART-drug suspended in water) or water (for vehicle 
treated groups) was therefore injected directly in the stomach of the animal. 
 
 
 
2.2.4. Experimental Design, Groups and Sample Sizes (N) 
 
 
Animals were randomly divided into lean control and HFD groups. The lean- and HFD 
groups were further randomly subdivided into antiretroviral treatment (+ART) and vehicle 
treated (-ART) groups. Therefore, the total number of study groups was as follows (Fig. 
2.1): 
 
 A vehicle treated lean control group (C/-ART), 
 A drug treated lean control group (C/+ART), 
 A vehicle treated HFD group (HF/-ART), 
 A drug treated HFD group (HF/+ART). 
 
 
 
 
 
Fig. 2.1. Experimental Study Design and Groups. Abbreviations: N: Sample Size; C: 
Lean Control; HFD: High Fat/Sucrose Diet; +ART: ART Treated; -ART: Vehicle Treated. 
 
A total number of 118 animals (N = 56 Lean control animals + N = 62 HFD animals) 
started the feeding programme. A total number of 28 animals were randomly assigned to 
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Drug Treated 
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each experimental group. An additional HF/+ART group of 6 animals was added to 
compensate for animal-loss due to gavage (Fig. 2.1). 
 
 
 
2.2.5. General Overview of the Study and Methods Used 
 
 
At the start of this randomised control study, animals were randomly assigned to 4 
experimental groups (Section 2.2.4) (Fig. 2.2). The experimental groups were placed on a 
16-week feeding programme (Section 2.2.6) where all the animals followed an ad libitum 
diet (Free access to normal rat chow and water). 
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Randomly 
 
Experimental Groups 
C/#ART 
HF/#ART 
 
Weight Monitoring 
Drug# 
Treatment 
Programme 
 
 
 
 
 
Feeding 
Assigned to 
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Fig. 2.2. General Overview of the Investigations. Abbreviations: IHP: Isolated Heart 
Perfusion; I/R: Ischaemia Reperfusion; WB: Western Blot; IS: Infarct Size; C: Lean 
Control; HFD: High Fat/Sucrose Diet; +ART: Antiretroviral Treated; -ART: Vehicle Treated. 
 
Additionally to the normal rat chow and water, the HFD groups (HF/-ART and HF/+ART) 
received free access to high-calorie food (Section 2.2.7), which aimed to induce obesity 
and insulin resistance. This HFD-induced model of obesity in rats has previously been 
established and characterised in our laboratory (Salie et al., 2014). During the feeding 
programme, the general condition of the animals was monitored daily and TBM recorded 
weekly. 
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Animals were placed on a feeding programme at the age of five to eight weeks (mean 
initial TBM: 199.2 ± 8.18 g), which lasted a total of 16 weeks. The drug-treatment regime 
(Section 2.2.8) commenced at the onset of week 11 of the feeding programme and 
continued for the remaining 6 weeks of the feeding programme. The drug dosage for each 
specific group was calculated (Section 2.2.9) according to the average TBM recorded 
weekly and administered (suspended in water) by means of oral gavage (Section 2.2.8). 
Vehicle-treated groups (C/-ART and HF/-ART) received only water in the same volume as 
drug-treated groups (C/+ART and HF/+ART), also by means of gavage. During the first 31 
days of the drug-treatment programme, the food- and water consumption of all the 
experimental groups were monitored daily (Section 2.2.8). 
 
At the end of the feeding programme, animals were randomly sacrificed by means of 
euthanasia (Section 2.2.11) and biometric measurements (all animals) (Sections 2.2.12 
& 2.2.13) and biochemical samples (fasted animals) (Section 2.2.14) were taken. Glucose 
(directly after anaesthesia) and insulin levels (from stored serum at a later stage) of fasted 
animals were also measured and recorded. Hearts were excised (Section 2.2.12) and 
either snap-frozen and stored in liquid nitrogen for subsequent Western blot analyses 
(Section 2.2.16) or used for isolated heart perfusion experiments (Section 2.2.15). 
Isolated heart perfusion protocols included global ischaemia for functional analysis or 
regional ischaemia for infarct size determination (Section 2.2.15.4). Hearts were also 
snap-frozen after the global isolated heart perfusion protocol for later Western blot 
analysis (Section 2.2.16). 
 
 
 
2.2.6. Feeding Programme 
 
 
At the end of the study, seven staggered groups completed the feeding & drug treatment 
programme (Fig.e 2.3). An additional 8th staggered group consisting of only HFD, drug- 
treated, animals (HF/+ART; N = 6) was added during the course of study. 
 
The randomly assigned animals started the 16-week feeding- and drug treatment 
programme in staggered groups consisting of 16 animals (N = 4 animals / experimental 
group). The staggered groups were separated by at least 2-week intervals to allow 
sufficient time to complete the necessary laboratory procedures that followed the animal 
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sacrifice (biometric measurements, serum collection for biochemical analyses, glucose 
level determinations, and isolated heart perfusion experiments). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3.  Feeding-  and  Drug-Treatment  Programmes.  Abbreviations:  C:   Lean 
Control; HF: High Fat Diet; +ART: Antiretroviral Treated; -ART: Vehicle Treated; TBM: 
Total Body Mass; FDC: Fixed Drug Combination; N: Sample Size. 
 
As mentioned previously, all the animals were individually weighed and monitored for any 
observable changes in their health during the feeding- and drug treatment programme. 
The initial total body mass of each animal was recoded on the day the feeding programme 
commenced (Day 1) and continued to be measured weekly (7-day cycles) until the final 
day of the feeding- and drug treatment programme (Day 112). A final total body mass 
measurement was recorded on the day the animal was sacrificed. 
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2.2.7. Diet and HFD Food Preparation 
 
 
The animals followed an ad libitum diet throughout the feeding programme (112 days), up 
until the day of sacrifice (< 2 weeks following the 16-week feeding programme). The diet 
consisted of standard rat chow and tap water for all the experimental groups. 
The HFD experimental groups (HF/-ART and HF/+ART) had additionally free access to a 
special mixture of HFD food that was prepared and placed separately in each relevant 
cage, and replaced daily. 
 
The HFD was prepared with Holsum™ butter, condensed milk and normal rat chow and 
was high in fat, carbohydrate, and sucrose content compared to normal rat chow (Table 
2.1) (See Appendix A For the method of HFD food preparation and nutritional values of 
Holsum™ butter and condenced milk). 
 
Table 2.1.     Composition of the Normal Rat Chow and HFD (Salie et al., 2014). 
 
 
 Lean Diet (Standard 
Rat Chow) 
High Fat Diet 
Total Fat (g / 100 g) 4.8 11.5 
Saturated Fat (g / 100 g) 0.9 7.6 
Cholesterol (mg / 100 g) 2.2 13 
Protein (%) 17.1 8.3 
Carbohydrate (%) 34.6 42 
Sucrose (%) 5.3 20.4 
 
 
 
2.2.8. Drug Treatment Programme 
 
 
At the beginning of Week 11 of the 16-week feeding programme, drug administration was 
initiated and continued for the remaining 6 weeks alongside the feeding programme (Fig. 
2.3). The drug-treated animals received Odimune®, which is a commercially available 
fixed-dose combination ART drug. Odimune® was obtained on a prescription from a 
pharmacy and contained the active ingredients EFV, FTC, and TDF. 
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The dosage of Odimune® was determined specifically for each treated group of animals 
(HF/+ART and C/+ART) and prepared weekly by calculations based on the weekly 
average TBM (mg / kg) of animals in each respective group (Section 2.2.9). Staff at the 
animal care facility administered the correct drug dosage as a water suspension daily by 
means of oral gavage (see Fig. 2.3). 
 
 
 
2.2.9. Drug Preparation and Dosage Calculations 
 
 
Odimune® was purchased as tablets containing the human recommended daily dose of 
active ingredients (600 mg EFV, 200 mg FTC, and 300 mg TDF) for an average person 
(70 kg). Tablets were grounded to a fine powder, weighed, and the proper mass of powder 
for each respective drug-treated group calculated weekly and weighed according to the 
average total body mass of the group. The appropriate dosage (dose / cage) was adjusted 
weekly according to the respective change in average total body mass of each drug- 
treated group (See Appendix B for Method of Drug Dose Calculation). 
 
 
 
2.2.10. Animal Relocation for Laboratory Procedures 
 
 
After completing the feeding- and drug-treatment programmes, the animals in each 
staggered group were weighed and transferred to the animal care facility of the Division of 
Medical Physiology as needed for experiments and housed temporarily until the day of 
sacrifice (about 2 animals / experimental group = 8 animals / week). This had to be done in 
view of logistical reasons. Care was taken to keep this interim relocation period as short as 
possible (< 1 weeks). During the interim period, the HFD feeding program continued in 
order to avoid metabolic changes (due to a change in diet) until the day of sacrifice. 
 
 
 
2.2.11. Euthanasia 
 
 
The animals were anesthetized (IP injection of 160 mg / kg sodium pentobarbitone in the 
lower right abdomen). Deep anesthesia was confirmed by the disappearance of the pedal 
pain withdrawal reflex and absence of eye reflexes.  Euthanazia was achieved by means 
Stellenbosch University  https://scholar.sun.ac.za
30  
of a clamshell thoracotomy and eventually exuangunation of the heart. After euthanasia, 
biometric measurements were performed (TBM, heart-, liver-, and IP fat mass). 
 
 
 
2.2.12. Biometric Measurements 
 
 
To determine the heart mass, the heart of each animal was quickly excised through a 
clamshell thoracotomy. After the heart was excised, excess tissue was removed from the 
heart and rapidly weighed in a weighing boat on an electronic scale. Finally, the liver and 
all the IP fat (from the abdominal cavity) of each animal were also excised and weighed in 
a weighing boat on an electronic scale. 
 
 
 
2.2.13. Glucose Level Determinations 
 
 
The blood glucose levels of fasted- and non-fasted anesthetized animals were determined 
from blood obtained from a prick of the tail’s dorsal vein with a sharp needle, using a 
commercially purchased glucometer (GlucoPlus™). This was performed while the animal 
was still under deep anesthesia. 
 
 
 
2.2.14. Serum Collection and Analysis 
 
 
One or two animals from each experimental group were randomly fasted overnight (16- to 
24 hours) and serum obtained from blood collected from the thoracic cavity after the heart 
was excised (Section 2.2.12). Serum samples were stored at  -80 °C for subsequent 
analyses of TC-, TG-, HDL cholesterol, conjugated diene (CD)- and Thiobarbuturic Acid 
Reactive Substance (TBARS) levels by Dr Blackhurst of the Division of Chemical 
Pathology at UCT. Insulin levels were determined by means of a commercially available 
ELISA assay kit for rat/mouse insulin levels, purchased from Merck (see Appendix C for 
the principal of the ELISA Assay). 
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2.2.15. Isolated Heart Perfusions 
 
 
2.2.15.1. Pre-Ischaemic Stabilisation on the Isolated Heart Perfusion System 
 
 
After the heart was excised it was immediately placed in ice-cold Krebs-Henseleit buffer to 
arrest and decrease cardiac metabolism until it was mounted onto the perfusion system. 
An ex vivo isolated heart perfusion system with circulating, pre-heated (36.8 °C) Krebs- 
Henseleit buffer (perfusate) that was continuously gassed with 5 % CO2 and 95 % O2 
through a sintered glass oxygenator (to keep the pH at 7.4) was used for all ischaemia- 
reperfusion experiments (Bell et al., 2011). 
All the hearts were normothermically perfused at 36.8 °C with a preload of 15 cm H2O 
hydrostatic pressure and a left ventricle ejection afterload of 100 cm H2O hydrostatic 
pressure. 
 
Hearts were mounted on the isolated heart perfusion system. After aortic cannulation, 
each heart was securely tied and retrogradely perfused in Langendorff mode (non- 
recirculating manner; opposite to normal physiological flow) for the first 15 minutes of the 
30-minutes stabilisation period in order to allow atrial perfusion. During this 15-minute 
period of stabilisation, the left atrium was cannulated and a temperature probe 
(Thermistor) was inserted into the left coronary sinus through a small incision in the right 
ventricular outflow tract of the pulmonary artery. This was done in order to monitor, control, 
and keep the myocardial temperature constant at 36.8 °C throughout the whole 
experimental protocol. Following the initial 15 minutes of stabilisation, the perfusion 
system’s mode was switched to working-heart mode for a further 15 minutes of 
stabilisation. After the full stabilisation period of 30 minutes, each heart was subjected to 
either global- or regional ischaemia-reperfusion protocols (Sections 2.2.15.2 and 
2.2.15.3). 
 
 
 
2.2.15.2. Global Ischaemia-Reperfusion 
 
 
After the period of stabilization (30 minutes), the heart was subjected to global ischaemic 
injury (Zero-flow: Coronary flow (CF) rate = 0 ml / min) for 20 minutes (Fig. 2.4) by the 
cessation of perfusate (Krebs-Henseleit buffer) supply though both the aortic- and the 
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ventricular cannulas and kept at a constant temperature of 36.8 °C. The 20-minute period 
of ischaemia was selected after considering the time it takes for ischaemia to have effect 
on all proteins of interest and as suggested in literature (Bell et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.4. Protocol for Global Ischaemia-Reperfusion. Abbreviations: CF: Coronary 
Flow; AO: Aortic Output; Min: Minutes; PM: Perfusion Mode; WH: Working Heart. 
 
Following global ischaemia, the heart was reperfused for 1 hour (10 minutes retrograded 
perfusion + 20 minutes Working Heart + 30 minutes retrograded perfusion). During each 
time period, haemodynamic data (Section  2.2.15.5) were recorded and the functional 
recovery calculated. 
 
 
 
2.2.15.3. Regional Ischaemia-Reperfusion 
 
 
After the period of stabilization (30 minutes), hearts allocated for regional ischaemia- 
reperfusion studies were subjected to a regional ischaemia injury protocol (Fig. 2.5) by 
ligating the left anterior descending coronary artery of the heart. This was achieved by 
inserting a silk suture underneath and around the proximal left anterior descending 
coronary artery and tightening the ligation in a snare (Fig. 2.6). 
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Fig. 2.5. Protocol for Regional Ischaemia-Reperfusion. Abbreviations: CF: Coronary 
Flow; AO: Aortic Output; Min: Minutes; PM: Perfusion Mode; WH: Working Heart; LCA: 
Left Coronary Artery. 
 
After the initial 30 minutes stabilization (as for global ischaemia; Section 2.2.15.1), the 
isolated heart perfusion system was switched back to retrograded perfusion mode before 
commencing with the regional ischaemia protocol. 
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Fig. 2.6.        The Heart After Regional Ischaemia was Completed. 
 
 
The snare was tightened until the CF was reduced to about 33 % and secured into place. 
Regional ischaemia injury was induced for 35 minutes at 36.8 °C. For the rat heart, 
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be between 30 minutes and 40 minutes (Bell et al., 2011). After 35 minutes of regional 
ischaemia, the snare was loosened and 1-hour reperfusion initiated (as for global 
ischaemia). 
 
During each time period, haemodynamic data were recorded and the functional recovery 
and other parameters calculated (Section 2.2.15.5). 
 
 
 
2.2.15.4. Infarct Size Determination 
 
 
At the end of the regional ischaemia protocol, the silk suture that occluded the coronary 
artery was securely tied in a knot. Evans blue suspension (0,002 g / ml) was infused 
(Approximately 0.6 ml – 1 ml) via the aorta cannula until the correct coloring was 
observed. The heart was removed from the isolated heart perfusion system and stored at - 
10 °C for subsequent infarct size determination. Hearts were cut transversely into 2 mm 
segments and incubated for 30 minutes in the TTC containing buffer solution (20 ml of 100 
mM NaH2PO42H2O, 15.6 g / L distilled water (d.H2O) added to 80 ml of 100 mM Na2HPO4 
14.2 g / L d.H2O; 1 % w / v; pH 7.4 and TTC (0.05 g / heart) to generate a contrast in 
colouring between necrotic-, at-risk-, and viable tissue areas. The TTC solution was 
extracted after 1 hour and the slices of heart tissue fixed in formaldehyde solution (10 % v 
/ v; 5 ml / heart) to halt the colouration process. 
 
 
The heart tissue slices were removed from the formaldehyde solution, compressed 
between two glass plates, and scanned to produce a digital image. The digital image was 
used to determine the size of the left ventricle area at risk (AR; red colored tissue), the 
area of the necrotic infarcted tissue area (unstained, white colored tissue) in the risk zone, 
and the viable tissue area (VA; blue) by means of computerized planimetry (Image Tool: 
University of Texas: Health Science Center at San Antonio, Texas) (Fig. 2.7). Finally, the 
infarct size was expressed as a % of the AR. 
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Infarct Area 
Area at Risk 
 
Viable Area 
 
 
 
 
Fig. 2.7.  Representative example of a Heart Tissue Segment. Colouration: Infarct 
Area (IS): White; Area at Risk (AR): Red; Viable Area (VA): Blue. 
 
 
 
2.2.15.5. Haemodynamic Data for Isolated Heart Perfusions 
 
 
Functional hemodynamic data was recorded both manually and by a computerized system 
(Fig. 2.4 and Fig. 2.6) that was connected via a pressure transducer to the isolated heart 
perfusion system. Manual measurements taken included the CF rate (< 20 ml / min) 
measured each time before the perfusion mode was changed and the aortic flow rate 
(Aortic output; AO; > 34 ml / min) measured at the end of each working heart mode. Total 
cardiac output (CO; ml / min) was calculated as the sum of the CF and the AO. 
 
The computerized system, connected to a pressure transducer (Viggo Spectromed) 
through a side branch of the aortic cannula, was used to record and calculate the intra- 
aortic pressure changes (Peak aortic systolic- and diastolic pressure; mmHg), the heart 
rate (HR) and the stroke volume (SV) ((ml / min) = CO / HR). 
Furthermore, the pressure power (Wp) and kinetic power (Wk) generated by the heart 
muscle were calculated to determine the total work power (Wt) performance generated by 
the heart (Wt = Wp + Wk). The computerized system also calculated the mean external 
power produced by the left ventricle (TW; mWatts) as TW = 0.002222 (PAO-11.25)(CO) 
where PAO = aortic pressure. Finally, the maximum rate of the left ventricular pressure 
rise (dP/dTmax) and fall (dP/dTmin) were also recorded by the computerized system. To 
determine functional recovery after ischaemic injury, post-ischaemic AO was expressed as 
a % of pre-ischaemic AO. 
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2.2.16. Western Blot Analysis 
 
 
2.2.16.1. Proteins of Interest 
 
 
The following proteins of interest were analyzed: 
 
 
Total- and phosphorylated: 
 eNOS (140 kDa) - Endothelial Nitric Oxide Synthase; 
 PKB/Akt (58 kDa) - Protein Kinase B; 
 AMPK (62 kDa) - 5’ Adenosine Monophosphate-activated Protein Kinase. 
 
 
 
Total: 
 Nitrotyrosine (90 kDa); 
 p22 Phox (22 kDa) - NADPH Oxidase; 
 IκBα (55 kDa) - Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B- 
cells Inhibitor, Alpha. 
 
 
 
2.2.16.2. Protein Extraction 
 
 
Frozen cardiac tissue (approximately 30 mg / heart), previously stored in liquid nitrogen, 
was mechanically pulverized and fully homogenized (Polytron PT10 homogenizer; 2 x 5 
seconds) in 800 µl lysis buffer (Table 2.2) on ice. The supernatant containing the whole 
protein content of the samples was obtained by homogenizing the pulverized tissue 
samples in lysis buffer and centrifugation at 15 000 revelutions per minute (RPM’s) for 15 
minutes. 
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Table 2.2. Preparation of Lysis Buffer. Abbreviations: d.H2O: Distilled Water; EDTA: 
Ethylenediaminetetraacetic Acid; SDS: Sodium Dodecyl Sulphate; PMSF: 
Phenylmethylsulfonyl fluoride. 
 
 
Reagent Stock Concentra.on Amount for 30ml 
d.H2O 
 18.45 ml 
Tris1HCl (pH 7.5) 20 nM 3.0 ml 
EDTA 1 nM 300 μl 
NaCl 150 nM 4.5 ml 
β1glycerophosphate 1 nM 0,006 g 
Sodiumpyrophosphate 2.5 nM 0,03 g 
SDS 0.1 % 300 μl 
Na3VO4 1 nM 300 μl 
Triton® X1100 1 % 3 ml 
LeupepQn 10 μg/ml 30 μl 
AproQnin 10 μg/ml 30 μl 
NaF 50 nM 0,0639 g 
PMSF 50 μg/ml 90 μl – Added last 
 
 
 
2.2.16.3. Determination of Protein Sample Concentrations 
 
 
The protein concentration of the samples was determined by the Bradford method 
(Bradford, 1976). Diluted BSA solution (1:5; 100 µl BSA in 400 µl d.H2O) was used to 
prepare protein standards (total volume = 100 µl) in duplicate (0 µl, 5 µl, 10 µl, 20 µl, 40 µl, 
80 µl BSA solution in 100 µl, 95 µl,90 µl, 80 µl, 60 µl, 40 µl, and 20 µl d.H2O respectively). 
Duplicate samples of supernatant were diluted at a 1:10 and assayed at a 1:20 ratio. A 
volume of 900 µl Bradford reagent (500 mg commassie brilliant blue, 250 ml 95 % ethanol, 
500 ml phosphoric acid; 1:5 dilution; 20 ml Bradford reagent in 80 ml d.H2O) was filtered 
(X 2) and added to each duplicate protein standard and samples and left for 15 minutes to 
allow the colour development to take place. Spectrophotometry (optical density = 595 nm) 
was used to determine the respective absorbance values and a standard curve was 
plotted (Absorbance vs. protein concentration). 
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2.2.16.4. Preparation of the Lysates 
 
 
Lysates were prepared by adding the respective amounts of the protein sample 
(determined by Bradford assay), sample buffer (2.5 mM Tris-HCl (pH 6.8); 25 % glycerol, 2 
% SDS, 0.01 % bromophenol blue) and lysis buffer, boiled for 5 minutes (to allow for 
denaturation of proteins) and stored at -80 °C until further use. 
 
 
 
2.2.16.5. Protein Loading and Separation 
 
 
The previously stored (-80 °C) lysates were boiled again for 5 minutes, centrifuged and 
loaded onto a polyacrylamide gel. Proteins were separated using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE; 12 % loading gel: PKB/Akt, IκBα, p22 
Phox, and AMPK; 7.5 % gel: eNOS, Nitrotyrosine) (Table 2.3). 
 
Table 2.3. Preparation of the Loading Gel. Abbreviations: d.H2O: Distilled Water; SDS: 
Sodium Dodecyl Sulphate; APS: Ammonium Persulfate; TEMED: 1,2- 
Bis(dimethylamino)ethane. 
 
Reagent Stock 
Concentra.on 
7.5 % Running 
Gel 
12 % Running 
Gel 
d.H2O (Millipore) 
 5.525 ml 4.4 ml 
Tris5HCL (pH 8.8) 1.5 M 2.5 ml 2.5 ml 
SDS 10 % 100 μl 100 μl 
Acrylamide 40 % 1.875 ml 3.0 ml 
APS 10 % 50 μl 50 μl 
TEMED 99 % 20 μl 20 μl 
 
 
 
The samples were subsequently loaded into wells created in the stacking gel (4% gel 
loaded on top of the loading gel) (Table 2.4). 
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Table 2.4. Preparation of the Stacking  Gel.  Abbreviations:  d.H2O:  Distilled  Water; 
SDS: Sodium Dodecyl Sulphate; APS: Ammonium Persulfate; TEMED: 1,2- 
Bis(dimethylamino)ethane. 
 
 
Reagent Stock 
Concentra.on 
4 % Cas.ng Gel 
d.H2O (Millipore) 
 3.05 ml 
Tris6HCL (pH 6.8) 0.5 M 1.25 ml 
SDS 10 % 50 μl 
Acrylamide 40 % 500 μl 
APS 10 % 50 μl 
TEMED 99 % 10 μl 
 
A molecular marker was loaded into the first well to locate the position of each protein after 
protein separation. A volume of 12 µl of each lysate sample (30 µg of protein) was loaded 
into each well consecutively and proteins separated according to their molecular weights 
during further electrophoresis in a running buffer (250 mM Tris, 192 mM glycine, and 1 % 
SDS) added to the protein separation system. 
 
 
 
2.2.16.6. Protein Transfer 
 
 
The separated proteins were transferred onto PVDF membrane in transfer buffer (25 mM 
Tris-HCl, 192 mM glycine, and methanol (20 % v / v)) for 1 hour. The Ponceau staining 
technique was used to visually assess proper protein transfer and equal loading. The 
Ponceau red stain was washed off with TBS-tween (Tris-buffered saline and 0.1  % 
Tween® 20) before visualizing. 
 
 
2.2.16.7. Immunoblotting 
 
 
Fat free powdered milk (5 %) dissolved in TBS-tween was used to block non-specific 
binding sites on all the membranes. After the membranes were thoroughly washed with 
TBS-Tween, they were incubated overnight at 4 ⁰C in a polyclonal primary antibody 
solution   (a   1:1000   dilution   in   TBS-Tween   for   all   antibodies),   specific   to   each 
phosphorylated- and/or total protein. Following the overnight incubation, the membranes 
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were thoroughly washed in TBS-Tween to remove non-immobilized primary antibody. 
Immobilized primary antibody was then conjugated with secondary antibody (Horseradish 
peroxidase-conjugated anti-rabbit) diluted in TBS-Tween (1:4000 dilution) for 1 hour at 
room temperature, followed by another thorough wash with TBS-Tween. 
 
 
 
2.2.16.8. Protein Detection and Quantification 
 
 
The proteins were detected by covering the membranes with ECL detection reagent. In the 
first set of Western blot analysis the light emitting from the luminescence was captured on 
medical x-ray film and the image analysed by densitometry. Where necessary, β-tubulin 
was used as a control for equal protein loading. The Western blot analyses of hearts after 
a global ischaemic insult were performed by utilizing the Chemidoc™  MP Imager System 
with Image Lab™- 5 software. Values were obtained and normalized to the corresponding 
controls for equal protein loading. 
 
 
 
2.3. Statistical Analysis 
 
GraphPad Prism® (version 6) was used for all statistical analysis. A student’s t-test was 
used for comparison of two variables. A one- or two-way analysis of variance (ANOVA) 
with Bonferroni post hoc correction was used for more the comparison of more than two 
variables. Values were expressed as the mean ± standard error of the mean (SEM). 
Statistical significance was set at a p-value < 0.05. 
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Chapter 3 – Results 
 
 
 
 
3.1. Introduction 
 
 
This chapter describes the data from the food and water monitoring, biometric 
measurements (TBM, IP fat mass, heart mass, liver mass), serum biochemical analyses 
from fasted animals (glucose, insulin, TC, HDL cholesterol, TG, CD, and TBARS levels), 
isolated heart perfusion experiments (functional recovery and infarct size) and protein 
signalling in cardiac tissue: Western blot analysis of important signalling proteins in the 
NOS, ROS and inflammatory protein signalling cascade (baseline and after ischaemia- 
reperfusion) (Fig. 3.1). 
 
 
 
 
Fig. 3.1. Chapter 3: Results Outline. Abbreviations: TBM: Total Body Mass; IP: Intra- 
Peritoneal; HDL: High Density Lipoproteins. 
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3.2. Food and Water Monitoring During the First Month of the 
Drug Treatment Programme 
 
3.2.1. Rat Chow Consumption 
 
 
The normal rat chow consumption (g / animal / day) remained constant for all the groups 
during the first 31 days of drug administration. The untreated and treated lean, control 
groups consumed more rat chow compared to their respective HFD counterparts. There 
were no differences between the untreated vs. treated lean, control and HFD groups 
respectively (Fig. 3.2; See Appendix D for Food and Water Monitoring). 
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Fig. 3.2. Mean Rat Chow Consumption / Animal (g / animal / day) (data expressed as 
mean ± SEM / group). C/-ART: 21.05 ± 0.23 g / animal / day; HF/-ART: 0.95 ± 0.11 g / 
animal / day; C/+ART): 20.27 ± 0.53 g / animal / day; HF/+ART: 1.10 ± 0.11 g / animal / 
day. N = 20 / group. 
 
 
 
3.2.2. Water Consumption 
 
 
The water consumption (ml / animal / day) also remained constant for all the groups during 
the first 31 days of drug administration. The untreated and treated lean, control groups 
consumed more water on a daily basis compared to their respective HFD counterparts. 
There were no differences between the untreated vs. treated lean, control and HFD 
groups respectively (Fig. 3.3). 
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Fig. 3.3. Mean Water Consumption / Animal (ml /animal /day) (data expressed as 
mean ± SEM / group). C/-ART: 29.43 ± 0.56 ml / animal / day; HF/-ART: 16.25 ± 0.53 ml / 
animal / day; C/+ART: 27.66 ± 0.47 ml / animal / day and HF/+ART: 17.14 ± 0.65 ml 
/animal / day. N = 20/ group. 
 
 
 
3.2.3. High Fat Diet (HFD) Consumption 
 
The HFD groups (HF/-ART and HF/+ART) consumed the same amount (g / animal / day) 
of HFD food per animal daily, during the first 31 days of the drug treatment programme 
(Fig. 3.4). 
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Fig. 3.4. Mean High Fat Food Consumption / Animal (g/animal/day) (data expressed 
as mean ± SEM / group). HF/-ART: 34.24 ± 0.53 g / animal / day and HF/+ART: 33.14 ± 
0.51 g / animal / day. N = 20 / group. 
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3.3. Biometric Measurements During and After the Feeding and 
Drug Treatment Programme 
 
Biometric measurements (TBM, IP fat mass, heart mass and liver mass) were recorded 
during the feeding and drug treatment programme and on the day the animals were 
sacrificed. 
 
 
 
3.3.1. Total Body Mass (TBM) 
 
 
3.3.1.1. Changes  in  Total  Body  Mass  (TBM)  During  the  Feeding  and  Drug 
Treatment Programme 
 
The TMB (g) of the animals of all groups at the commencement of the feeding and drug 
treatment programme ranged between 151 g and 272 g. There were no differences in the 
initial mean TBM (g) / group (C/-ART, HF/-ART, C/+ART, HF/+ART) at the start of the 
feeding programme (Fig. 3.5). 
 
 
300 
Initial Mean Total Body Mass / Group (g) 
 
 
200 
 
 
100 
 
 
 
 
 
 
 
Groups 
 
■ Lean 
■ HFD 
 
 
Fig. 3.5. Mean TBM / Group (g on Day 1 of the Feeding and  Drug  Treatment 
Programme (data expressed as mean TBM ± SEM / group). C/-ART: 199.20 ± 8.18 g; HF/- 
ART: 202.00 ± 7.70 g; C/+ART: 196.20 ± 8.36 g; HF/+ART: 207.40 ± 8.16 g. N = 20 / 
group. 
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# 
** 
The mean TBM of all groups increased during the 16-week feeding and drug treatment 
programme. The C/-ART group had a 99.50 % higher final mean TBM compared to the 
initial mean TBM; The HF/-ART group had a 116.14 % higher mean TBM compared to the 
initial mean TBM; The C/+ART group had a 104.08 % higher final mean TBM compared to 
initial mean TBM and the HF/+ART had a 112.49 % higher mean TBM compared to the 
initial mean TBM (Fig. 3.6). 
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Fig. 3.6. Weekly Change in the Mean TBM / Group (g) (data expressed as mean TBM 
± SEM / group, p < 0.05). 
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At the end of the 16-week feeding and drug treatment programme, the mean TBM of the 
HF/-ART and HF/+ART groups was 39.13 g, and 40.25 g higher compared to their 
respective age-matched lean, control groups (vs. C/-ART: 9.86 %; p = 0408 and vs. 
C/+ART: 10.06 %; p = 0382). The ART drug treatment per se had no additional effects on 
the mean TBM in the lean, control and HFD groups compared to their respective untreated 
control groups (C/-ART vs. C/+ART; and HFD/-ART vs. HF/+ART) (Fig. 3.7). 
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Fig. 3.7. Mean TBM / Group (g) on the Last Day of the Feeding and Drug Treatment 
Programme (data expressed as mean TBM ± SEM / group). C/-ART: 397.40 ± 10.53 g; 
HF/-ART: 436.60 ± 10.68 g; C/+ART: 400.40 ± 9.24 g and HF/+ART: 440.70 ± 11.66 g. N 
= 25 – 28 / group. 
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3.3.1.2. Mean Total Body Mass (TBM) / Group on the Day of Sacrifice 
 
 
On the day of sacrifice, the mean TBM (g) was 43.63 g higher in the HF/-ART compared to 
the C/-ART group (11.25 %; p = 0.0157), and 41.88 g higher in the HF/+ART compared to 
the C/+ART group (9.56 %; p = 0.026). There were no differences between the untreated 
lean, control (C/-ART vs. C/+ART) and HFD (HFD/-ART vs. HFD/+ART) groups 
respectively (Fig. 3.8). 
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Fig. 3.8. Mean TBM / Group (g) on the Day of Sacrifice (data expressed as mean ± 
SEM / group). C/-ART (N = 28): 387.90 ± 9.81 g; HF/-ART (N = 25): 431.60 ± 10.70 g; 
C/+ART (N = 24): 396.00 ± 9.72 g and HF/+ART (N = 27): 437.90 ± 11.63 g. N = 24 – 28 / 
group. 
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3.3.2. Intra-Peritoneal (IP) Fat Mass 
 
 
The mean IP fat mass / group (expressed as a % of TBM) was 61.24 % higher in the HF/- 
ART group compared to the C/-ART group (p < 0.0001), and 90.98 % higher in the 
HF/+ART compared to the C/+ART group (p < 0.0001). There were no differences 
between lean, control (C-/ART vs. C/+ART) and the HFD (HF/-ART vs. HF/+ART) groups 
(Fig. 3.9). 
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Fig. 3.9. Mean IP Fat Mass / Group (% of TBM) (data expressed as mean ± SEM / 
group). C/-ART: 3.61 ± 0.24 %; HF/-ART: 5.82 ± 0.29 %; C/+ART: 3.09 ± 0.25 % and 
HF/+ART: 5.91 ± 0.34 %. N = 24 – 26 / group. 
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3.3.3. Heart Mass 
 
 
The actual mean heart mass (g) of the HF/-ART group was 0.17 g higher compared to the 
C/-ART group (10.32 %; p < 0.0360) (Fig. 3.10 A). The mean heart mass / group 
(expressed as % of TBM) showed no differences between any of the groups (Fig. 3.10 B). 
No other differences between any groups were observed. 
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Fig. 3.10. Heart Mass / Group (% of TBM (A) and g (B)) (data expressed as mean ± 
SEM / group). % of TBM: C/-ART: 0.40 ± 0.01 %; HF/-ART: 0.39 ± 0.01 %; C/+ART: 0.40 
± 0.019 % and HF/+ART: 0.39 ± 0.01 %. Heart mass in g: C/-ART: 1.55 ± 0.04 g; HF/- 
ART: 1.71 ± 0.06 g; C/+ART: 1.58 ± 0.06 g and HF/+ART: 1.64 ± 0.06 g. N = 9 – 11 / 
group. 
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3.3.4. Liver Mass 
 
 
The mean liver mass / group (expressed as a % of TBM) was significantly higher in the 
HF/+ART group vs. HF/-ART: 0.32 % (10.92 % increase; p = 0.0125). No further 
differences were observed in any of the groups (Fig. 3.11). There were also no differences 
in the actual liver mass / group (g) between any of the groups. 
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Fig. 3.11. Mean Liver Mass / Group (% of TBM) (data expressed as mean ± SEM / 
group). C/-ART: 3.13 ± 0.58 %; HF/-ART: 2.93 ± 0.64 %; C/+ART: 3.31 ± 0.08 % and 
HF/+ART: 3.25 ± 0.09 %. N = 24 – 28 / group. 
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3.4. Biochemical  Analyses  –  Glucose,  Insulin  and  Lipid  Level 
Determination. 
 
3.4.1. Glucose Levels 
 
 
There were no differences in the mean glucose levels / group between any of the groups. 
(Fig. 3.12). 
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Fig. 3.12. Mean Fasted Glucose Levels / Group (mmol / L) (data expressed as mean ± 
SEM / group). C/-ART: 6.67 ± 0.55 mmol / L; HF/-ART: 5.82 ± 0.38 mmol / L; C/+ART: 
8.92 ± 0.57 mmol / L and HF/+ART: 6.88 ± 0.70 mmol / L. N = 5 – 6 / group. 
Mean Fasted Glucose Levels 
M
e
a
n
 F
a
s
te
d
 G
lu
c
o
s
e
 
L
e
v
e
l 
(m
m
o
l 
/ 
L
) 
Stellenbosch University  https://scholar.sun.ac.za
52  
 
3.4.2. Insulin Levels 
 
 
Mean fasting insulin levels were significantly lower in the C/+ART group compared to other 
groups (vs. C-ART: 270.63 %; p = 0.0204; vs. HF/+ART: 359.11 %; p = 0.045) (Fig. 3.13). 
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Fig. 3.13. Mean The Insulin Levels / Group (ng / ml) (data expressed as mean ± SEM / 
group). C/-ART: 9.34 ± 2.22 ng / ml; HF/-ART: 9.26 ± 2.24 ng / ml; C/+ART: 2.52 ± 0.80 ng 
/ ml and HF/+ART: 10.33 ± 2.96 ng / ml. N = 5 – 6 / grou 
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3.4.3. Lipid Profile 
 
 
3.4.3.1. Total Cholesterol (TC) Levels 
 
 
Mean fasting TC levels / group (mmol / L) were 45.79 % lower in the HF/+ART compared 
to C/+ART (p = 0.0134). No further differences were observed between any of the groups 
(Fig. 3.14). 
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Fig. 3.14. Mean Total Cholesterol Levels / Group (mmol / L) (data expressed as mean 
± SEM / group). C/-ART: 1.18 ± 0.16 mmol / L; HF/-ART: 1.11 ± 0.067 mmol / L; C/+ART: 
1.56 ± 0.14 mmol / L and HF/+ART: 1.07 ± 0.07 mmol / L. N = 4 – 6 / group. 
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3.4.3.2. High Density Lipoprotein (HDL) Cholesterol Levels 
 
 
The mean HDL cholesterol levels (mmol / L) did not differ between any of the groups (Fig. 
3.15). 
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Fig. 3.15. Mean HDL Cholesterol Levels / Group (mmol / L) (data expressed as mean ± 
SEM / group). C/-ART (N = 5): 0.65 ± 0.049 mmol / L; HF/-ART (N = 5): 0.73 ± 0.05 mmol / 
L; C/+ART (N = 5): 0.58 ± 0.05 mmol / L and HF/+ART (N = 6): 0.65 ± 0.08 mmol / L. N = 
5 – 6 / group. 
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3.4.3.3. Triglyceride (TG) Levels 
 
 
The mean TG levels / group were 85.00 % higher in the HF/-ART group compared to the 
C/-ART group (p = 0.0338), and 36.36 % higher in the HF/+ART group compared to the 
C/+ART group (p = 0.0395) (Fig. 3.16). 
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Fig. 3.16. Mean TG Levels / Group (mmol / L) (data expressed as mean ± SEM / 
group). C/-ART (N = 4): 0.20 ± 0.04 mmol / L; HF/-ART (N = 5): 0.37 ± 0.061 mmol / L; 
C/+ART (N = 5): 0.22 ± 0.02 mmol / L and HF/+ART (N = 6): 0.30 ± 0.02 mmol / L. N = 5 – 
6 / group. 
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3.4.4. Indicators of Lipid Peroxidation and Oxidative Stress 
 
 
TBARS and CD levels were chosen to assess lipid peroxidation and oxidative stress as 
they have been implicated in the potential pathways, linking oxidation status to the 
pathophysiological pathways that leads to CVD. TBARS in particular have been linked to 
represent a composite number of oxidative damage products such as malondialdehyde 
and has also been associated with the progression of carotid atherosclerosis (Trevisan et 
al. 2001). 
 
3.4.4.1. Conjugated Diene (CD) Levels 
 
 
The CD level was 18.1 mmol / L lower in the in the HF/+ART group compared tot the HF/- 
ART group (p = 0.0293). There were no further differences observed in the mean CD 
levels (mmol / L) between any of the other groups (Fig. 3.17). 
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Fig. 3.17. Mean CD Levels / Group (mmol / L) (data expressed as mean ± SEM / 
group). C/-ART: 119.50 ± 4.74 mmol / L; HF/-ART: 136.00 ± 7.76 mmol / L; C/+ART: 
133.60 ± 15.48 mmol / L and HF/+ART: 117.90 ± 2.71 mmol / L. N = 5 – 6 / group. 
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3.4.4.2. Thiobarbituric Acid Reactive Substance (TBARS) Levels 
 
 
The mean TBARS levels / group (µmol / L) were 15.19 % higher in the HF/-ART group (p = 
0.024), and 23.09 % higher in the C/+ART group compared to the untreated, lean, control 
(C/-ART) group (p = 0.024). No further differences were observed (Fig. 3.18). 
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Fig. 3.18. Mean TBARS Levels / Group (µmol/L) (data expressed as mean ± SEM / 
group). C/-ART: 20.01 ± 0.71 µmol / L; HF/-ART: 23.05 ± 0.90 µmol / L; C/+ART: 24.63 ± 
1.15 µmol / L and HF/+ART: 22.35 ± 2.38 µmol / L. N = 4 – 6 / group. 
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3.5. Isolated Heart Perfusions 
 
All hearts were perfused on the Langendorff retrograded perfusion system to determine 
functional recovery after a global ischaemia-reperfusion insult and infarct size after a 
regional ischaemia-reperfusion insult. 
 
 
 
3.5.1. Global Ischaemia-Reperfusion 
 
 
3.5.1.1. Functional Recovery after Global Ischaemia-Reperfusion 
 
 
In order to assess functional recovery after a global ischaemia-reperfusion insult, six 
endpoints were measured before and after the global ischaemia-reperfusion insult, 
namely: heart rate (beats / min), CF (ml / min), AO (ml / min), total CO (ml / min), peak 
systolic pressure (PSP; mmHg) and total power (mW). These endpoints were measured 
after 30 minutes of stabilization (15 minutes of retrograde perfusion + 15 minutes of 
working heart perfusion) prior to ischaemia (pre-ischaemia-reperfusion; baseline) and at 
the end of the ischaemia-reperfusion protocol (post-ischaemia-reperfusion). Post- 
ischaemia-reperfusion values were compared to pre-ischaemia-reperfusion, baseline 
values to determine functional recovery and expressed as a percentage of the pre- 
ischaemia values (% recovery). As the pre-ischaemic protocol for both global and regional 
ischaemia-reperfusion was the same, these two sample groups were grouped together to 
yield a larger sample size. The results for global ischaemia-reperfusion are summarised in 
Table 3.1 (See Appendix D for Other Haemodynamic Data for Global Ischaemia- 
Reperfusion). 
Stellenbosch University  https://scholar.sun.ac.za
59  
Table 3.1. Summary of Haemodynamic Data  – Global Ischaemia-Reperfusion (data 
expressed as mean ± SEM / group (% Recovery)). Abbreviations: HR: Heart Rate; AO: 
Aortic Output; CF: Coronary Flow; CO: Total Cardiac Output; PSP: Peak Systolic 
Pressure; Wt: Total Power; Pre: Pre-ischaemia-reperfusion; Post: Post-Ischaemia- 
reperfusion. Pre-Ischaemia vs. Post-Ischaemia: * = p < 0.05; ** = p < 0.01; *** = p < 
0.001; **** = p < 0.0001. 
 
 
Haemodynamic Data 
Pre$Ischaemia vs. Post$Ischaemia 
Mean ± SEM 
(% Recovery) 
C/:ART 
(Pre: N = 16; Post: N = 6) 
HF/:ART 
(Pre: N = 14; Post: N = 6) 
C/+ART 
(Pre: N = 11; Post: N = 4) 
HF/+ART 
(Pre: N = 13; Post: N = 6) 
HR 
(BPM) 
Pre 224.80 ± 12.67 234.80 ± 8.72 245.90 ± 6.18 259.40 ± 17.47 
Post 205.80 ± 41.72 105.30 ± 50.13 *** 210.00 ± 23.82 201.50 ± 45.35 
% Recovery 78.87 % 44.02 % 82.94 % 77.78 % 
AO 
(ml / min) 
Pre 42.09 ± 1.51 41.21 ± 1.48 42.36 ± 1.87 38.46 ± 1.57 
Post 16.58 ± 5.34 **** 7.08 ± 5.27 **** 14.50 ± 5.85 **** 7.16 ± 4.83 **** 
% Recovery 39.34 % 16.99 % 32.12 % 19.16 % 
CF 
(ml / min) 
Pre 14.13 ± 0.74 14.11 ± 0.51 15.36 ± 0.74 16.08 ± 1.13 
Post 10.75 ± 2.17 6.25 ± 2.58 *** 15.75 ± 4.08 10.75 ± 2.40 * 
% Recovery 76.48 % 44.12 % 93.86 % 68.16 % 
CO 
(ml / min) 
Pre 56.22 ± 1.84 55.32 ± 1.73 57.91 ± 1.81 54.54 ± 2.41 
Post 27.33 ± 7.00 **** 13.33 ± 7.56 **** 30.25 ± 9.84 *** 17.92 ± 6.10 **** 
% Recovery 48.55 % 23.28 % 48.92 % 32.59 % 
PSP 
(mmHG) 
Pre 105.10 ± 1.57 100.80 ± 2.05 101.70 ± 1.69 99.15 ± 2.03 
Post 83.32 ± 16.79 41.00 ± 19.17 **** 86.0 ± 8.37 66.83 ± 16.79 * 
% Recovery 77.80 % 40.94 % 82.94 % 64.44 % 
Wt 
(mW) 
Pre 13.24 ± 0.52 12.35 ± 0.43 13.24 ± 0.53 12.24 ± 0.61 
Post 6.08 ± 1.58 **** 2.44 ± 1.68 **** 6.37 ± 2.28 *** 3.56 ± 1.41 **** 
% Recovery 44.90 % 19.45 % 44.21 % 27.07 % 
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3.5.1.1.1. Heart Rate (HR) 
 
 
There were also no differences in the mean % recovery of HR between any of the groups 
(Fig. 3.19). 
 
 
Mean % Recovery: Heart Rate 
 
1 
 
 
1 
 
 
5 
 
 
 
 
 
 
 
Groups 
 
 
 
Fig. 3.19.   Mean HR % Recovery After Global Ischaemia-Reperfusion (data expressed 
as mean ± SEM / group). C/-ART: 87.87 ± 16.11 %; HF/-ART: 44.02 ± 21.33 %; C/+ART: 
82.94 ± 8.93 %; HF/+ART: 77.48 ± 18.40 %. N = 4 – 6 / group. 
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3.5.1.1.2. Aortic Output (AO) 
 
 
There were no differences in the mean % recovery of AO between any of the groups (Fig. 
3.20). 
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Fig. 3.20.   Mean OA % Recovery After Global Ischaemia-Reperfusion (data expressed 
as mean ± SEM / group). C/-ART: 39.34 ± 12.64 %; HF/-ART: 16.19 ± 11.99 %; C/+ART: 
32.12 ± 12.08 %; HF/+ART: 19.16 ± 13.71 %. N = 4 – 6 / group. 
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3.5.1.1.3. Coronary Flow (CF) 
 
 
There were no differences in the mean % recovery of CF between any of the groups (Fig. 
3.21). 
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Fig. 3.21.   Mean CF % Recovery After Global Ischaemia-Reperfusion (data expressed 
as mean ± SEM / group). C/-ART: 76.48 ± 15.39 %; HF/-ART: 44.12 ± 17.44 %; C/+ART: 
93.86 ± 20.93 %; HF/+ART: 68.16 ± 17.48 %. N = 4 – 6 / group 
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3.5.1.1.4. Cardiac Output (CO) 
 
 
There were no differences in the mean % recovery of CO between any of the groups (Fig. 
3.22). 
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Fig. 3.22.   Mean CO % Recovery After Global Ischaemia-Reperfusion (data expressed 
as mean ± SEM / group). C/-ART: 48.55 ± 12.21 %; HF/-ART: 23.28 ± 12.75 %; C/+ART: 
48.92 ± 14.39 %; HF/+ART: 32.59 ± 12.91 %. N = 4 – 6 / group. 
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3.5.1.1.5. Peak Systolic Pressure (PSP) 
 
 
There were no differences in the mean % recovery of PSP between any of the groups 
(Fig. 3.23). 
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Fig. 3.23.   Mean PSP % Recovery After Global Ischaemia-Reperfusion (data expressed 
as mean ± SEM / group). C/-ART: 77.80 ± 15.70 %; HF/-ART: 40.94 ± 18.99 %; C/+ART: 
82.94 ± 8.93 %; HF/+ART: 64.44 ± 16.12 %. N = 4 – 6 / group. 
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3.5.1.1.6. Total Power (Wt) 
 
 
There were no differences in the % recovery Wt between any of the groups (Fig. 3.24). 
 
 
 
 
100 
Mean % Recovery: Total 
Power 
 
80 
 
60 
 
40 
 
20 
 
0 
 
 
 
Groups ■ Lean 
■ HFD 
 
 
 
Fig. 3.24.   Mean Wt % Recovery After Global Ischaemia-Reperfusion (data expressed 
as mean ± SEM / group). C/-ART: 44.90 ± 11.17 %; HF/-ART: 19.45 ± 13.04 %; C/+ART: 
44.21 ± 14.22 %; HF/+ART: 27.07 ± 12.00 %. N = 4 – 6 / group. 
 
 
 
3.5.2. Regional Ischaemia-Reperfusion 
 
 
The infarct size (expressed as a % of the AR) was determined after a regional ischaemic 
insult of 35 minutes. At the end of the stabilisation period of 30 minutes the heart was 
ligated for the 35-minute regional ischaemic insult and subsequently allowed to reperfuse 
for 1 hour by loosening the ligation (see chapter 2, section 2.2.15.3). After the full regional 
ischaemia-reperfusion protocol hearts were stained and infarct size determined as 
discussed in detail in chapter 2 (section 2.2.15.4). 
See Appendix F for Haemoadynaoic Data for Regional Ischaemia-Reperfusion) 
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3.5.2.1. Infarct Size Determination 
 
 
The mean VA was constant for all groups (between 40 % and 60 %) (Fig. 3.25). 
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Fig. 3.25. Mean Viable Area / Group (expressed as % of total area) After Regional 
Ischaemia-Reperfusion (data expressed as mean ± SEM / group). C/-ART: 51.03 ± 3.10 
%; HF/-ART: 50.60 ± 2.46 %; C/+ART: 51.25 ± 3.44 %; HF/+ART: 51.18 ± 5.39 %. N = 4-8 
/ group. N = 4 – 8 / group. 
 
 
The mean AR was also similar between all groups (between 40 % and 60 %) (Fig. 3.26). 
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Fig. 3.26. Mean Area at Risk / Group (including Infarct Size) (expressed as % of total 
area) After Regional Ischaemia-Reperfusion (data expressed as mean ± SEM / group). C/- 
ART: 48.97 ± 3.10 %; HF/-ART: 49.40 ± 2.47 %; C/+ART: 48.75 ± 3.44 %; HF/+ART: 
48.83 ± 5.39 %. N = 4 – 8 / group. 
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The mean infarct size was 18.3 % lower in the HF/-ART group compared to C/-ART (p = 
0.0025), and 20 % lower in the HF/+ART group compared to HF/-ART (p = 0.0065). No 
further differences were observed (Fig. 3.27). 
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Fig. 3.27. Mean Infarct Size (expressed as a % of AR and Infarct Size Combined) After 
Regional Ischaemia-Reperfusion (data expressed as mean ± SEM / group). C/-ART: 18.26 
± 1.66 %; HF/-ART: HF/-ART: 35.40 ± 4.95 %; C/+ART: 19.91 ± 1.30 %; HF/+ART: 19.95 
± 2.70 %. N = 4 – 8 / group. 
 
 
 
3.6. Biochemical Analysis – Western Blot Analysis 
 
 
For pre-ischaemia-reperfusion (baseline) measurements, hearts of fasted animals were 
excised, weighed and snap-frozen in liquid nitrogen for subsequent Western blot analyses, 
whilst for the post-ischaemia-reperfusion measurements, hearts were snap-frozen at the 
end of the global ischaemia/perfusion protocol for subsequent Western blot analyses. 
 
The proteins analysed for both pre-ischaemia-reperfusion and post-ischaemia-reperfusion 
included: 
 NOS signalling: Total- and phosphorylated eNOS, total- and phosphorylated 
PKB/Akt and total- and phosphorylated AMPK 
 ROS signalling: Total nitrotyrosine and total p22 Phox 
 Inflammatory signalling: Total IκBα 
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3.6.1. Nitric Oxide Synthase (NOS) Signalling 
 
 
3.6.1.1. Endothelial Nitric Oxide Synthase (eNOS) 
 
 
3.6.1.1.1. eNOS: Pre-ischaemia-Reperfusion 
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Fig. 3.28 A- C.      eNOS: Pre-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART 
(= 1) (data expressed as mean ± SEM / group). A. Total eNOS: C/-ART: 1.00; HF/-ART: 
0.85 ± 0.10; C/+ART: 0.64 ± 0.14 and HF/+ART: 0.58 ± 0.04. B. Phosphorylated eNOS: 
C/-ART: 1.00; HF/-ART: 0.89 ± 0.03; C/+ART: 0.90 ± 0.18 and HF/+ART: 0.68 ± 0.03. C. 
Phosphorylated/Total eNOS Ratio: C/-ART: 1.00; HF/-ART: 1.07 ± 0.10; C/+ART: 1.42 ± 
0.06 and HF/+ART: 1.18 ± 0.05. N = 3 - 4 / group. 
 
Total eNOS expression was 36 % lower in the C/+ART compared to C/-ART group (p = 
0.0412) and 58 % in the HF/+ART compared to HF/-ART group (p = 0.0184) (Fig. 3.28 A). 
Phosphorylated eNOS decreased 11 % in the HF/-ART compared to C/-ART group (p = 
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0.0234) and 21 % in the HF/+ART compared to HF/-ART group (p = 0.0035) (Fig. 3.28 B). 
The phosphorylated/total ratio of eNOS was 42 % greater in the C/+ART compared to C/- 
ART group (p = 0.0012), and 17 % lower in the HF/+ART compared to the C/+ART group 
(p = 0.0118) (Fig. 3.28 C). No further differences were observed. 
 
 
 
3.6.1.1.2. eNOS: Post-Ischaemia-Reperfusion 
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Fig. 3.29 A - C.     eNOS: Post-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART 
(= 1) (data expressed as mean ± SEM / group). A. Total eNOS: C/-ART: 1.00; HF/-ART: 
0.60 ± 0.061; C/+ART: 0.92 ± 0.038 and HF/+ART: 0.75 ± 0.088. B. Phosphorylated 
eNOS: C/-ART: 1.00; HF/-ART: 2.46 ± 0.53; C/+ART: 4.58 ± 0.34 and HF/+ART: 5.73 ± 
0.30. C. Phosphorylated/Total eNOS Ratio: C/-ART: 1.00; HF/-ART: 4.00 ± 0.45; C/+ART: 
5.02 ± 0.37 and HF/+ART: 7.89 ± 82. N = 3 - 4 / group. 
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Total eNOS expression was 40 % lower in the HF/-ART compared to C/-ART group (p = 
0.0014) (Fig. 3.29 A). Phosphorylated eNOS increased 2.46-fold in the HF/-ART (p = 
0.0253) and 3.58-fold in the C/+ART (p = 0.0001) compared to the C/-ART group. 
Phosphorylated eNOS levels were 2.3-fold higher in the HF/+ART compared to HF/-ART 
group (p = 0.0011) and 25 % higher compared to the C/+ART group (p = 0.0001) (Fig. 
3.29 B). Phosphorylated/total eNOS ratio increased 4-fold in the HF/-ART (p = 0.0013) 
and 5.02-fold in the C/+ART (p = 0.0001) compared to C/-ART group. The 
phosphorylated/total eNOS ratio was 2-fold higher in the HF/+ART compared to HF/-ART 
group (p = 0.0067) and 57 % higher compared to the C/+ART group (p = 0.0092) (Fig. 
3.29 C). No further differences were observed. 
Stellenbosch University  https://scholar.sun.ac.za
71  
 
3.6.1.2. Protein Kinase B (PKB/Akt) 
 
 
3.6.1.2.1. PKB/Akt: Pre-Ischaemia-Reperfusion 
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Fig. 3.30 A - C. PKB/Akt: Pre-Ischaemia-Reperfusion - Expressed as a Ratio of C/- 
ART (= 1) (data expressed as mean ± SEM / group). A. Total PKB/Akt: C/-ART: 1.00; HF/- 
ART: 0.95 ± 0.05; C/+ART: 0.85 ± 0.05 and HF/+ART: 1.09 ± 0.05. B. Phosphorylated 
PKB/Akt: C/-ART: 1.00; HF/-ART: 0.98 ± 0.10; C/+ART: 0.84 ± 0.04 and HF/+ART: 1.12 ± 
0.06. C. Phosphorylated/Total PKB/Akt Ratio: C/-ART: 1.00; HF/-ART: 1.03 ± 0.06; 
C/+ART: 1.00 ± 0.01 and HF/+ART: 1.03 ± 0.03. N = 3 - 4 / group. 
 
Total PKB/Akt decreased 15 % in the C/+ART compared to C/-ART group (p = 0.0136). 
Total PKB/Akt increased 24 % in the HF/+ART compared to C/+ART group (p = 0.0053) 
(Fig. 3.30 A). Phosphorylated eNOS increased 28 % in the HF/+ART compared to 
C/+ART group (p = 0.0238), and decreased 16 % in the C/+ART group compared to C/- 
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ART (Fig. 3.30 B). No differences were observed in phosphorylated/total PKB/Akt ratios 
between any of the groups (Fig. 3.30 C). 
 
 
 
3.6.1.2.2. PKB/Akt: Post-Ischaemia-Reperfusion 
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Fig. 3.31 A - C. PKB/Akt: Post-Ischaemia-Reperfusion - Expressed as a Ratio of C/- 
ART (= 1) (data expressed as mean ± SEM / group). A. Total PKB/Akt: C/-ART: 1.00; HF/- 
ART: 0.78 ± 0.03; C/+ART: 0.86 ± 0.04 and HF/+ART: 0.78 ± 0.04. B. Phosphorylated 
PKB/Akt: C/-ART: 1.00; HF/-ART: 0.74 ± 0.02; C/+ART: 0.85 ± 0.01 and HF/+ART: 0.62 ± 
0.10. C. Phosphorylated/Total PKB/Akt Ratio: C/-ART: 1.00; HF/-ART: 0.95 ± 0.02; 
C/+ART: 1.00 ± 0.02 and HF/+ART: 0.78 ± 0.09. N = 3 - 4 / group. 
 
Total PKB/Akt decreased 22 % in the HF/-ART (p = 0.0055) and 14 % in the C/+ART (p = 
0.0055) compared to C/-ART group (Fig. 3.31 A). Phosphorylated PKB/Akt decreased 26 
% in the HF/-ART (p < 0.0001) and 15 % in the C/+ART (p = 0.0002) compared to C/-ART 
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group, and 23 % in the HF/+ART group compared to C/+ART (Fig. 3.31 B). 
Phosphorylated/total PKB/Akt decreased by 5 % in the HF/-ART compared to C/-ART 
group (p = 0.0334) and 22 % in the HF/+ART compared to C/+ART group (p = 0.0332) 
(Fig. 3.31 C). No further differences were observed. 
 
 
 
3.6.1.3. Adenosine Monophosphate Kinase (AMPK) 
 
 
3.6.1.3.1. AMPK: Pre-Ischaemia-Reperfusion  
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Fig. 3.32 A - C.     AMPK: Pre-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART 
(= 1) (data expressed as mean ± SEM / group). A. Total AMPK: C/-ART: 1.00; HF/-ART: 
2.01 ± 0.17; C/+ART: 1.46 ± 0.19 and HF/+ART: 1.46 ± 0.09. B. Phosphorylated AMPK: 
C/-ART: 1.00; HF/-ART: 1.09 ± 0.12; C/+ART: 0.94 ± 0.09 and HF/+ART: 0.82 ± 0.07. C. 
Phosphorylated/Total AMPK ratio: C/-ART: 1.00; HF/-ART: 0.56 ± 0.09; C/+ART: 0.67 ± 
0.09 and HF/+ART: 0.57 ± 0.08. N = 3 - 4 / group. 
4 * 
p = 0.0021 
3 
** 
p = 0.0149 
** 
2 
 
1 
 
0 
P
h
o
s
p
h
o
ry
la
te
d
 A
M
P
K
 
P
h
o
p
h
o
ry
la
te
d
/T
o
ta
l 
A
M
P
K
 R
a
ti
o
 
T
o
ta
l 
A
M
P
K
 
Stellenbosch University  https://scholar.sun.ac.za
74  
P
h
o
s
p
h
o
ry
la
te
d
/T
o
ta
l 
A
M
P
K
 R
a
ti
o
 
Total AMPK increased 2.01-fold in the HF/-ART (p = 0.0021) and 46 % in the C/+ART (p = 
0.049) compared to the C/-ART group. Total AMPK decreased 55 % in the HF/+ART 
compared to HF/-ART group (p = 0.0149) (Fig. 3.32 A). Phosphorylated AMPK decreased 
27 % in the HF/+ART compared to HF/-ART group (p = 0.0473) (Fig. 3.32 B). 
Phosphorylated/total AMPK ratio decreased 44 % in the HF/-ART (p = 0.0043) and 33 % 
in the C/+ART (p = 0.0143) compared to the C/-ART group (Fig. 3.32 C). No further 
differences were observed. 
 
 
 
3.6.1.3.2. AMPK: Post-Ischaemia-Reperfusion 
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Fig. 3.33 A - C.     AMPK: Post-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART 
(= 1) (data expressed as mean ± SEM / group). A. Total AMPK: C/-ART: 1.00; HF/-ART: 
0.59 ± 0.06; C/+ART: 0.91 ± 0.05 and HF/+ART: 0.32 ± 0.13. B. Phosphorylated AMPK: 
C/-ART: 1.00; HF/-ART: 0.61 ± 0.05; C/+ART: 0.67 ± 0.03 and HF/+ART: 0.51 ± 0.07. C. 
Phosphorylated/Total AMPK ratio: C/-ART: 1.00; HF/-ART: 1.04 ± 0.14; C/+ART: 0.74 ± 
0.01 and HF/+ART: 2.74 ± 0.92. N = 3 - 4 / group. 
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Total AMPK decreased 41 % in the HF/-ART compared to C/-ART group (p = 0.001) and 
59 % in the HF/+ART compared to C/+ART group (p = 0.003). (Fig. 3.33 A). 
Phosphorylated AMPK decreased 39 % in the HF/-ART (p = 0.0006) and 33 % in the 
C/+ART (p = 0.0002) compared to C/-ART group. Phosphorylated AMPK also decreased 
16 % in the HF/+ART compared to C/+ART group (p = 0.0368) (Fig. 3.33 B). 
Phosphorylated/total AMPK ratio decreased 26 % in the C/+ART compared to C/-ART 
group (p = 0.0369), but increased 3.70-fold in the HF/+ART compared to C/+ART group (p 
= 0.0369) (Fig. 3.33 C). No further differences were observed. 
 
 
 
3.6.2. Indicators of Oxidative Stress 
 
 
3.6.2.1. Nitrotyrosine 
 
 
3.6.2.1.1. Nitrotyrosine: Pre-Ischaemia-Reperfusion 
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Fig. 3.34.    Nitrotyrosine: Pre-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART 
(= 1) (data expressed as mean ± SEM / group). Nitrotyrosine: C/-ART: 1.00; HF/-ART: 
0.87 ± 0.01; C/+ART: 0.77 ± 0.19 and HF/+ART: 0.69 ± 0.05. N = 3 - 4 / group. 
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Total nitrotyrosine decreased 13 % in the HF/-ART compared to C/-ART group (p = 
0.0001) and 18 % in the HF/+ART compared to HF/-ART group (p = 0.0123) (Fig. 3.34). 
No further differences were observed. 
 
 
 
3.6.2.1.2. Nitrotyrosine: Post-Ischaemia-Reperfusion 
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Fig. 3.35.    Nitrotyrosine: Post-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART 
(= 1) (data expressed as mean ± SEM / group). Nitrotyrosine: C/-ART: 1.00; HF/-ART: 
1.01 ± 0.11; C/+ART: 1.38 ± 1.38 and HF/+ART: 1.07 ± 0.09. N = 3 - 4 / group. 
 
Total nitrotyrosine expression increased by 38 % in the C/+ART compared to C/-ART 
group (p = 0.0274), but decreased 31 % in the HF/+ART compared to C/+ART group (p = 
0.0471) (Fig. 3.35). No further differences were observed. 
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3.6.2.2. P22 Phox Expression 
 
 
3.6.2.2.1. P22 Phox Expression: Pre-Ischaemia-Reperfusion 
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Fig. 3.36. P22 Pho: Pre-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART (= 1) 
(data expressed as mean ± SEM / group). P22 Phox: C/-ART: 1.00; HF/-ART: 0.76 ± 0.06; 
C/+ART: 0.50 ± 0.04 and HF/+ART: 0.51 ± 0.01. N = 3 - 4 / group. 
 
 
Total p22 phox decreased 24 % in the HF/-ART (p = 0.0081) and 50 % in the C/+ART (p < 
0.0001) compared to C/-ART group. Total p22 phox also decreased 25 % in the HF/+ART 
compared to HF/-ART group (p = 0.0024) (Fig. 3.36). No further differences were 
observed. 
P
2
2
 P
h
o
x
 
Stellenbosch University  https://scholar.sun.ac.za
78  
3.6.2.2.2. P22 Phox Expression: Post Ischaemia-Reperfusion 
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Fig. 3.37.      P22 Phox: Post-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART (= 
1) (data expressed as mean ± SEM / group). P22 Phox: C/-ART: 1.00; HF/-ART: 0.63 ± 
0.10; C/+ART: 0.78 ± 0.10 and HF/+ART: 1.28 ± 0.08. N = 3 - 4 / group. 
 
 
Total p22 phox decreased 37 % in the HF/-ART compared to C/-ART group (p = 0.0103). 
Total p22 phox increased 65 % in the HF/+ART compared to HF/-ART group (p = 0.0016) 
and 50 % in the HF/+ART compared to C/+ART group (p < 0.0040) (Fig. 3.37). No further 
differences were observed. 
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3.6.3. Inflammatory Signalling 
 
 
3.6.3.1. Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-cells 
Inhibitor, Alpha (IκBα) 
 
3.6.3.1.1. IκBα: Pre-Ischaemia-Reperfusion 
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Fig. 3.38. IκBα: Pre-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART (= 1) 
(data expressed as mean ± SEM / group). IκBα: C/-ART: 1.00; HF/-ART: 0.83 ± 0.08; 
C/+ART: 1.62 ± 0.30 and HF/+ART: 1.11 ± 0.07. N = 3 - 4 / group. 
 
Total IκBα decreased 14 % in the HF/-ART compared to C/-ART group (p = 0.0464), and 
increased 28 % in the HF/+ART compared to HF/-ART group (p = 0.0189) (Fig. 3.38). No 
further differences were observed. 
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3.6.3.1.2. IκBα: Post-Ischaemia-Reperfusion 
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Fig. 3.39. IκBα: Post-Ischaemia-Reperfusion - Expressed as a Ratio of C/-ART (= 1) 
(data expressed as mean ± SEM / group). IκBα: C/-ART: 1.00; HF/-ART: 0.53 ± 0.11; 
C/+ART: 0.89 ± 0.06 and HF/+ART: 0.59 ± 0.13. N = 3 - 4 / group. 
 
Total IκBα decreased 47 % in the HF/-ART compared to C/-ART group (p = 0.007) and 30 
% in the HF/+ART compared to C/+ART group (p = 0.04) (Fig. 3.40). No further 
differences were observed. 
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Chapter 4 – Discussion 
 
 
4.1. Feeding Programme and Biometric Measurements 
 
 
Table 4.1. Summary of the Effects of Different Experimental Conditions on Various 
Parameters in the Research Animals. Symbols: = Increase; = Decrease; - = No 
Effect. 
 
 
Parameter C/-ART HF/-ART C/+ART HF/+ART 
 
During 
Feeding- and 
Drug 
Treatment 
Programme 
TBM (g) − 
!(vs. C/-ART, 
at week 12) 
− 
!(vs. C/+ART, 
at week 7) 
Rat Chow 
Consumption 
− "(vs. C/-ART) − "(vs. C/+ART) 
Water 
Consumption 
− "(vs. C/-ART) − "(vs. C/+ART) 
 
 
 
On Day of 
Sacrifice 
 
TBM (g) 
 
− 
 
!(vs. C/-ART) 
 
− 
 
!(vs. C/+ART) 
IP Fat Mass (%) − 
!(vs. C/-ART) 
− !(vs. C/+ART) 
Heart Mass (%) − − − − 
Heart Mass (g) − !(vs. C/-ART) − − 
Liver Mass (%) − − − !(vs. HF/-ART) 
 
 
 
4.1.1. Food and Water Consumption 
 
 
Normal rat chow and water consumption remained constant within each experimental 
group during the first 31 days of the drug treatment programme. ART had no effect on the 
food and water consumption when comparing the treated groups (C/+ART and HF/+ART) 
with their respective untreated counterparts (C/-ART and HF/-ART) (see Fig. 3.2 – 3.3). 
Animals on the HFD received normal rat chow plus the additional HFD food mixture, and 
their normal rat chow consumption was significantly reduced compared to their respective 
lean, controls (see Fig. 3.2). It therefore appears that the animals in these groups 
preferred the sweet HFD food compared to the normal rat chow. As the HFD food was 
freely available to the HFD groups, rats mostly consumed the sweet HFD food while the 
lean, control animals only had access to normal rat chow. This observation is consistent 
with literature that shows that rodents have a preference for sweet foods rather than 
normal rat chow (Avena et al., 2008; Lenoir et al., 2007). 
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Interestingly, as seen in Table 4.1, the water consumption for HFD groups was lower 
compared to their respective lean controls (with and without ART) (see Fig. 3.3). This 
finding is in contrast to another study, where a diet (containing 15 % kcal sugar, 35 % kcal 
lard and 50 % kcal standard rat chow) was fed to rats and water consumption monitored 
over a period of 24 days (La Fleur et al., 2014). They found that the rats on the high fat 
diets, consumed more water than the rats that were fed normal rat chow. The decrease in 
water consumption between the HFD groups compared to the lean, control groups in the 
present study can possibly be attributed to the higher content of water in the HFD food. 
Studies have also inversely associated water consumption with energy intake and 
positively associated increased water consumption with high fibre intake (Kant AK et al., 
2009), which supports our findings. 
 
As seen in Table 4.1, ART or its combination with a HFD had no effect on food and water 
consumption. These findings are regarded novel as this is the first study that uses this 
specific ART combination in a rat model of obesity. According to literature, ART per se 
mostly affects food and water intake through ART-associated side effects including 
nausea, vomiting and other gastrointestinal complications. Adverse effects also differ 
between types of drugs, drug classes, dosage and combinations of ART drugs (Shevitz 
and Knox, 2001). 
 
 
 
4.1.2. Biometric  Measurements  During  and  After  the  Feeding  and  Drug 
Treatment Programme 
 
4.1.2.1. Total Body Mass (TBM) and Intra-Peritoneal (IP) Fat Mass 
 
 
The mean TBM of the four experimental groups were identical at the start of the feeding 
programme (Fig. 3.5). The mean TBM of the HFD groups (with and without ART) showed 
a greater increase than the lean, control groups (with and without ART) indicating that the 
HFD was successful in causing significant body mass increase compared to the lean, 
control groups (Fig. 3.6 and 3.7). The increase in mean TBM continued for the duration of 
the feeding programme, including the final six weeks after addition of the ART drug 
treatment programme and was maintained until the day of sacrifice (Fig. 3.8). 
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The increase in mean TMB corresponds with previous data from our laboratory that used a 
similar diet and feeding period (Salie et al., 2014; Huisamen and Flepisi, 2014). Also, 
another study by Zou et al., 2006 found similar final mean TBM’s in lean (375.63 g; weight 
gain 139.0 g) and HFD groups (433.6 g; weight gain 189.3 g) compared to this study, 
although their feeding programme consisted of the administration of a high fat emulsion 
(10 mg / kg; 4342 kcal / L) via oral gavage and free access to saccharose (18 %) solution 
for 6 weeks. 
 
As seen in Table 4.1, ART drug treatment had no effects on mean TBM increases in 
either, the lean control animals or the animals on the HFD (Fig. 3.5 - 3.7). Only a few 
studies have described the effects of ART on body mass per se and findings are often 
contradictory with HIV-associated weight loss, still prevalent in HIV-populations (Wanke et 
al., 2000). Nonetheless, it has been shown that ART can reverse HIV/AIDS-associated 
weight loss, and obesity and lipodystrophy (peripheral lipoathropy and abdominal 
lipohypertrophy in particular) are becoming more prevalent in HIV-infected populations 
using ART (Mulligan et al., 2005; Malewa et al., 2008). Also, metabolic dysregulation in 
PLWH on ART is on the rise and usually associated with prolonged ART-use (Islam et al., 
2012; Anderson et al., 2004; Fedele et al., 2011). The exact mechanistic interplay between 
a HFD, ART and obesity is not well known (Islam et al., 2012; Fedele et al., 2011; Mulligan 
et al., 2001), but it appears that a combination of factors may contribute to increased TBM 
in PLWH. The hepatotoxic and toxic effect of ART-treatment on adipose tissue (in 
combination with metabolic abnormalities associated with a HFD and obesity) may 
contribute to an increased adiposity (especially in the abdominal area) and/or decreased 
adiposity (in the limb area) in PLWH (de Waal et al., 3013). Also, ART can contribute to 
hepatomegaly through the possible overlap of pathophysiological pathways and indirectly 
contribute to an increased TBM through metabolic dysregulation (e.g. through ART- 
associated lipodystrophy) (de Waal et al., 3013). 
 
The data of the present study demonstrated that the fixed ART drug combination had no 
effect on the TBM gains observed in both the lean, control and HFD groups. However, it is 
possible that longer ART exposure (beyond the treatment period of 6 weeks) may have 
more profound effects on the metabolic regulation of adiposity and subsequently could 
result in additional increases in mean TBM. Further studies investigating this possibility 
may shed more light. NRTIs have also been shown to be less toxic to adipose tissue than 
PIs (Estrada et al., 2006; Silva et al., 1998). The specific drug combination used in the 
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present study may also explain why the TBM of the treated groups was not affected, as 
EFV (contained in Odimune™) has previously been associated with limb fat loss 
(lipohypotrophy) due to its toxic effect on adipocytes (de Waal et al., 3013) rather than 
lipohypertrophy (Estrada et al., 2002). Studies have also shown better health outcomes in 
terms of medication adherence and reduced adverse effects when PIs are replaced by 
NRTIs in combination ART (Carr et al., 2003). This indicates that NRTI-associated adverse 
effects may affect health outcomes in general to a lesser extent than PIs. 
 
The ability of the HFD programme to induce a rat model of obesity was further validated by 
the significant increases observed in the mean IP fat mass % in the HFD groups compared 
to their respective lean, controls (Fig. 3.9). The mean IP fat mass was 60.22 % higher in 
the HF/-ART vs. C/-ART groups, and 91.26 % higher in the HFD/+ART vs. C/+ART groups 
respectively. This increase in mean IP fat mass associated with the HFD corresponded 
with those observed in other studies (Salie et al., 2014; Huisamen and Flepisi, 2014; Cole 
et al., 2011; Pancani et al., 2013). In the present study, ART drug treatment did not exert 
any additional effects on IP fat mass in the HFD group. As far as we are aware, the effects 
of this specific fixed ART drug combination on IP fat mass in rats (both lean and diet- 
induced obese) has not previously been described and this data can therefore be 
considered novel. 
 
Although the ART drug combination in our study did not exert any additional effects on IP 
fat mass, it has been reported that lipohypertrophy (especially in the abdominal area) is a 
major health concern in PLWH (Han S et al., 2009; Van der Valk et al., 2001). 
Mitochondrial toxicity of ARTs has been pointed out as a key factor that can contribute to 
limb lipoatrophy (De Waal et al., 3013; Carr S, 2003; Freitas et al., 2013). NRTIs have 
been mostly associated with limb-fat wasting though possible inhibition of mitochondrial 
DNA synthesis while NNRTIs are associated with both adipogenesis in the abdominal area 
(Flint et al., 2009; Saint-Marc et al., 2000; Freitas et al., 2013) and promoting lipolysis in 
the limb area (Carr S, 2003; Freitas et al., 2013). Many questions remain unanswered 
regarding the exact mechanisms and need further investigation. 
 
To summarise: The HFD in our study successfully increased the mean TBM and mean IP 
fat mass of HFD groups compared to lean, control groups. The specific FDC of ART had 
no additional effects on either the mean TBM or IP fat mass, and this might be due to the 
either the combination, dosage or period of administration of the drugs. It seemed that the 
Stellenbosch University  https://scholar.sun.ac.za
85  
IP fat mass increase was more pronounced when ART was administered in combination 
with our HFD (60 % increase in HF/-ART compared to C/-ART, and 91 % increase in HF/+ 
ART compared to C/+ART), although this difference was not significant. 
 
 
 
4.1.2.2. Heart and Liver Mass 
 
 
Although there was no difference in the mean heart mass (% of TBM) in any of the groups 
(Fig. 3.10 B) the absolute heart mass (expressed in g) of the HFD/-ART was 0.16 g higher 
compared to the C/-ART group (p = 0.036) (Fig. 3.10 B). This represents a 10.30 % 
increase, while there was no difference in the heart mass (g) between the groups receiving 
ART. These findings are in agreement with those of other studies where the actual mean 
heart mass of rats receiving a high fat diet (although not similar in composition and feeding 
period) also increased, but when expressed as % of TBM no differences were observed 
(Cole et al., 2011; Pancani et al., 2013). Ouwens et al. (2005) did indeed find an increased 
heart / body mass ratio after the HFD feeding programme (25 % fat; 32 % protein, 25 % 
carbohydrate; 7 weeks), with a two-fold increase in cardiac TG content compared to the 
control group. Although TG content in cardiac tissue was not measured in our study, 
increased circulating TG levels were observed in the HFD groups compared to their 
respective lean, control groups (Fig. 3.16) and this is positively associated with cardiac 
hypertrophy in other studies (Ouwens et al., 2005). ART-treatment per se had no effect on 
the mean heart mass in our study. Also, the HFD in combination with ART-treatment had 
no effect on the mean heart mass (Fig. 3.10 A). To our knowledge, this finding is novel in 
the context of our study, although ART drug combinations have been associated with 
lipodystrophy and dyslipidaemia that could lead to anthropometric abnormalities such as 
myocardial hypertrophy (Leite et al., 2008; Keithley et al., 2009; Grim et al., 2010). 
 
As seen in Table 4.1, the diet and the treatment per se had no effect on mean liver mass, 
but the combination of the HFD and ART increased the mean liver mass significantly 
(10.69 %) compared to the untreated HFD group (Fig. 3.11). A study by Zou et al. (2006) 
found an increase in mean liver mass (% of TBM) in the HFD group (3.46 %; N = 12) 
compared to the lean, control (2.59 %; N = 12) (feeding programme: gavaging animals 
with a high fat emulsion: 10 mg / kg; 4342 kcal / L and free access to saccharose (18 %) 
solution; 6 weeks). They also found increased hepatic lipid content compared to the lean 
control  group.  The  reason  for  the  elevated  mean  liver  mass  in  the  HF/+ART  group 
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compared to the HF/-ART group can possibly be attributed to the combination of the 
hepatotoxic effect of ART (Sutinen et al., 2002), combined with the effects of a HFD on 
liver function. Liver damage and non-alcoholic fatty liver disease are frequently seen in 
HIV-positive subjects on ART (Maida et al., 2006; Maide et al., 2006). NNTRTIs have been 
associated with liver injury, hepatotoxicity and hepatomegaly (Carr and Cooper et al., 
2000; Carr A et al., 2000; Dieterich et al., 2004). Increased liver mass appears to be a 
common feature in HIV-1 infected patients on ART (Moreno-Tores et al., 2007), especially 
in PLWH on ART with lipodystrophy (Sutinen et al., 2002). The reason for the increased 
liver mass in the HF/+ART group (compared to HF/-ART) in our study can thus possibly be 
explained by a combination of factors. These factors include a possible synergistic 
relationship between ART-associated hepatotoxicity and the HFD, possible intra-hepatic 
TG deposition in the liver (increased circulating TG levels in both the HF/-ART and 
HF/+ART were observed in the current study compared to lean, controls), and/or a 
combination of these factors. 
 
To summarise: Obesity has been associated with the ectopic lipid deposition in the heart 
and liver (associated with increased liver and heart mass) (Tchernof and Després, 2013). 
In the present study, an increase in actual heart mass (g) was observed in the HFD group 
compared to the lean, control animals, with no changes in the liver mass. The increased 
heart mass observed in our study may be the result of enhanced ectopic lipid deposition, 
as indicated by increased circulating TG levels (see later). Increased cardiac work-load 
associated with obesity (Tchernof and Després, 2013) may have resulted in increased 
heart mass in our study and is further underscored by the increased expression of AMPK 
observed in the HF/-ART group compared to the C/-ART group in our study (Dyck, 2006; 
Miller et al., 2005; Heinrich et al., 2010). Increased expression of AMPK prepares the heart 
for a substantial increase in energy demand required during physical activity in obesity 
compared to lean (Dyck, 2006). During physical activity the increased expression of AMPK 
can lead to rapid activation when ATP levels drop, resulting in rapid compensation for 
energy demand. In our study, animals remained mostly sedentary and this could explain 
the increased AMPK expression but not activation as seen in our study. 
On the other hand the ART administration in the HFD animals increased the mean liver 
mass (% of TBM) by 10.92 %. The effects of this ART drug combination in the context of 
obesity may have contributed to possible liver damage. These findings associated with 
ART-use in our study are also regarded as novel since the use of this ART combination in 
a HFD rat model of obesity has not yet been described. 
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4.2. Results of Biochemical Analyses – Glucose, Insulin and Lipid 
Levels. 
 
Table 4.2. Summary of the Effects of Different Experimental Conditions on Various 
Biochemical Parameters in the Research Animals. Symbols: = Increase; = 
Decrease; - = No Effect. 
 
 
 
Parameters 
(fasted) 
C/-ART HF/-ART C/+ART HF/+ART 
Glucose Level 
(mmol/L) 
− − − − 
Insulin (ng / ml) 
 
− 
 
− 
!(vs. 
HF/+ART and 
C/-ART) 
 
− 
TC (mmol/L) − − 
"(vs. 
HF/+ART) 
 
HDL (mmol/L) − − − − 
TG (mmol/L) − "(vs. C/-ART) − "(vs. C/+ART) 
CD (mmol/L) − − − 
!(vs. HF/- 
ART) 
TBARS (µmol/L) − "(vs. C/-ART) "(vs. C/-ART) − 
 
 
 
4.2.1. Glucose and Insulin Levels 
 
 
As can be seen from the summary in Table 4.2, none of the experimental conditions 
exerted any effects on mean fasting glucose levels (Fig. 3.12). This is contradictory to 
other studies that found a difference in mean glucose levels after a similar 16-week HFD 
feeding programme (Salie et al., 2014). A study by Zou et al. (2006) also found an 
increase in mean glucose levels (mmol / L) in animals receiving a HFD (8.36 mmol / L; N = 
12) compared to the lean (5.36 mmol / L; N = 12) group in their study. On the other hand, 
Ouwens et al. (2005) found similar mean glucose levels to the current study in rats 
receiving a high fat, high carbohydrate diet for 7 weeks compared to lean, control. Also, 
Nduhirabandi et al. (2011) found no difference in mean glucose levels compared to lean, 
control after completing a similar HFD feeding programme (N = 6). 
 
The HFD per se had also no effect on mean insulin levels in our study (Fig. 3.13) and was 
therefore unsuccessful in inducing insulin resistance. This finding was unexpected, as it is 
known  that  the  risk  for  developing  insulin  resistance  and  diabetes  increases  with 
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increasing body weight. In support of our findings, a study by Ouwens et al. (2005) could 
also not show increased insulin levels after a HFD feeding programme. In contrast, 
Nduhirabandi et al. (2011) found a 245 % increase in serum insulin in the HFD group 
compared to lean, control (following a similar diet and period of feeding). In a study by Zou 
et al. (2006), an increase in insulin levels were also found in the HFD group compared to 
the lean group. In the study by Salie et al. (2014) insulin resistance was induced, but their 
increase in mean TBM during their feeding programme was approximately double than 
that of our study. The type of fat used in the HFD feeding programme has been shown to 
induce insulin resistance with variable results and may have also played a role (Beuttner 
et al., 2006). In this respect, Beuttner et al. (2006) showed that the classic physiological 
effects of HF diets, including insulin resistance, manifested more prominently when lard 
and olive oil (mainly long-chain, saturated and monounsaturated fatty acids) were used in 
HF diets compared to HF diets containing coconut oil or Fish oils. It may be possible that if 
a greater TBM in the HFD groups were achieved either though following a different diet or 
a longer period of feeding beyond our 16-week feeding programme, a significant 
difference in fasting glucose levels between lean and HFD groups may have been 
observed. 
 
In the present study, ART led to a marked reduction in insulin levels in the lean, control 
animals (see Table 4.2), where mean insulin levels were 73.02 % lower in the C/+ART 
group compared the C/-ART group and 75.61 % lower compared to the HF/+ART group 
(Fig. 3.13). This finding is difficult to explain, especially in view of the fact that the fasting 
glucose levels were unaffected in this group. However, previous studies have associated 
the use of ARTs with insulin resistance and insulin level dysregulation (Mayosi et al., 2009; 
Signorini et al., 2012; Islam et al., 2012) (Fig. 4.1). 
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Fig. 4.1.   NRTIs Involvement in Metabolic Dysregulation Associated with Lipdystrophy 
and CVD. Abbreviations: NRTIs: Nucleoside Reverse Transcriptase Inhibitors; CVD: 
Cardiovascular Disease; FFA: Free Fatty Acid; TNFα: Tumor Necrosis Factor Alpha. 
Symbols: = Increase; = Decrease; - = No Effect. (Freitas et al., 2013). 
 
The mechanism by which insulin level dysregulation associated with ART use is induced is 
not fully understood, but may involve inhibition of peripheral glucose uptake (inhibition of 
glucose transporter GLUT-4) and also inhibition of hepatic glucose production (Flint et al., 
2009). It has also been shown that the ability of insulin to suppress glucose production and 
lipolysis is reduced in PLWH on ART (Van der Valk et al., 2001). Insulin resistance in 
patients on ART may furthermore be a result of chronic hypertriglyceridemia (Flint et al., 
2009; Malangu N, 2014). An increased mean TG level in the C/+ART group compared to 
HF/+ART was observed (see later) and thus, may have contributed to the reduced insulin 
level in the C/+ART group compared to HF/+ART. Pancreatitis is a known adverse effect 
of ART and NRTI and could affect insulin secretion (Moore at al., 2001; Smith et al., 2008). 
ART has also been associated with pancreatic β-cell dysfunction, mediated through 
numerous possible pathways that include pancreatic lipid deposition (associated with β- 
cell dysfunction and reduced pancreatic insulin secretion) (Domingo et al., 2012; Haugard 
et al., 2005; Pi et al., 2010). Studies have further shown a decrease in insulin secretion 
associated with ART use and in particular with NRTIs (Maassen and Heine, 2007). 
NRTIs 
Lipid Metabolism disturbances and fat redistribu8on 
!Visceral Fat and "Subcutaneous Fat 
Insulin 
Resistance 
!FFA, Resis8n, TNFα "Lep8n, Adiponec8n 
"Glucose    Tolerance/Diabetes/Dyslipidaemia/Metabolic 
Syndrome 
!CVD Risk 
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Although it is indeed possible that the ART exerted adverse or toxic effects on the 
pancreas leading to ß-cell dysfunction and a subsequent reduction in serum insulin levels, 
the question remains why this was only observed in the C/+ART group. Future studies with 
larger sample sizes, and closer inspection of pancreas morphological changes may prove 
or disprove the current unexpected findings. 
 
To summarise: although the HFD in the present study led to increased TBM and IP fat 
mass (obesity), it was unsuccessful in inducing insulin resistance. Overall, treatment with 
the ART drug failed to exert any additional effects; however, the surprisingly low insulin 
levels observed in the C/-ART group (in the absence of any changes in the other groups) 
warrants further investigations. 
 
 
 
4.2.2. Lipid Profile 
 
 
It is well known that obesity affects the lipid profile and can be associated with increased 
LDL, TC, and TG levels and decreased HDL levels (Alwan, 2011; Fedele et al., 2011; 
Tchernof and Després, 2013). Furthermore, ART has previously been shown to affect the 
lipid profile and is associated with elevated TC, LDL, TG levels and reduced HDL levels 
(Sweeney et al., 2007; Pradier et al., 2004). Dysregulation of the lipid profile may be 
related, at least in part, to ART-associated effects on peripheral adipocytes resulting in 
increased free fatty acid (FFA) release (Mathers and Loncar, 2002; Levitt et al., 2011; 
Mayosi et al., 2009). Other consequences related to these effects include lipoathropy, 
decreased cellular glucose uptake, mitochondrial damage and inhibition of hepatic TG 
synthesis (Flint et al., 2009). ART is associated in particular with increased circulating FFA 
and deposition in various organs such as the liver (steatosis) and pancreas promoting 
insulin resistance and dyslipidaemia (Flint et al., 2009). On the other hand, ART drugs 
such as Tenofovir have been shown to improve the lipid profile somewhat, compared to 
some other ARTs, such as PIs (Claas et al., 2007). 
 
 
 
4.2.2.1. Total Cholesterol (TC) Levels 
 
 
Increased TC levels have previously been associated with exposure to a HFD (Tchernof 
and Després, 2013; Guh et al., 2009); however, this was not observed in the present study 
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(Fig. 3.14). In support of our data, another study from our laboratory by Nduhirabandi et al. 
(2011; with a similar diet and feeding period), also observed no increase in mean TC 
levels. However, a study by Zou et al. (2006) found an increase in mean TC levels in the 
HFD group compared to the lean, control group. Zou et al. (2006) showed greater 
differences in TBM and IP fat mass between their HFD and lean control groups than in our 
study. Also, a greater rate in weight gain in their study compared to our study was 
observed. Factors that may have contributed to unchanged mean TC levels in the HFD 
group in our study, include duration of HFD feeding programme, degree of weight and IP 
fat gain and also type of fat used in the HFD (Beuttner et al., 2006). The source of lipids 
and carbohydrates in the HFD have also been shown to variably effect TC levels in rodent 
models of obesity (Jurgońskie et al., 2014). Jurgońskie et al. (2014) used a HFD that was 
rich in lard or soybean oil (source of saturated or unsaturated fatty acids, respectively). 
Each of these diets contained fructose or corn starch (source of simple or complex 
carbohydrates) respectively and it was found the lard- and fructose-rich diet increased 
serum TC and TG levels significantly, and increased the atherogenic index by more than 
5-fold compared to the other diet combinations. Any of these factors and/or a combination 
of these factors may have contributed to the non-elevated TC level observed in our study. 
 
Interestingly, as seen in Table 4.2, the TC levels were significantly higher in the ART- 
treated lean,  control  group (C/+ART)  when  compared  to the  HF/-ART  and  HF/+ART 
groups (Fig. 3.14). The mean TC levels in the C/+ART group was 45.79 % higher 
compared to the HF/+ART group. Additionally, the insulin levels (decreased vs. C/-ART 
and HF/+ART), and the TBARS levels (increase vs. C/-ART) levels were also affected by 
the ART. The increase in TC levels observed in the C/+ART compared to HF/+ART is 
difficult to explain, as the exact mechanism still needs to be elucidated. Treatment with 
NRTIs has been associated with dyslipidaemia and lipodystrophy and have been 
characterised by the reduction in LDL catabolism, increased LDL production, impaired FFA 
catabolism, increased liver TG synthesis, increased secretion of apolipoprotein-B 
containing lipoproteins, and reduced expression of LDL receptors as seen in Fig. 4.1 
(Freitas et al., 2013). 
As far as we are aware, there is no data available on the effects of this specific ART drug 
combination on TC levels in a rat model of obesity. However, in human studies, increased 
TC and LDL cholesterol levels have previously been shown to be associated with ART- 
treatment (Shevitz et al., 2001) while higher TC levels have been associated with a greater 
risk for developing lipohypertrophy (Han S et al., 2009). Evafirenz, one of the compounds 
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in the ART drug used in the current study, in particular has been shown to increase TC 
levels (Fontas et al., 2004). The fact that TC levels were not increased in the HFD group 
receiving ART (HF/+ART) is difficult to explain and requires further investigation to 
elucidate possible mechanisms. 
 
In summary: Although ART administration in the HFD group had no effects on the mean 
TC levels, the TC levels in the C/+ART group were increased compared to the HF/+ART, 
an interesting and novel finding which warrants further investigation. 
 
 
 
4.2.2.2. High Density Lipoprotein (HDL) Levels 
 
 
HDL cholesterol is cardio-protective (and low HDL cholesterol level regarded as a CVD 
risk factor) (Poulter, 2003). There were no differences observed in HDL levels in any of the 
experimental conditions in the present study (Fig. 4.15) (see Table 4.2). However, 
Nduhirabandi et al., 2011 (with a similar diet and feeding period), found an increase in 
HDL cholesterol in the HFD group. In contrast to this, a study by Zou et al. (2006) found a 
decrease in HDL cholesterol level (mg/dL) in the HFD group compared to the lean group. 
The reason why the HFD did not affect HDL levels in our study is unknown, but factors that 
may have played an important role could be the rate of weight gain, the period of feeding 
of the HFD and the source of lipids and carbohydrates in the HFD. All these factors have 
been shown to variably effect HDL levels in rodent models of obesity (Aguila et al., 2002; 
Inai and Matsua, 2011; Jurgońskie et al., 2014). 
Overweight/obesity (Poulter, 2003) and increased viral load (as found in HIV-infection) 
have also been associated with decreased HDL cholesterol (Dubé et al., 2015; Chaves et 
al., 2003). Furthermore, long term ART, such as tenofovir (Claas et al., 2007) has been 
associated with reduced HDL cholesterol (Hansen et al., 2006; Shevitz et al., 2001; 
Malangu N, 2014) and dyslipidaemia (characterized by high LDL cholesterol and low HDL 
cholesterol) (Dubé et al., 2015; Chaves et al., 2003; Flint et al., 2009), but this was not 
observed in our study. 
 
In summary: Although none of the experimental conditions had an effect on HDL 
cholesterol levels, a longer period of exposure to the HFD and/or ART might have had 
more pronounced effects on lipid regulation and result in a reduction in mean HDL 
cholesterol levels, as obesity and ART have previously been associated with a reduction in 
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HDL cholesterol. The specific ART drug combination used in the current study did not 
affect mean HDL cholesterol levels. This ART combination might thus only increase 
protective HDL cholesterol indirectly though suppressing viral replication (i.e. in the 
presence of HIV-infection), which was not possible to emulate in the current study. 
 
 
 
4.2.2.3. Triglyceride (TG) Levels 
 
 
Studies in which animals receive a HFD usually show increased levels of circulating TGs 
in the body (Aguila et al., 2002; Inai and Matsua, 2011; Jurgońskie et al., 2014) and 
indeed this was also observed in the present study (see Table 4.2). Mean TG levels 
increased by 85 % in the untreated HFD group compared to the untreated lean control 
group, and by 40 % in the treated HFD group compared to its respective treated lean, 
control group (Fig. 3.16). The increased mean TG levels (hypertriglyceridemia) observed 
in the HFD groups in the present study served to further characterise and validate the HFD 
model, although it was not associated with insulin resistance. In terms of the effects of the 
HFD on mean TG levels, similar findings were observed in previous studies from our 
laboratory by Salie et al., 2014 and Nduhiabandi et al., 2014. Furthermore, Ouwens et al. 
(2005) found increased TG deposition in the heart associated with their HFD that 
translated into an increased heart mass similar to this study. This was further supported by 
a study by Zou et al. (2006) who found an increase in TG levels in their HFD group. 
 
Increased circulating TG levels have previously been associated with ectopic lipid 
deposition in organs such as the heart (increased heart mass was found in the HFD group 
in the present study) (Haslam and James, 2005; Kopelman, 2007). Thus, the increased 
TG level may also have contributed to the increased mean heart mass (g) (C/-ART vs. 
HF/-ART) and also, at least in part, the increased liver mass in the HF/+ART group 
compared to the HF/-ART group observed in this study as discussed earlier. 
As can be seen in Table 4.2, ART on its own had no effect on mean TG levels, suggesting 
that the changes observed were mainly driven by the effects of the HFD, but increased 
saturated fat intake in PLWH on ARTs has been noted and contributes to 
hypertriglyceridemia, especially among patients who have developed metabolic 
abnormalities such as dyslipidaemia (Joy et al., 2007; Malaza et al., 2012; Fedele et al., 
2011; Lo and Plutzky, 2012; Lo et al., 2010). Although increased mean TG levels (10-12 
%) have been associated with long term ART-treatment in human studies (Hansen et al., 
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2006; Shevitz et al., 2001; Flint et al., 2009), the ART combination in our study had no 
effect on the mean TG levels, even though Evafirenz has been associated with increased 
TG levels previously in human studies (Fontas et al., 2004. 
 
In summary: The HFD resulted in increased TG levels in our study and possibly 
associated, in part at least, with increased heart mass in the HF/-ART group. The fact that 
TG levels were not affected by our ART drug combination in a rat model of obesity has not 
been described before and can therefore be considered novel; however, further 
investigation in this phenomenon is required. 
 
 
 
4.2.3. Oxidative Stress and Lipid Peroxidation 
 
 
4.2.3.1. Conjugated Diene (CD) Levels 
 
 
Conjugated dienes (CD) are indicators of free radical production and produced as result of 
unsaturated fatty acids oxidation and elevated CD levels have previously been associated 
with obesity (Chanta et al., 2006; Clarkson et al., 2000). CDs are thus good markers of 
early-stage lipid peroxidation (Chanta et al., 2006; Clarkson et al., 2000). Although obesity 
is associated with increased lipid peroxidation and, hence, increased CD levels (Chanta et 
al., 2006; Clarkson et al., 2000), the HFD per se had no effect on the mean CD levels in 
our study (see Table 3.2) (Fig. 3.17). Nduhirabandi et al. (2011) also found no difference 
in CD levels between control and HFD groups following the same feeding programme for 
the same period of time. Interestingly, the mean CD level in the HF/+ART group was 13.3 
% lower compared to the HF/-ART group. The reason for this seemingly reduced oxidative 
stress status is unknown, as a similar effect was not observed in the TBARS levels (see 
later). 
 
In summary: The HFD had no effect on the CD levels in the present study. Although 
overweight/obesity (Poulter, 2003) and ART (Dubé et al., 2015; Hasse et al.,  2011; 
Chaves et al., 2003) are known to lead to lipid-peroxidation and oxidative stress and 
subsequently an increase in the CD levels (Clarkson et al., 2000; Matsuzawa-Nagata et 
al., 2008), this was not observed in context of this study, but the reduction in CD level of 
the HF/+ART group compared to HF/-ART suggest that a possible anti-oxidant interplay 
exists between the HFD and ART. The results in terms of this ART combination in the 
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context of our study can be considered novel, as it has not been described to our 
knowledge. 
 
 
 
4.2.3.2. Thiobarbituric Acid Reactive Substance (TBARS) Levels 
 
 
TBARS is a by-product of lipid-peroxidation (products of lipid degradation) and produced 
during ROS-associated cellular damage (Trevisan et al., 2001; Kumar et al., 2012). 
Because ROS has a very short half-life, measuring TBARS is a good indicator of the level 
of oxidative stress and lipid-peroxidation (Trevisan et al., 2001; Kumar et al., 2012). It is 
known that overweight/obesity (and associated metabolic abnormalities) can lead to 
oxidative stress (Lavie et al., 2009; Tchernof and Després, 2013; Guh et al., 2009). Also, 
HIV-replication (Dubé et al., 2015; Breive et al., 2004; Chaves et al., 2003) can lead to 
oxidative stress and systemic inflammation (associated with CVD such as IHD (Murdoch et 
al., 2006; Rochette et al., 2013) through ROS production (Pacher et al., 2005; Turko and 
Murad, 2002; Peluffo and Radi, 2007). 
The mean TBARS levels were increased by 15.19 % in the HFD group compared to its 
lean control group and by 23.09 % in the lean, control animals receiving ART compared to 
untreated control animals (see Table 4.2) (Graph 3.18). Therefore, the HFD and ART on 
their own resulted in an increased mean TBARS levels and were therefore both 
associated with increased lipid-peroxidation and oxidative stress in our hands. In contrast 
to the present study, Feillet-Coudray et al., 2009 found no differences in the mean TBARS 
levels after a high-fat, high-sucrose diet feeding programme. Nduhirabandi et al., 2011 
also found no difference in TBARS levels following a similar feeding programme as in our 
study. 
 
In summary: The observation that the HFD resulted in increased TBARS levels further 
underscores the harmful physiological effects of the HFD. The increased TBARS levels 
observed in the ART treated lean, control group, confirmed that there was a measure of 
oxidative stress associated with ART as shown previously by others in human studies 
(Fukui et al., 2001; Flint et al., 2009). In our study, the ART in combination with a HFD had 
no effect on TBARS levels. To our knowledge the effect of ART on TBARS in a rat model 
of obesity has not yet been described and can be considered as novel. 
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4.3. Isolated Heart Perfusions 
 
 
4.3.1. Functional Recovery 
 
 
The haemodynamic data obtained during the global ischaemia-reperfusion studies are 
summarised in Table 4.2. 
 
Table 4.3. Summary of Haemodynamic Data  – Global Ischaemia-Reperfusion (data 
expressed as mean ± SEM / group (% Recovery)). Abbreviations: HR: Heart Rate; AO: 
Aortic Output; CF: Coronary Flow; CO: Total Cardiac Output; PSP: Peak Systolic 
Pressure; Wt: Total Power; Pre: Pre-ischaemia-reperfusion; Post: Post-Ischaemia- 
reperfusion. Pre-Ischaemia vs. Post-Ischaemia: * = p < 0.05; ** = p < 0.01; *** = p < 
0.001; **** = p < 0.0001. (For convenience Table 3.1. is shown here again as Table 4.3) 
 
 
Haemodynamic Data 
Pre$Ischaemia vs. Post$Ischaemia 
Mean ± SEM 
(% Recovery) 
C/:ART 
(Pre: N = 16; Post: N = 6) 
HF/:ART 
(Pre: N = 14; Post: N = 6) 
C/+ART 
(Pre: N = 11; Post: N = 4) 
HF/+ART 
(Pre: N = 13; Post: N = 6) 
HR 
(BPM) 
Pre 224.80 ± 12.67 234.80 ± 8.72 245.90 ± 6.18 259.40 ± 17.47 
Post 205.80 ± 41.72 105.30 ± 50.13 *** 210.00 ± 23.82 201.50 ± 45.35 
% Recovery 78.87 % 44.02 % 82.94 % 77.78 % 
AO 
(ml / min) 
Pre 42.09 ± 1.51 41.21 ± 1.48 42.36 ± 1.87 38.46 ± 1.57 
Post 16.58 ± 5.34 **** 7.08 ± 5.27 **** 14.50 ± 5.85 **** 7.16 ± 4.83 **** 
% Recovery 39.34 % 16.99 % 32.12 % 19.16 % 
CF 
(ml / min) 
Pre 14.13 ± 0.74 14.11 ± 0.51 15.36 ± 0.74 16.08 ± 1.13 
Post 10.75 ± 2.17 6.25 ± 2.58 *** 15.75 ± 4.08 10.75 ± 2.40 * 
% Recovery 76.48 % 44.12 % 93.86 % 68.16 % 
CO 
(ml / min) 
Pre 56.22 ± 1.84 55.32 ± 1.73 57.91 ± 1.81 54.54 ± 2.41 
Post 27.33 ± 7.00 **** 13.33 ± 7.56 **** 30.25 ± 9.84 *** 17.92 ± 6.10 **** 
% Recovery 48.55 % 23.28 % 48.92 % 32.59 % 
PSP 
(mmHG) 
Pre 105.10 ± 1.57 100.80 ± 2.05 101.70 ± 1.69 99.15 ± 2.03 
Post 83.32 ± 16.79 41.00 ± 19.17 **** 86.0 ± 8.37 66.83 ± 16.79 * 
% Recovery 77.80 % 40.94 % 82.94 % 64.44 % 
Wt 
(mW) 
Pre 13.24 ± 0.52 12.35 ± 0.43 13.24 ± 0.53 12.24 ± 0.61 
Post 6.08 ± 1.58 **** 2.44 ± 1.68 **** 6.37 ± 2.28 *** 3.56 ± 1.41 **** 
% Recovery 44.90 % 19.45 % 44.21 % 27.07 % 
 
 
The most important trends in terms of % recovery are discussed below: 
 
 
Heart Rate (HR): Although no significant inter-group differences were observed in terms of 
% HR recovery, it was noticeable that the HFD group was the only group that presented 
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with a significantly lower post-ischaemia-reperfusion HR vs. pre-ischaemia-reperfusion HR 
values (HR recovery: %) (see Table 4.3). 
 
Aortic output (AO): The AO after global ischaemia-reperfusion injury was significantly 
reduced compared to pre-ischaemia-reperfusion values in all the groups. Although there 
were no significant inter-group differences in the % AO recovery, it was again noticeable 
that the HFD groups recovered by smaller margins (range: 17 % - 19 %) compared to the 
lean, control hearts (range: 32 % - 39 %) (see Table 4.3). 
 
Coronary flow (CF): Although no significant inter-group differences were observed in terms 
of % CF recovery, it was again observed that the hearts of the HFD groups performed 
poorly after the ischaemia-reperfusion insult, whereas the lean, control hearts (treated and 
untreated) showed better recovery rates. The addition of ART to the HFD seemed to 
improve the % recovery of CF when compared to the HFD without treatment (see Table 
4.3). 
 
Cardiac output (CO): Although, the % recovery of CO was significantly reduced in all the 
groups, the CO of the untreated HFD hearts (23.28 %) seemed to be lower than that of the 
lean control (48.55 %) and again the addition of ART to the HFD seemed to somewhat 
improve CO recovery to 32.55 % (see Table 4.3). 
 
Peak systolic pressure (PSP): As for HR and CF, the HFD hearts (treated and untreated) 
were the only two groups showing significantly lower recovery in PSP. Again it seemed as 
though the addition of ART improved the % recovery from 41 % to 64 % (see Table 4.3). 
 
Total power (Wt): Although statistically, there were no differences in the Wt recovery 
between the groups, it seems that the lean, control hearts performed better (range: 44 – 
45 %) compared to the HFD groups (range: 19.5 – 27 %). Again we observed that the 
addition of ART to the HFD hearts resulted in an improved recovery (see Table 4.3). 
 
From Table 4.3 it is clear that the untreated HFD group (HF/-ART) was the only group in 
which ALL the recovery endpoints were significantly lower after ischaemia-reperfusion. 
Furthermore, the HF/-ART group was the only group in which the HR recovery was 
significantly poorer compared to pre-ischaemia-reperfusion (baseline) values. These 
trends  suggest  that  the  HFD  induced  myocardial  changes  that  affected  functional 
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performance in terms of the hearts’ ability to recover from an ischaemia-reperfusion insult. 
These findings only apply to the recovery after the post-ischaemia-reperfusion insult, as 
the HFD had no effect on actual baseline values in any of the groups (see Table 4.3). 
Although assessing the effect of preconditioning in terms of a HFD (similar to the present 
study) vs. lean during ischaemia-reperfusion (protocol similar to the present study), Salie 
et al. (2014) found a similar trend in functional recovery (asolute values) as observed in 
our study when absolute values were compared within groups (Pre- vs. post-ischaemia- 
reperfusion: reduction in post-ischaemic recovery CF, OA, CO and Wt in the HFD group 
compared to HFD pre-iechaemic absolute values). Also, Nduhirabandi (2014), compared 
only post-ischaemia-reperfusion (absolute) values of groups with each other and, similar to 
our own observations, did not find differences between the lean, control and HFD groups 
when absolute values were compared (except for AO post-ischaemic absolute values of 
lean vs. HFD). In the present study, we furthermore compared the % recoveries within 
groups and the % recoveries between groups, but no statistical differences were observed 
in both comparison (see Fig. 3.19 -24). 
 
However, as mentioned earlier, some important intra-group observations comparing mean 
post-ischaemia-reperfusion values with pre-ischaemia-reperfusion values in the HFD 
group suggested poorer outcomes following ischaemia-reperfusion injury. It is important 
that our findings are seen in context. The HFD in the present study did not induce insulin 
resistance, as opposed to the studies by Salie et al. (2014) and Nduhirabandi (2014), 
which could explain why the poorer outcomes observed in especially the HR, CF and PSP 
were not sufficiently strong to translate into inter-group statistically significant differences. 
Small sample sizes, leading to large standard errors should also be considered. On the 
other hand, the HFD in the present study was associated with increased TG and lipid 
peroxidation (TBARS) levels, both of which are associated with myocardial dysfunction. It 
is therefore proposed that we observed early and moderate myocardial changes in the 
HFD hearts, leading to poorer recovery in all endpoints measured, the only experimental 
group in which this was observed. 
 
Statistically, ART per se did not have any effects on any of the functional parameters 
assessed and as far as we aware there are no studies that have investigated or described 
the effects of this specific ART drug combination nor its combination with a HFD on these 
parameters. Although the mean insulin level in the C/+ART group was significant lower 
compared to the HF/+ART and C/-ART groups and TC was significantly elevated in the 
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C/+ART group compared to HF/+ART, it did not translate into myocardial dysfunction in 
our hands. Functionally, however, the data suggested improvements in some of the 
endpoints when ART was added to the HFD. Our findings in this respect can therefore be 
considered as novel. 
 
 
 
4.3.2. Infarct Size 
 
 
There were no differences in the VA size between all groups. Also, the AR size (including 
the infarcted area) did not differ between groups. The infarct size (expressed as a % of 
AR) was greater in the HF/-ART group (35.40 %) compared to the C/-ART (18.26 %) and 
the HF/+ART group (19.95 %) (Fig. 4.2). 
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Fig. 4.2.  Mean VA (green), AR (red + blue) and Infarct Area (blue) as % of Total Area 
after Regional Ischaemia. C/-ART: N = 8; HF/-ART: N = 7; C/+ART: N = 4; HF/+ART: N = 
8. 
 
In contrast of our findings, a study by Salie et al. (2014) found an infarct-sparing effect in 
the HFD group compared to lean, control. Bester et al. (2010) also found their HFD 
(including red-palm oil) to be infarct-sparing compared to lean, control. Obesity has 
previously been shown to protect the heart against ischaemia-reperfusion injury in some 
studies (via activation of the risk pathway) (Donner et al., 2013; Salie et al., 2014; 
Kalakech et al., 2014) while others have shown a detrimental effect in terms of ischemia- 
%
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reperfusion (Aoyagi et al., 2015). Similar to the findings in our study, a study by Littlejohns 
et al. (2014), found an increase in infarct size in isolated mouse hearts (N = 5-7) 
associated with their HFD (10-22 weeks feeding programme) compared to the  lean, 
control group. The increased infarct size observed in the present study is supported by our 
functional recovery data where the HFD appeared to be more detrimental in terms of % 
recovery in all parameters measured. Where the addition of ART seemed to improve the 
functional recovery somewhat, we also observed a significant reduction in infarct size 
when ART is combined with the HFD. 
 
In summary: The HFD was associated with increased infarct size during ischaemia- 
reperfusion in our study. On the other hand ART per se had no effect on infarct size. The 
combination of ART and HFD appeared to have infarct sparing properties. The effects of 
this specific ART combination in terms of isolated heart perfusions and infarct size have 
not been described yet and is considered novel. 
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4.4. Western Blot Analysis 
 
 
The results from Western blot analysis were obtained from hearts freeze-clamped pre- and 
post-ischemia. Pre-ischaemic results are summarised in Table 4.4, while results from 
post-ischaemia-reperfusion are summarised in Table 4.5. 
 
Table 4.4. Summary of the Effects of Different Experimental Conditions on the 
Expression and Phosphorylation of Various Proteins of Interest (Pre-ischaemia- 
reperfusion). Symbols: = Increase; = Decrease; - = No Effect. 
 
 
Protein C/-ART HF/+ART C/+ART HFD/+ART 
NOS Signalling 
Total eNOS − − !(vs. C/-ART) !(vs. HF/-ART) 
Phosphorylated  eNOS − !(vs. C/-ART) − !(vs. HF/-ART) 
Phosphorylated/Total 
eNOS 
− − "(vs. C/-ART) !(vs. C/+ART) 
Total PKB/Akt − − !(vs. C/-ART) "(vs. C/+ART) 
Phosphorylated 
PKB/Akt 
− − − "(vs. C/+ART) 
Phosphorylated/Total 
PKB/Akt 
− − − − 
Total AMPK − "(vs. C/-ART) "(vs. C/-ART) !(vs. HF/-ART) 
Phosphorylated  AMPK − − − !(vs. HF/-ART) 
Phosphorylated/Total 
AMPK 
− !(vs. C/-ART) !(vs. C/-ART) − 
ROS Signalling 
Nitroryrosine − !(vs. C/-ART) − !(vs. HF/-ART) 
Total P22 phox − !(vs. C/-ART) !(vs. C/-ART) !(vs. HF/-ART) 
Inflammatory Signalling 
Total IκBα − !(vs. C/-ART) − "(vs. HF/-ART) 
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Table 4.5. Summary of the Effects of Different Experimental Conditions on the 
Expression and Phosphorylation of Various Proteins of Interest (Post-ischaemia- 
reperfusion). Symbols: Symbols: = Increase; = Decrease; - = No Effect. 
 
 
Protein C/-ART HF/-ART C/+ART HF/+ART 
NOS Signalling 
Total eNOS − !(vs. C/-ART) − − 
Phosphorylated 
eNOS 
− "(vs. C/-ART) "(vs. C/-ART) 
"(vs. C/+ART 
and HF/-ART) 
Phosphorylated/Total 
eNOS 
− "(vs. C/-ART) "(vs. C/-ART) 
"(vs. C/+ART 
and HF/-ART) 
Total PKB/Akt − !(vs. C/-ART) !(vs. C/-ART) − 
Phosphorylated 
PKB/Akt 
− !(vs. C/-ART) !(vs. C/-ART) !(vs. C/+ART) 
Phosphorylated/Total 
PKB/Akt 
− !(vs. C/-ART) − !(vs. C/+ART) 
Total AMPK − !(vs. C/-ART) − !(vs. C/+ART) 
Phosphorylated 
AMPK 
− !(vs. C/-ART) !(vs. C/-ART) !(vs. C/+ART) 
Phosphorylated/Total 
AMPK 
− − !(vs. C/-ART) "(vs. C/+ART) 
ROS Signalling 
Nitroryrosine − − 
"(vs. C/-ART 
and HF/+ART) 
− 
Total P22 phox − !(vs. C/-ART) − 
"(vs. C/+ART 
and HF/-ART) 
Inflammatory Signalling 
Total IκBα − !(vs. C/-ART) − !(vs. C/-ART) 
 
 
 
4.4.1. Nitric Oxide Synthase (NOS) Signalling 
 
 
eNOS, PKB/Akt and AMPK play a central role in NO production and thus cardio-protection 
(Huang, 2009; Chatterjee and Catravas, 2006; Simon et al., 2014). Increased expression 
(total) and activation (phosphorylation) of these proteins in response to oxidative stress 
and/or inflammation (damage to the myocardium) can lead to an increase in NO 
production to counteract the damage and improve cardiac function (Fig. 4.3) (Huang, 
2009; Chatterjee and Catravas, 2006; Simon et al., 2014). 
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Fig. 4.3. Summary of the Role of eNOS as a Downstream Target of PKB/Akt and 
AMPK in the Cardiovascular System. Abbreviations: eNOS: Endothelial Nitric Oxide 
Synthase; PKB/AKT: Protein Kinase B; AMPK: 5' Adenosine Monophosphate-Activated 
Protein Kinase; ET-1: Endothelin-1; PI3K: Phosphatidylinositol-3-Kinase; VEGF: Vascular 
Endothelial Growth Factor. PKB/Akt: Protein Kinase B; P: Phosphate. Symbols: = 
Increase; = Decrease; + = Activate; - =Inhibit. (Huang, 2009; Chatterjee and Catravas, 
2006; Simon et al., 2014; Deng et al., 2010; Dudzinski et al., 2007). 
 
These proteins interact with each other directly or indirectly causing up- or down-regulation 
to control NO production (Huang, 2009; Chatterjee and Catravas, 2006; Simon et al., 
2014). NO production inhibits apoptosis, promotes proliferation and migration of ECs, 
inhibits smooth muscle cell proliferation and migration (reduce thrombosis) (Napoli et al., 
2013; Wheeler-Jones C, 2005), inhibits platelet aggregation, adhesion of platelets, 
leucocytes, and monocytes to the endothelium, and reduces LDL oxidation (scavenging 
lipid radicals) (Lei et al., 2013; Naseem, 2005; Liu et al., 2008; Dias et al., 2011). 
 
 
 
4.4.1.1. eNOS: Pre-Ischaemia-Reperfusion 
 
 
Obesity and its associated comorbidities (diabetes, insulin resistance, 
hypercholesterolemia, hyperglycaemia, and hypertension) (Huang, 2009; Chatterjee and 
Catravas, 2006; Ceriello et al., 2002) and ART (Dubé et al., 2015; Hasse et al., 2011) 
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contribute to CVD through ED and atherosclerosis and is associated with decreased NO 
production (Chatterjee and Catravas, 2006; Mudau et al., 2012; Tabib et al., 2000). In our 
study, the HFD had no effect on total eNOS, but the combination of HFD with ART 
significantly reduced total eNOS expression (see Table 4.4). ART itself also resulted in a 
36 % reduction of total eNOS compared to lean control (see Table 4.4). On the other 
hand, the HFD resulted in a reduction in phosphorylated eNOS and when combined with 
ART, resulted in a further decrease (21 %) (see Table 4.4). When the phosphorylated 
eNOS was expressed as a ratio of total, ART per se resulted in a 42 % increase compared 
to lean, control and the combination of HFD and ART in a 17 % decrease compared to the 
HFD only (see Table 4.4). However, the increase in phosphorylated / total eNOS ratio by 
ART was likely caused by the decreased expression of eNOS, rather than increased 
phosphorylation. Therefore, from our results it seems that all the experimental conditions 
led to an overall downregulation of eNOS (despite the increased eNOS ratio in the ART 
treated control group). This was supported by a study by Coa et al., (2011) who also found 
a decrease in phosphorylated / total eNOS in their HFD group compared to lean, controls. 
 
To conclude: Obesity and its associated metabolic abnormalities such as insulin resistance 
and dyslipidaemia (Huang, 2009; Chatterjee and Catravas, 2006; Youn et al., 2014) and 
ART (Dubé et al., 2015; Hasse et al., 2011) have been shown to contribute to CVD though 
ED dysfunction (via down-regulating eNOS (Chatterjee and Catravas, 2006) and this was 
indeed observed in our study as far as the HFD is concerned. The specific ART 
combination does not seem to contribute to CVD though eNOS in the context of our study. 
To our knowledge, the effects of this ART drug combination in the context of our study 
have not been described yet and can be considered as novel. 
 
 
 
4.4.1.2. eNOS: Post-Ischaemia-Reperfusion 
 
 
The role of NO in terms of ischaemia-reperfusion is not fully understood and studies 
reports on NO production in terms of cardio-protection in ischaemia-reperfusion have been 
inconsistent (protective, deleterious and no effects) (Flögel et al., 1999; Simon et al., 2014; 
Shulz et al., 2004). Studies have shown that the administration of NO might prevent 
ischaemic injury in vivo and blood-perfused models (Flögel et al., 1999; Simon et al., 2014; 
Shulz et al., 2004). The mechanism for this effect appears to involve the preservation of 
endothelium  cell  integrity  and  reduction  of  neutrophil  infiltration  (Flögel  et  al.,  1999; 
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Naseem, 2005; Simon et al., 2014; Shulz et al., 2004). 
 
 
In our study, the HFD reduced total eNOS after ischaemia-reperfusion by 40 % compared 
to the lean controls (see Table 4.5). Apart from this reduction an overall increase in eNOS 
in all experimental conditions was seen after a global ischaemic insult (see Table 4.5). 
These trends were observed in the phosphorylation as well as the phosphorylation / total 
eNOS ratio in all experimental groups (see Table 4.5). 
 
Although the HFD, ART and the combination of ART and HFD did not up-regulate eNOS 
pre-ischaemia-reperfusion, the HFD, ART and the combination of ART and obesity 
exhibited cardio-protective properties in terms of eNOS up-regulation (through activation 
as well as the ratio) post-ischaemia-reperfusion. The up-regulation of eNOS after 
ischaemic injury can be considered as cardio-protective, but did not appear to be sufficient 
to counter the reduced functional recovery and increased infarct size found in the HFD 
group. ART also exhibited cardio protective properties by up-regulating eNOS after 
ischaemia-reperfusion and even more so in combination with a HFD. This may have 
contributed to the improved functional recovery and smaller infarct size in the HFD 
combined with treatment group. 
 
To conclude: HFD, ART and the combination of HFD and ART resulted in up-regulation of 
eNOS post-ischaemia-reperfusion and may have translated into cardio-protection in terms 
of improved functional recovery and reduced infarct-size when ART was combined with a 
HFD. 
 
 
 
4.4.1.3. PKB/Akt: Pre-Ischaemia-Reperfusion 
 
 
PKB/Akt is an important mediator in intracellular signal transduction (Lawlor and Alessi, 
2001; Sussman et al., 2011; Hemmings and Restuccia, 2012). Its activation starts with the 
attachment cytokines, and insulin to cell receptors that trigger the attachment of lipid 
kinase known as phospoinositide 3-kinase (PI3-kinase) to the cellular membrane (Fig. 4.4) 
(Lawlor and Alessi, 2001; Sussman et al., 2011; Hemmings and Restuccia, 2012). 
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Fig. 4.4. PKB/Akt Activation and Cellular Functions. Abbreviations: PKB: Protein 
Kinase B; PI3K: Phosphoinositide 3-kinase; P: Phosphate; eNOS: Endothelial Nitric Oxide 
Synthase; PFK1: Phosphofrictokinase 1; PFK2: Phosphofructokinase 2; NF-κβ: Nuclear 
factor kappa-light-chain-enhancer of activated B cells; NO: Nitric Oxide. Symbols: + = 
Activate; - = Inhibit. (Lawlor and Alessi, 2001; Sussman et al., 2011; Hemmings and 
Restuccia, 2012; Morello et al., 2008; Downward et al., 2005; Flemming and Busse, 1999) 
 
Activated PKB/Akt mediates downstream responses that include cell survival, growth, 
proliferation, migration, and angiogenesis by phosphorylating/activating various 
intracellular proteins (Sussman et al., 2011; Hemmings and Restuccia, 2012; Shiojima and 
Walsh, 2006; Morello et al., 2008). PKB/Akt also positively regulates eNOS and ultimately 
NO release (Morello et al., 2008; Heusch et al., 2008; Large et al., 2008). 
 
In our study, ART itself resulted in the decrease in total PKB/Akt (see Table 4.4). The 
combination of ART with a HFD however caused an increase in total and phosphorylated 
PKB/Akt (see Table 4.4). This increase was lost when expressed as a ratio (phospho / 
total PKB/Akt) (see Table 4.4). A study by Coa et al. (2011) found a decrease in 
phosphorylated PKB/Akt after their HFD programme compared to controls. However, in 
support of our findings, Ouwens et al. (2005) found similar changes in PKB/Akt expression 
between their lean control and HFD group, but with decreased levels of phosphorylated 
PKB/Akt. Down-regulation of PKB/Akt can be considered a CVD risk factor and is 
associated with obesity and cardiovascular risk in the heart as it can lead to decreased 
eNOS activity and the decreased NO production though the PKB/Akt (Huang, 2009; Simon 
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et al., 2014; Lei et al., 2013;). However, in our study, PKB/Akt was relatively unaffected in 
all the experimental conditions. 
 
To conclude: Neither obesity, not ART, or the combination of obesity and ART had an 
effect on PKB/Akt 
 
 
 
4.4.1.4. PKB/Akt: Post-Ischaemia-Reperfusion 
 
 
PKB/Akt is involved in promoting cell survival in the presence of apoptotic stimuli like 
ischaemia (Porstmann et al., 2005; Fujio et al., 2000). PKB/Akt is also involved in the 
regulation of nuclear factor kappa-light-chain-enhancer of activated Beta cells (NF-kB) and 
thus its expression of many pro-survival genes (Porstmann et al., 2005). PKB/Akt is 
furthermore part of the reperfusion injury salvage kinase (RISK) pathway and form part of 
a group of pro-survivial proteins (e.g. PKB/Akt, extracellular receptor kinase (ERK) 1 and 2 
and jun N-terminal kinase (JNK) in the heart (Hausenloy and Yellon, 2007). PKB/Akt’s 
involvement in this RISK-pathway  plays a key role in cardio-protection in ischaemia- 
reperfusion (Fig. 4.5) (Hausenloy and Yellon, 2007; Yellon et al., 2011). 
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Fig. 4.5. PKB/Akt and The RISK Pathway. Abbreviations: RISK: Reperfusion Injury 
Salvage Kinase; GPCR: G-Protein Coupled Receptor; PKB: Protein Kinase B; PI3K: 
Phosphoinositide 3-kinase; eNOS: Endothelial Nitric Oxide Synthase; Ras: Rat Sarcome; 
ERK: Extracellular Receptor Kinase. (Hausenloy and Yellon, 2007). 
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In our study, the HFD, ART and HFD combined with ART, resulted in an overall 
downregulation of the PKB/Akt signalling pathway after the global ischaemia-reperfusion 
insult (see Table 4.5). HFD as well as ART caused a reduction in total PKB/Akt. HFD, ART 
and the combination caused a decrease in phosphorylated PKB/Akt. All three 
experimental groups showed a reduction in the phosphorylated / total ratio PKB/Akt (see 
Table 4.5). Contradictory to this study, study by Salie et al. (2014) found no difference in 
PKB/Akt activation after a global ischaemic insult. 
The HFD-associated down-regulation of PKB/Akt post-ischaemia-reperfusion observed in 
our study may have contributed to the poor functional recovery and increased infarct size 
also observed. Although other studies have associated obesity in rat models, with 
improved functional recovery and infarct-sparing properties (though activation of RISK 
pathway) (Salie et al., 2014), this was not observed in our study. 
 
To conclude: The HFD, ART and combination with ART in our study led to an overall 
down-regulation of PKB/Akt after ischaemia-reperfusion and in the case of the HFD might 
be in part related to the poor recovery and increased infarct size observed. Although a 
similar down-regulation was observed in the combination of HFD with ART, this did not 
completely translate to poor recovery and was not at all reflected in the reduced infarct 
size. Another interesting fact is that despite this overall downregulation in PKB/Akt, we still 
observed an overall up-regulation of eNOS after ischaemia-reperfusion, suggesting that 
other upstream factors may have been involved. 
 
 
 
4.4.1.5. AMPK: Pre-Ischaemia-Reperfusion 
 
 
In addition to its role as an upstream activator of eNOS, AMPK is also an energy 
regulating protein and is activated when ATP levels are low and regulates energy through 
activating energy generating pathways and inhibiting energy consumption pathways 
(Carling, 2004; Towler and Hardie, 2007; Heidrich et al., 2010). Activated AMPK 
furthermore plays a further role in regulating insulin secretion and gene expression in the 
pancreatic β cells, while insulin in turn inhibits AMPK (e.g. in the heart), suggesting a 
complex interplay (Carling, 2004; Carling, 2005; Kahn et al., 2005). AMPK is activated 
during obesity due to several factors that include increased obesity-associated energy 
demand, hypoglycaemia, associated increased haemodynamic load and associated 
metabolic stress (Dyck, 2006). Glycolosis is also directly stimulated by AMPK by directly 
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activating phosphofrictokinases while activated AMPK decreases glycogen synthase 
activity (Arad et al., 2007). Activated AMPK can have many downstream consequences in 
cells as shown in Fig. 4.6. 
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Fig. 4.6. An Overview of AMPK Activation and Role in Cardiac Cells. Abbreviations: 
LKB1: Liver Kinase-1; GLUT-4: Glucose Transporter-4; ROS: Reactive Oxygen Species; 
AMPKK: AMPK Kinase; FAT: FA Transporter; eNOS: Endothelial Nitric Oxide Synthase. 
Symbols: + = Activate (Miller et al., 2005; Heinrich et al., 2010; Minokishi et al., 2002; 
Nagendran et al., 2013). 
 
In our study, only the combination of the HFD with ART seemed to decrease both total and 
phosphorylated eNOS (see Table 4.4). The reductions observed in the HFD and the ART 
groups (compared to lean control), could be due to the increase found in total AMPK and 
no change in phosphorylated (activated) AMPK. Therefore these two experimental 
conditions did not seem to have an effect on AMPK pre-ischaemia-reperfusion. A study by 
Pang et al., 2008 found a decrease in AMPK in their HFD group. Contradictory to this 
study, a study by Coa et al. (2011) found an increase in phosphorylated AMPK in their 
HFD group. 
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To conclude: Only the combination of a HFD with ART seemed to have an effect 
(decrease) in AMPK (total and phosphorylated), although this was not the case when 
phosphorylated AMPK was expressed as a ratio of total AMPK. 
 
 
 
4.4.1.6. AMPK: Post-Ischaemia-Reperfusion 
 
 
Ischaemia decreases ATP concentration (due to hypoxia) in the cardiac cells and 
increases cellular glucose uptake in the heart through GLUT-4 to increase ATP production 
for continued contractility of the heart muscle (Fig. 4.7) (Miller et al., 2005; Paiva et al., 
2010; Heinrich et al., 2010). 
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Fig. 4.7. AMPK Activation During Ischaemia. Abbreviations: AMP: Adenosine Mono 
Phosphate; ATP: Adenosine Triphosphate; AMPKK: AMPK Kinase. Symbols: + = 
Activate; = Increase; = Decrease (Miller et al., 2005; Paiva et al., 2010). 
 
 
 
Activated AMPK during ischaemic stress leads to increased glucose uptake, glycolysis and 
FA oxidation that subsequently lead to cardio-protection through preventing apoptosis 
(Miller et al., 2005; Paiva et al., 2010). 
In our study, all three experimental conditions seemed to cause an overall downregulation 
of AMPK (see Table 4.5). This reduction observed in the phosphorylated / total AMPK 
ratio is in agreement with the findings of a study by Pang et al., 2008. Contradictory to this 
study, a study by Coa et al. (2011) found an increase in phosphorylated AMPK in their 
HFD group. 
 
To conclude: All of the experimental conditions (with the exception of the increased 
phosphorylated / total AMPK in the HFD + ART group), seemed to downregulate AMPK. 
Again this was somewhat surprising as despite the overall downregulation of both PKB/Akt 
and AMPK (upstream activators of eNOS), we still found an overall increase in eNOS. 
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4.4.2. Proteins Associated with Oxidative Stress 
 
Pathophysiological conditions such as oxidative stress increases the production of 
superoxide (O2-) and NO (Strijdom, 2012; Shishehbor et al., 2003; Pacher et al., 2007). A 
diffusion-controlled reaction (spontaneous) between NO with O2- leads to the formation of 
peroxinitrite (ONOO-) (Strijdom, 2012; Shishehbor et al., 2003; Turko and Murad, 2002; 
Peluffo and Radi, 2007). Increased generation of ROS, such as superoxide (O2-), result in 
oxidative stress, which is harmful to the myocardium (Strijdom, 2012; Pacher et al., 2007; 
Peluffo and Radi, 2007). Nitrotyrosine is a by-product in the production of the harmful 
radical, peroxynitrite (ONOO-), and thus a good marker of ONOO- (Strijdom, 2012; Pacher 
et al., 2007; Peluffo and Radi, 2007). ONOO- in turn is a destructive free radical oxidant 
that can damage DNA, membrane lipids, and mitochondria and can result in cellular 
apoptosis and necrosis (Fig. 4.8) (Strijdom, 2012; Shishehbor et al., 2003; Pacher et al., 
2007). 
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Fig. 4.8. Nitrotyrosine as a Marker for Peroxynitrite and Ultimate ED and CV 
Dysfunction. Abbreviations: NO: Nitric Oxide; NOS: Nitric Oxide Synthase; NF-κβ: 
Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells; TNF-α: Tumor Necrosis 
Factor Alpha; DNA: Deoxyribonucleic Acid; PARP: Poly ADP Ribose Polymerase. 
Symbols: - =Inhibit. (Strijdom, 2012; Shishehbor et al., 2003; Pacher et al., 2007; Turko 
and Murad, 2002; Peluffo and Radi, 2007; Buonocore et al., 2010; Ray et al., 2005). 
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P22 phox is one of several subunits of the O2- generating NADPH oxidase and thus a 
good marker of NADPH-oxidase activation and hence NADPH-oxidase dependent O2- 
production (Fig. 4.9) (San Jose et al., 2008; Griendling et al., 2000; Cahilly et al., 2000). 
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Fig. 4.9. Schematic Illustration of Vasculature NADPH Oxidase Activation and Its 
Component P22  Phox. Abbreviations: Nox: Vasculature NADPH  Oxidase; rac: Ras- 
Related C3 Botulinum Toxin; P22 Phox, p47, p67: Subunits of the NADPH-Oxidase 
Complex. NO: Nitric Oxide. eNOS: Endothelial Nitric Oxide Synthase; NADPH: 
Nicotinamide Adenine Dinucleotide Phosphate (San Jose et al., 2008; Griendling et al., 
2000; Cahilly et al., 2000; Bedard and Krause, 2007). 
 
 
 
4.4.2.1 Nitrotyrosine: Pre-Ischaemia-Reperfusion 
 
 
Obesity and its metabolic abnormalities such as insulin resistance, hyperglycaemia and 
hypercholesterolemia are known to cause nitrosative and oxidative stress in the heart 
(increase in ROSs such as O2- and ONOO
-) and contribute to CVD (Fig. 4.10) (Pacher et 
al., 2005; Hensley et al., 2000; Csaba et al., 2007). 
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Fig. 4.10. Nitrotyrosine and Oxidative Stress in Obesity. Abbreviation: ROS: Reactive 
Oxygen Species; NO: Nitric Oxcide. Symbols: = Increase; = Decrease; (Pacher et 
al., 2005; Hensley et al., 2000). 
 
In our study, the HFD and when combined with ART led to decreased nitrotyrosine (see 
Table 4.4) pre-ischaemia. In contrast to our study, Rennison and Wagoner (2009) showed 
increased nitrotyrosine levels in a HFD rat model, but Relling et al. (2006) did not find any 
changes in nitrotyrosine levels after their HFD rat model. Although obesity has been 
associated with increased oxidative stress (nitrotyrosine level is an indicator of oxidative 
stress) due to the production of ROS (such as peroxynitrite) in the vasculature and has 
been associated with atherosclerosis and other CVDs (Pacher et al., 2005; Hensley et al., 
2000; San Jose et al., 2008), the opposite was found in our study. Interestingly, the 
combination of ART and HFD resulted in even lower nitrtotyrosine levels. 
 
To conclude: Surprisingly, obesity reduced nitrotyrosine levels pre-ischaemia-reperfusion 
and induced even a further reduction when combined with ART, although ART per se did 
not affect nitrotyrosine levels. These findings in terms of ART, has not been described yet 
and can thus be considered as novel. 
 
 
 
4.4.2.2. Nitrotyrosine: Post-Ischaemia-Reperfusion 
 
 
During global and regional ischaemia oxidative and nitrosative stress is increases (Pacher 
et al., 2005; Hensley et al., 2000; Yasmin et al., 1997). OONO- is rapidly produced during 
acute reperfusion of ischaemic hearts and leads to the formation of nitrotyrosine (Fig. 
4.11) (Ferdinandy and Schulz, 2003; Ferdinandey P, 2015). This can lead to decreased 
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left ventricular function, increased myocardial damage, apoptosis, increased neutrophil 
infiltration, increased circulating tumor necrosis factor alpha (TNF-α), and increased infarct 
size (Pacher et al., 2005; Hensley et al., 2000). 
 
 
 
 
Fig. 4.11. Nitrotyrosine and Oxidative Stress in Ischaemia-Reperfusion. Symbols: = 
Increase; = Decrease (Pacher et al., 2005; Hensley et al., 2000). 
 
In our study, only ART resulted in a 35 % increase in nitrotyrosine compared to lean, 
control as well as HFD with ART (see Table 4.5). Although obesity has been associated 
with increased nitrotyrosine production post ischaemia (Pacher et al., 2005; Hensley et al., 
2000), this was not observed in our study. ART increased post-ischaemic nitrotyrosine 
levels. This may be related to the ART-associated AMPK and PKB/Akt down-regulation we 
also observed in post-ischaemia-reperfusion in our study, but needs further investigation. 
 
To conclude: In the present study, ART was associated with increased nitrotyrosine levels 
compared to lean control in the post-ischaemia-reperfusion setting. This is consistent with 
findings in human studies that also associated ART with increased oxidative stress, but 
interestingly obesity ameliorated this. These findings in terms of ART is considered novel, 
as it has not been described yet, to our knowledge. 
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4.4.2.3. P 22 Phox: Pre-Ischaemia-Reperfusion 
 
 
Obesity, insulin resistance and hyperlipidaemia have been associated with oxidative stress 
through NO dysregulation and increased ROS generation due to decreased NOS 
bioavailability that leads to CVD (Roberts et al., 2006; Shulman GI, 2000). ROS may 
increase expression and phosphorylation of NADPH-oxidase (Murdoch et al., 2006). 
NADPH oxidase can also be activated and expressed via numerous other factors (Fig. 
4.12) (Murdoch et al., 2006). 
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Fig. 4.12. Factors that Lead to Increased NADPH Oxidase Activation and 
Expressionand its Component P22 Phox. Abbreviations: P22 Phox: Subunits of the 
NADPH-Oxidase Complex. NADPH: Nicotinamide Adenine Dinucleotide Phosphate; LDL: 
Low-Density Lipoprotein; TNF-α: Tumor Necrosis Factor Alpha. Symbols: + = Activation 
(Murdoch et al., 2006; Heymes et al., 2003; Jones et al., 2005). 
 
Interestingly, a decrease in p22 phox expression was observed in all the experimental 
conditions compared to the untreated lean control group pre-ischaemia-reperfusion (see 
Table 4.4). Contrary to our findings, Feillet-Coudray et al. (2009) found an increase in 
NADPH activity in their HFD group. Also, Liu J and Lloyd (2013) found increased NADPH 
activity following their HFD. The decreased level of p22 phox is, amongst others, an 
indicator of decreased NADPH-oxidase induced ROS production and could reflect a state 
of reduced oxidative stress, which is cardio-protective (San Jose et al., 2008; Griendling et 
al., 2000; Bedard and Krause, 2007; Cai, 2005). Although obesity has previously been 
shown to be associated with increased p22 phox levels (Murdoch et al., 2006; Roberts et 
al., 2006), this was not observed in the current study. On the other hand, ART has also 
previously been associated with oxidative stress (Dubé et al., 2015; Hasse et al., 2011; 
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Chaves et al., 2003) in human studies, but in terms of p22phox and NADPH oxidase 
signalling, this ART FDC appeared to be beneficial as it reduced ROS production (even 
more so in combination with a HFD). The decrease in p22 phox levels is also in contrast to 
increased TBARS levels observed in the HF/-ART group compared to the lean, control, 
suggesting another protective mechanism may have been activated in the heart against 
obesity-associated systemic oxidative stress. The reason for the decreased p22 phox level 
in lean, treated group compared to the lean, control may indicate that this specific ART 
combination might be beneficial in protecting the heart against oxidative stress although 
this was not observed in terms of nitrotyrosine. 
 
To conclude: The HFD, ART and the combination of HFD with ART seemed to be cardio- 
protective in terms of p22 phox-associated oxidative stress. These ART related findings is 
considered novel as the effects of this ART combination in the context of our study has not 
yet been described. 
 
 
 
4.4.2.4. P22 Phox: Post-Ischaemia-Reperfusion 
 
 
Numerous factors during ischaemia contribute to the activation of NADPH-oxidase and its 
p22 phox subunit (Fig. 4.13) (Murdoch et al., 2006; Kimura et al., 2005). 
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Fig. 4.13. Factors that Lead to Increased NADPH Oxidase and Its Component P22 
Phox Activation and Expression During Ischaemia-Reperfusion. Abbreviations: P22 
Phox: Subunits of the NADPH-Oxidase Complex. NADPH: Nicotinamide Adenine 
Dinucleotide Phosphate (Murdoch et al., 2006; Yoshikawa and Abe, 2001). 
 
P22 phox, TBARS, and NF-kB levels have been associated with increased infarction after 
MI (Fukui et al. (2001) Fukui et al., 2004). In our study, the HFD reduced p22 phox levels 
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compared to lean control (32 %) post ischaemia-reperfusion. Although ART itself did not 
affect p22 phox levels in our study, the combination of ART and obesity increased p22 
phox by 50 % compared to lean, treated and 65 % compared to the HFD itself (see Table 
4.5). These results indicate that the HFD reduced oxidative stress and the reason for this 
may be due to the HFD-associated up-regulation of eNOS observed after ischaemia- 
reperfusion in our study. This reduction in oxidative stress did not translate in improved 
functional recovery as infarct size was increased and functional recovery reduced 
compared to all experimental conditions. 
 
To conclude: The HFD in our study resulted in decreased levels of p22 phox and thus 
reduced oxidative stress compared to lean, controls (not reflected in poor functional 
recovery and increased infarct size). When the HFD was combined with ART, oxidative 
stress (in terms of p22 phox) was increased. Findings in terms of ART have not been 
describe in the context of your study and was considered novel. 
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4.4.3. Pro-Inflammatory NF-κβ Signalling 
 
 
NF-κβ activates the transcription of many genes associated with inflammation (Jones et 
al., 2005; Brasier, 2006; Pierce et al., 2009). IκBα regulates the transcription factor NF-κβ 
by keeping it in an inactive state and thus inhibiting inflammatory signalling (Huxford and 
Ghosh, 2009; Jacobs and Harrison, 1998; Baeuerle, 1998) (Fig. 4.14). 
 
 
 
 
 
Fig. 4.14. IκBα Inhibition of NF-κβ. Abbreviations: IκBα: Nuclear Factor of Kappa Light 
Polypeptide Gene Enhancer in B-cells Inhibitor, Alpha; NF-κβ: Nuclear factor kappa-light- 
chain-enhancer of activated B cells; IκB-Kinase: Multi-kinase complex; P: Phosphate. 
Symbols: + = Activate. (Huxford and Ghosh, 2009; Jacobs and Harrison, 1998; Baeuerle, 
1998) 
 
In the CV system, NF-κβ activation is associated with myocarditis, ischaemic injury, MI, 
dilatation, heart failure, cardiac hypertrophy, atherosclerosis and ED (Jones et al., 2005). 
IκBα inhibition of NF-κβ plays thus an important role in CV function (Jones et al., 2005). 
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4.4.3.1. IκBα: Pre-Ischaemia-Reperfusion 
 
 
During obesity, NF-κβ expression is increased and positively related to nitrotyrosine 
(Pierce et al., 2009). Studies further found that vascular ED in obesity is in part mediated 
via the NF-κβ pathway (Fig. 4.15) (Pierce et al., 2009). 
 
 
 
 
 
Fig. 4.15. Obesity Leading to Inflammation and NF-κβ Activation. Abbreviations: IκBα: 
Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-cells Inhibitor, Alpha; NF- 
κβ: Nuclear Factor Kappa-Light-Chain-Enhancer of Activated Beta cells (Pierce et al., 
2009). 
 
In our study, the HFD caused a 14 % reduction in IκBα expression (compared to lean, 
controls), while the combination of the HFD with ART resulted in an increase of 28 % in 
IκBα levels (see Table 4.4). These findings suggest that the HFD induced activation of the 
pro-inflammatory NF-κβ pathway and reduced NF-κβ activation when combined with ART. 
Obesity (Pierce et al., 2009) and ART-treatment per se (Dubé et al., 2015; Hasse et al., 
2011; Chaves et al., 2003) have previously been associated with inflammation and this 
was reflected in our finding in terms of our HFD. The HFD in combination with ART 
exhibited ant-oxidative stress properties (decreased nitrotyrosine and p22 phox levels) and 
this was indeed reflected in decreased inflammatory signalling. 
 
To conclude: The HFD in our study seemed to induce pro-inflammatory signalling, while 
when combined with ART it seemed to result in a reduction. This is possibly due to the 
anti-oxidative stress properties observed. The effect of this ART combination in the context 
of our study has not been described yet, to our knowledge, and is considered novel. 
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4.4.3.2. IκBα: Post-Ischaemia-Reperfusion 
 
 
Ischaemia-reperfusion produces ROS (e.g. NO) and reactive nitrogen species such as 
peroxynitrite that’s involved in cell death (Jones et al., 2005). There is some controversy 
over whether NF-κβ is cardio-protective or cardio-damaging because of its role in 
activation pro-cell survival genes after hypoxia and ischaemia preconditioning also, but 
has been found to be predominantly cardio-damaging after ischaemia-reperfusion (Jones 
et al., 2005; Csonka et al., 2001; Downey et al., 2007). Nonetheless, NF-κβ is a powerful 
activator of pro-inflammatory cytokines and an activator of pro-apoptotic genes during 
ischaemia-reperfusion, which makes its inhibitor in response to inflammation in cardiac 
cells a powerful indicator of inflammation during ischaemia-reperfusion (Fig. 4.16) (Jones 
et al., 2005). 
 
 
 
 
 
 
Inﬂamma=on 
 
 
 
Fig. 4.16. IκBα Dissociates from NF-κβ During Ischaemia-Reperfusion Leading to 
Inflammation. Abbreviations: NO: Nitric Oxide; IκBα: Nuclear Factor of Kappa Light 
Polypeptide Gene Enhancer in B-Cells Inhibitor, Alpha; NF-κβ: Nuclear Factor Kappa- 
Light-Chain-Enhancer of Activated B Cells. NO: Nitric Oxide; Symbols: + = Activate; - = 
Inhibit (Jones et al., 2005). 
 
In our study, both the HFD and when combined with ART reduced IκBα levels after 
ischaemia-reperfusion (see Table 4.5). Thus inflammatory signalling was increased by 
both the HFD and the combination of the HFD with ART in our study after an ischaemic 
insult. These findings do not correlate with the reduced oxidative stress and overall up- 
regulation we observed in these groups post-ischaemia and needs further investigation. 
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In summary: In our study, both the HFD and its combination with ART led to increased pro- 
inflammatory NF-κβ signalling, ART did not have any effect on inflammatory signalling 
post-ischaemia-reperfusion. To our knowledge, the effects of this specific ART 
combination post-ischaemia-reperfusion in the context of this study had not been 
described yet and is thus considered novel. 
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4.5. Summary of the Main Findings 
 
 
 
 
 
 
 
 
 
Fig. 4.17. Summary  of  Results.  Abbreviations:  IS:  Infarct  Size;  I/R:  Ischaemima- 
Reperfusion Symbols: = Increase; = Decrease. 
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The HFD in our study was successful in inducing increased body weight, IP fat mass and 
heart mass (g). This was further validated by increased TG levels. Cardiovascular risk 
associated with a HFD was underscored in our study in terms of relatively poorer 
functional recovery and increased infarct size after an ischaemia-reperfusion insult. The 
HFD possibly contributed to decreased functional recovery and increased infarct size 
though increased TBM, increased IP fat mass, increased heart mass, increased TG and 
TBARS levels, down-regulation of AMPK, up-regulation of inflammatory signalling and 
down-regulation of PKB/Akt. The improvement observed when ART was combined with a 
HFD (especially in terms of infarct size and some of the functional recovery endpoints) 
was possibly due to reduced oxidative stress (reduced CD levels, reduced nitrotyrosine 
levels and reduced p22 phox expression) and an up-regulation of eNOS. Although there 
was an increase in TBARS levels, it was not supported by the reduction found in 
nitrotyrosine and p22 phox levels. 
ART on its own led to an increase in TC and TBARS levels as well as an increase in 
nitrotyrosine after ischaemia. However, on the other hand, it seemed to induce the cardio- 
protective eNOS pathway after an ischaemic insult. Apart from these findings, this specific 
ART drug combination did not seem to  have a profound effect on any of  the other 
parameters assessed. When the HFD was combined with ART, the ART seemed to 
ameliorate the harmful effects caused by the HFD itself, particularly in terms of the isolated 
heart perfusion studies, as was seen in the slight improvement in functional recovery as 
well as the reduced infarct size. 
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Chapter 5 – Final Conclusion 
 
 
5.1. Conclusion 
 
 
In the present study the HFD resulted in increased the TBM, IP fat mass and heart mass. 
Despite increasing the TG levels, the HFD was unsuccessful in inducing insulin resistance. 
Although the HFD increased oxidative stress as demonstrated by elevated TBARS levels, 
the other markers of oxidative stress (nitrotyrosine and p22 phox levels) were decreased 
both in the pre-and post-ischaemia-reperfusion scenario. Overall, ALL  endpoints 
measured as markers of myocardial function in the HFD group were significantly and 
negatively affected by the ischaemia-reperfusion insult, something which was not 
observed in any of the other groups, and this was associated with an increased infarct size 
following regional ischaemia-reperfusion. Although eNOS was upregulated (only after 
ischaemia-reperfusion) in the HFD, PKB/Akt (RISK pathway component) was 
downregulated. The overall downregulation in PKB/Akt signalling might explain the poor 
recovery and increased infarct size that we observed. There was also an increase in pro- 
inflammatory NF-κβ activation. 
 
Although ART in lean animals led to increased TC levels, it had no effect on TBM, IP fat 
and heart mass. ART led to increased TBARS levels, yet this was accompanied by 
decreased nitrotyrosine and p22 phox levels. Oxidative stress was evident in lean animals 
receiving ART after the global ischaemia-reperfusion insult as demonstrated by increased 
nitrotyrosine levels. Apart from the TBARS and increase in nitrotyrosine (post-ischaemia), 
ART did not seem to have any effect on any of the other parameters assessed. 
 
ART combined with a HFD exerted interesting effects. Although the increases in TBM and 
IP fat mass were not affected by ART, it did additionally result in liver mass in the HFD 
animals. The administration of ART to the HFD animals seemed to alleviate some of the 
harmful effects we observed in the HFD only. This could be observed in the overall 
upregulation of the cardioprotective eNOS enzyme, which was associated with a modest 
improvement functional recovery and a significant reduction in infarct size (when 
compared to HFD only). 
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This study thus underscores the detrimental effect of a HFD and obesity on cardiovascular 
health compared to lean, control. Interestingly, when combined with ART, there seemed to 
be an improvement in some endpoints of cardiovascular health compared to the HFD 
itself. ART administration to lean animals exhibited little effect on cardiovascular health in 
our study compared to lean, control, but improved when compared to in combination with 
a HFD (Fig. 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.1. Suggested Overall Cardiovascular Risk Associated with Each Experimental 
Condtion. 
 
Findings regarding this specific ART combination in terms of cardiovascular health 
parameters assessed in a rat model of obesity are considered novel, as it has not been 
described yet in the context of the present study. 
 
 
 
5.2. Shortcomings 
 
 
Although the HFD model in this study has previously been established, assessing the 
effect of this particular ART combination in a rat model of obesity was novel. No 
information from previous studies could be used for our study design or to improve on 
previous studies. Little is known on the effect of ART per se, in the context of obesity on 
cardiovascular health. Parameters assed in our study had to be carefully selected on 
limited information available from human studies mostly. As little is known about the 
overlap of obesity and ART in terms of cardiovascular risk/disease, selecting parameters 
to be assessed during our study, relied mostly on suggestions from literature (human 
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studies) in terms of some parameters that might lay at the intersection of obesity, ART and 
cardiovascular disease. 
 
The number of animals we could assign to each experimental group was also a limitation 
in our study. This was mainly due to the cost per animal on a 16-week diet program in the 
animal facilities as well as the time restraints in completing experimentation after a lengthy 
feeding programme. It was also originally decided to administer the drug combination in 
jelly cubes as has previously been used for other drug-studies in out laboratory. However, 
the animals refrained from eating the jelly cubes and we had to change our protocol from 
the above to gavaging of the animals to ensure daily administration of the drug. This 
resulted in the loss of animals and reduced our sample size per group for all parameters 
assessed. Some of these experimental procedures in our study require a larger than usual 
sample size as the data points does not tend to cluster. Greater sample sizes may have 
improved accuracy and elucidated borderline significant differences between experimental 
groups. 
Also, the cardiovascular effects of this ART combination may have become more 
pronounced if the 16-week feeing programme and/or the 6-week drug treatment 
programme were extened beyond 16 and 6 weeks. As HIV-populations are aging and 
becoming more drug-experienced, studying the long-term effects of ART is becoming 
more relavant (also in terms of obesity). 
Furthermore, our HFD did not succeed in inducing insulin resistance in the HFD groups. 
This may have implication on parameters assed in our study. 
It would have been ideal to investigate the effects of ART in an animal model of HIV and 
obesity combined, but this was not phesable. 
 
 
 
5.3. Future Directions 
 
Our study only focused on a few parameters that can be affected by obesity and ART. The 
effect of the ART combination on cellular studies, ex vivo, may yield interesting results in 
terms of underlying mechanisms. It would be interesting to elucidate the effect of this ART 
combination and in comparison to 2nd line ART as well in another model, such as an in 
vitro model. 
Many of the mechanisms involved the pathogenesis of ART-associated CVD disease need 
to  be  elucidated.  For  example,  our  study  indicated  that  this  ART  combination  may 
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contribute to insulin level dysregulation and hepatotoxicity, but this still needs to be 
described. 
Drug administration in our study lasted 6 weeks. Long-term exposure to ART has been 
shown to elucidate more adverse effects. The long-terms effects of this ART combination 
may in terms of obesity and a lean diet alone may generate interesting findings. Although 
our diet was high in sucrose and fat, ART may show other effects in terms of other diets. 
The drug combination consisted only of three ART drugs combined. Numerous other ART 
drug combinations are available. A study comparing the effects of different drug 
combinations may indicate which combinations are safer to use. The individual effects of 
our three drugs on cardiovascular health may have also indicated to which extent each 
drug contributes to cardiovascular health and other associated adverse effects associated 
with this specific drug component. 
In general, the cardiovascular effects of ART and HIV have only recently started to receive 
greater attention in the research world. With numerous drugs and drug combination 
available on the market, and limited research on the CV effects of these ARTs in human 
and animal studies available, leaves a great gap to fill in terms of scientific research. 
 
 
 
5.4. Research Outputs Associated with This Study 
 
 
Conference Contributions: 
 
 
Year: 2015 
Authors: F Everson, H Strijdom, T Ogundipe, T Grandjean and A Genis. 
Reference: Investigate the Cardiovascular Effects of Antiretroviral Therapy in Obesity. 
(Oral Presentation) 
Physiology Society of Southern Africa Annual Congress, Parys (Free State), 2015. 
 
 
 
Year: 2015 
Authors: A Genis, F Everson, T Ogundipe, T Grandjean and H Strijdom. 
Reference: NO, ROS andPro-Inflammatory Signalling in Ischemia-Reperfused Hearts from 
Obese Rats Treated With 1st line ART’s. (Poster Presentation) 
Physiology Society of Southern Africa Annual Congress, Parys (Free State), 2015. 
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Other outputs: 
 
 
Year: 2014 
Authors: F Everson, H Strijdom, T Ogundipe, T Grandjean and A Genis. 
Reference: Investigate the Cardiovascular Effects of Antiretroviral Therapy in Obesity. 
Annual Research Day, Faculty of Health Sciences, Stellenbosch University, 2014. 
 
 
Year: 2015 
Authors: F Everson, H Strijdom, T Ogundipe, T Grandjean and A Genis. 
Reference: The Effects of Antiretroviral Therapy on Cardiometabolic Parameters In a High 
Fat Diet Rat Model of Obesity. 
Annual Research Day, Faculty of Health Sciences, Stellenbosch University, 2015. 
 
 
Year: 2015 
Authors: F Everson, H Strijdom, T Ogundipe, T Grandjean and A Genis. 
Reference: Antiretroviral Therapy: The Cardiovascular Effects in a High Fat Diet Rat Model 
of Obsity. 
Annual  Research  Day,  Department  of  Biomedical  Sciences,  Stellenbosch  University, 
2015. 
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Appendix A - Preparation of HFD Food 
 
 
 
 
The HFD food was prepared by soaking normal rat chow (600 g) in a 250 ml mixture of 
warm water and dissolved sucrose (140 g standard household sugar) for about 30 
minutes. The soaked rat chow was thoroughly mixed with melted vegetable fat (4 X 125 g 
Holsum™), eight cans of full cream, sweetened, condensed milk (8 X 385 g / can; 
Clover™) and stored in a refrigerator for later use. 
 
Table A.1.    Nutritional Value of Holsom™ Butter. 
 
 
 
 
Energy (kJ) 
Per 100 g 
3700 
Protein (g) 0 
Glycaemic Carbohydrates (g) 0 
Of which total sugar (g) 0 
Total fat (g) 100 
Of which saturated fat (g) 
Trans fat (g) 
67.8 
<1 
Monounsaturated fat (g) 26.4 
Dietary ﬁbre (g) 0 
Total Sodium (mg) 0 
Vitamin A (μg) 1380 
Vitamin D (μg) 15 
 
 
Table A.2.    Nutritional Values of Condensed Milk. 
 
 
 
 
Energy (kJ) 
Per 100 g 
1381 
Protein (g) 6.5 
Glycaemic Carbohydrates (g) 54 
Of which total sugar (g) 54 
Total fat (g) 8.7 
Of which saturated fat (g) 5.5 
Dietary ﬁbre (g) 0 
Total Sodium (mg) 127 
Calcium (mg) 284 
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Appendix B - Method of Drug Dose Calculation 
 
 
The daily dose (mg / kg) of each active ingredient for a human was calculated as follow: 
!" 
AId  = 
!t 
AId = Daily dose of active ingredient (mg / kg). 
AI = Active ingredient (mg). 
mt = Average body mass of a human(kg). 
(8.6 mg / kg / day EFV; 2.9 mg / kg / day FTC; 4.3 mg / kg / day TDF) 
 
 
Daily dosage per animal (mg / kg) was calculated according to the USA FDA guidelines 
using a conversion factor of X 6 to convert human to rat ratio: 
AIrat  = 6(AId ) AIrat = Daily dose of active ingredient for a rat (mg / kg) 
AId = Daily dose of active ingredient (mg / kg) 
(EFV: 51.6 mg / kg / day; FTC: 17.4 mg / kg / day; TDF: 25.8 mg /kg / day). 
 
 
Thus, for treated groups, the daily dose of active ingredients per animal needed was 
calculated weekly based on the average TBM of each group as follow: 
AId/r  = AIrat(mavg) AId/r = Daily dose of active ingredient per rat (mg / kg). 
AIrat = Active ingredient for a rat (mg). 
mavg = Average TBMof rats in a group (kg). 
 
 
The mass of the 3 active ingredients combined in each tablet was 1100 mg (600 mg EFV 
+ 200 mg FTC + 300 mg TDF). The actual % (m / m) of the active ingredients in each 
tablet was calculated according to the mass of the tablet as follow: 
!"T AI%  = 
!T 
AI% = % Mass active ingredient in the tablet. 
AIT = Total mass of active ingredient, 1100 g. 
mT = Total mass of the crushed tablet (g). 
 
The amount (mg) of crushed powder of the tablet needed for a treated group with a certain 
average TBM (350 g per animal for example) was calculated as follow: 
EFV: AIrat  = 51.6 mg / kg / day 
AId/r  = AIrat(mavg) AId/r = Daily dose of active ingredient per rat (mg / kg). 
= (51.6 mg / kg)(0.35 kg) AIrat = Active ingredient for a rat (mg). 
= 33.22 mg mavg = Average TBM of rats in a group (kg). 
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If the % (m/m) of active ingredient is 68 % (for example), the amount (mg) of tablet powder 
weighed off was calculated as follow: 
AIw  = AId/r(AI%) AIw = Mass of the tablet powder weighed off per rat (mg) 
= 33.22 mg (68 %)  AId/r = Daily dose of active ingredient per rat (mg / kg). 
= 22.58 AI% = Mass % active ingredient in the tablet. 
 
 
mp  = 
!T 
!"w 
mp = Mass of the crushed tablet needed per rat daily (mg). 
mT = Total mass of the crushed tablet (mg). 
AIw = Mass of the tablet powder weighed off per rat (mg). 
 
 
To prepare enough of the FDC for 4 rats for 8 days: 
MTP = mp(N)(d)  MTP = Total mass of crushed powder per group per week (g). 
mp = Mass of the crushed tablet needed per rat daily (mg). 
N = Number of rats in the group. 
d = Number of days 
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Appendix C - Principles of the ELISA Assay 
 
 
The kit is used for the non-radioactive quantification of insulin in mouse and rat sera. The 
assay is a sandwich ELISA based. The principal of the procedure include: 
 
a) Capturing of the insulin molecules from samples to the wells of a microtiter plate 
coated by pre-titered amount of a monoclonal mouse anti-rat insulin antibodies 
and the binding of biotinylated polyclonal antibodies to the captured insulin. 
b) The wash away of unbound materials from samples. 
c) The binding of horseradish peroxidase to the immobelised biotinylated 
antibodies. 
d) The wash away of free enzyme conjugates by monitoring horseradish 
peroxidase activities in the presence of the substrate 3,3’,5,5’- 
tetramethylbenzidine. 
 
The enzyme activity is measured spectrophotochemically by the increased absorbency at 
450nm, corrected from the absorbency at 590nm, after acidification of formed products. 
Since the increase in absorbency is directly proportional to the amount of captured insulin 
in the unknown samples, the latter can be derived by interpolation from a reference curve 
generated in the same assay with reference standards of known concentrations of rat 
insulin. 
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Appendix D - Food and Water Monitoring 
 
 
 
 
 
 
 
 
 
 
 
 
C/$ART C/+ART HF/$ART 
 
   
 
  
 
 
 
Fig. D.1. Mean Amount of Rat Chow Consumed / Animal (g / animal / day) for each 
Experimental Group for the First 31 Days During the Drug Treatment Programme with 
Linear Trend Lines. Slope of Trend Line: C/-ART: -0.00; HF/-ART: 0.05; C/+ART: -0.01; 
HF/+ART: 0.02. N = 7 - 8 / day / group. 
 
 
 
 
 
Fig. D.2.  The Mean Amount of Water Consumed / Animal (ml / animal / day) for the 
first 31 Days of the Drug Treatment Programme with Linear Trend lines. Slope of Trend 
Line: C/-ART: -0.00; HF/-ART: 0.17; C/+ART: -0.05; HF/+ART: 0.18. N = 7 - 8 / day / 
group. 
y = $0,0525x + 28,482 
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Mean Amount (g) of Rat Chow Consumed per Animal Daily 
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 y = $0,0233x + 34,607  
y = $0,1423x + 35,404  
 
 
 
 
 
 
Fig. D.3. The Mean Amount of HFD Food Consumed / Animal (g / animal / day) for the 
First 31 Days of the Drug Treatment Programme with Linear Trend Lines. Slope of Trend 
Line: HF/-ART: -0.02; HF/+ART: -0.14. N = 7-8 / day / group. 
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Appendix E - Other Haemodynamic Data for Global Ischaemia- 
Reperfusion 
 
 
Table E.1. Summary of Other Haemodynamic Data – Global Ischaemia-Reperfusion 
(data expressed as mean ± SEM / group (% Recovery), p < 0.05). Abbreviations: DP: 
Diastolic Pressure; MAP: Mean Arterial Pressure; PST: Peak Systolic Time; ET; Ejection 
Time; CT: Cycle Time; KP: Kinetic Power; PP: Pressure Power; dP/dTMax: Maximum 
Rate of  Left  Ventricular  Pressure  Rise;  dP/dTMin:  Maximum  Rate  of  Left  Ventricular 
Pressure Fall. Pre-Ischaemia vs. Post-Ischaemia: * = p < 0.05; ** = p < 0.01; *** = p < 
0.001; **** = p < 0.0001. 
 
Haemodynamic Data 
Pre$Ischaemia vs. Post$Ischaemia 
Mean ± SEM 
(% Recovery) 
C/:ART 
(Pre: N = 16; Post: N = 6) 
HF/:ART 
(Pre: N = 14; Post: N = 6) 
C/+ART 
(Pre: N = 11; Post: N = 4) 
HF/+ART 
(Pre: N = 13; Post: N = 6) 
DP 
(mmHg) 
Pre 84.63 ± 1.48 82.29 ± 1.381 84.27 ± 1.657 82.31 ± 1.402 
Post 71.67 ± 14.58 35.17 ± 16.57 **** 60.75 ± 0.35 (72.09%) 40.33 ± 18.07 (49.0%) *** 
% Recovery 84.69 % 42.73 % 72.09 % 49.00 % 
MAP 
(mmHg) 
Pre 98.43 ± 1.225 95.12 ± 1.581 95.51 ± 1.55 93.69  ±  1.727 
Post 79.12 ± 15.95 38.60 ± 18.31 **** 68.00 ± 1.73 45.2 ± 20.26 (48.24%) *** 
% Recovery 80.38 % 40.58 % 71.20 % 48.24 % 
ET 
(sec) 
Pre 0.078 ± 0.00 0.075 ± 0.002 0.071 ± 0.00 0.08 ± 0.00 
Post 0.058 ± 0.01 (75.26%) 0.03 ± 0.02  **** 0.064 ± 0.00 0.05 ± 0.01 ** 
% Recovery 75.26 % 34.1 % 89.80 % 62.74 % 
CT 
(sec) 
Pre 0.29 ± 0.022 0.26 ± 0.01 0.24 ± 0.01 0.25 ± 0.01 
Post 0.20 ± 0.04 0.08 ± 0.05  **** 0.33 ± 0.04 0.02 ± 0.05 
% Recovery 71.46 % 31.00 % 130.31 % 81.89 % 
PSP 
(mmHG) 
Pre 105.10 ± 1.57 100.80 ± 2.05 101.70 ± 1.69 99.15 ± 2.03 
Post 83.32  ± 16.79 41.00 ± 19.17 **** 86.0 ± 8.37 66.83 ± 16.79 * 
% Recovery 77.80 % 40.94 % 82.94 % 64.44 % 
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Appendix F - Haemodynamic Data for Regional Ischaemia-Reperfusion 
 
 
Table F.1. Summary of Haemodynamic Data – Regional Ischaemia-Reperfusion (data 
expressed as mean ± SEM / group (% Recovery), p < 0.05). Abbreviations: HR: Heart 
Rate; AO: Aortic  Output; CF:  Coronary Flow;  CO: Total  Cardiac Output;  PSP: Peak 
Systolic Pressure; Wt: Total Power; Pre: Pre-ischaemia-reperfusion; Post: Post-Ischaemia- 
reperfusion. Pre-Ischaemia vs. Post-Ischaemia: * = p < 0.05; ** = p < 0.01; *** = p < 
0.001; **** = p < 0.0001. 
 
Haemodynamic Data 
Pre$Ischaemia vs. Post$Ischaemia 
Mean ± SEM 
(% Recovery) 
C/:ART 
(Pre: N = 16; Post: N = 8) 
HF/:ART 
(Pre: N = 14; Post: N = 7) 
C/+ART 
(Pre: N = 11; Post: N = 4) 
HF/+ART 
(Pre: N = 13; Post: N = 8) 
HR 
(BPM) 
Pre 224.80 ± 12.67 234.80 ± 8.72 245.90 ± 6.18 259.40 ± 17.47 
Post 162.70 ± 37.66 227.30 ± 17.07 230.20 ± 13.97 229.60 ± 57.86 
% Recovery 72.38 % 96.80 % 93.61 % 88.51 % 
AO 
(ml / min) 
Pre 42.09 ± 1.51 41.21 ± 1.48 42.36 ± 1.87 38.46 ± 1.57 
Post 16.58 ± 5.34 **** 7.08 ± 5.27 **** 14.50±5.85 **** 7.167 ± 4.83 **** 
% Recovery 14.73 % 7.28 % 22.24 % 15.97 % 
CF 
(ml / min) 
Pre 14.13±0.7353 14.11±0.5114 15.36 ± 0.74 16.0 ± 1.13 
Post 8.40 ± 1.90 *** 9.75 ± 0.94 * 15.42 ± 0.99 12.36 ± 1.81 
% Recovery 59.45 % 69.10 % 100.39 % 76.87 % 
CO 
(ml / min) 
Pre 56.22 ± 1.84 55.32 ± 1.73 57.91 ± 1.81 54.54 ± 2.41 
Post 14.60 ± 4.59 **** 12.75 ± 3.028 **** 26.25 ± 2.813 *** 18.50 ± 4.39 **** 
 
% Recovery 
 
25.97 % 
 
23.05 % 
 
45.33 % 
 
33.92 % 
PST 
(sec) 
Pre 0.07 ± 0.00 0.07 ± 0.00 0.06 ± 0.01 0.07 ± 0.00 
Post 0.05 ± 0.01 0.10 ± 0.02 * 0.08 ± 0.02 0.07 ± 0.02 
% Recovery 70.07 % 157.24 % 131.95 % 104.42 % 
Wt 
(mW) 
Pre 13.24 ± 0.52 12.35 ± 0.43 13.24 ± 0.53 12.24 ± 0.61 
Post 2.91 ± 0.99 **** 2.14 ± 0.79 **** 4.82 ± 0.49 **** 3.47 ± 1.02 **** 
% Recovery 21.99 % 17.30 % 36.37 % 29.34 % 
 
KP 
(mW) 
Pre 0.13 ± 0.03 0.09 ± 0.01 0.11 ± 0.00 0.08 ± 0.01 
Post 0.02 ± 0.01 0.01 ±0.01 *** 0.04 ± 0.02 0.01 ± 0.01 
% Recovery 16.64 % 8.20 % 41.71 % 18.03 % 
PP 
(mW) 
Pre 13.10 ± 0.50 12.26 ± 0.42 13.14 ± 0.52 12.08 ± 0.51 
Post 6.05 ± 1.57  **** 2.43 ± 1.68 **** 6.32 ± 2.25 *** 3.56 ± 1.41  **** 
% Recovery 46.21 % 18.32 % 48.12 % 29.43% 
dP/dTMax 
Pre 18.17 ± 1.71 17.30 ± 0.91 21.33 ± 1.68 15.24 ± 1.19 
Post 10.58±2.260 * 4.42 ± 2.91 **** 11.58 ± 2.14 * 9.38 ± 2.56 
% Recovery 58.23 % 25.53 % 54.29 % 61.52 % 
dP/dTMin 
Pre 916.65 ± 1.20 917.08 ± 1.10 917.62 ± 1.32 916.36 ± 1.36 
Post 910.01 ± 2.29 * 93.75 ± 2.49 **** 98.83 ± 2.00 * 97.19 ± 2.23 ** 
% Recovery 60.12 % 21.96 % 50.13 % 43.97 % 
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